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Abstract
‘Latent autoimmune diabetes in adults’ (LADA) is a controversial subtype of diabetes characterized by initial
insulin independency and the presence of diabetes associated autoantibodies. As a result, LADA is often
misclassified and can represent 5-10% of apparent type 2 diabetes (T2D) cases and is potentially more
prevalent than childhood-onset type 1 diabetes (T1D). Despite LADA sharing features with the two better
characterized classic diabetes subtypes, the genetic etiology of LADA remains largely unknown. Once there is
a more accurate definition of LADA, there will be an improvement in diabetes classification and consequently
better treatment and therapeutic interventions. The objective of this thesis is to understand the genetic basis
of LADA in order to bring clarity to the current definition of LADA by being the first to leverage genome-
wide genotype data from a LADA cohort and the subsequent application of statistical genetics approaches.
These investigations can be divided into three parts: 1) the role of T1D and T2D loci in LADA 2) the first
genome-wide association study (GWAS) of LADA, and 3) searching for genetic discrepancies between
LADA and childhood-onset T1D in the human leukocyte antigen (HLA) region. Four out of the five
strongest associations from the candidate locus study were known T1D loci (HLA, PTPN22, INS and
SH2B3) and reached genome-wide significance in the GWAS meta-analysis. However, a novel independent
signal at a known T1D locus was also observed to be genome-wide significant, near the PFKFB3 gene, which
had not been implicated in previous T1D or T2D GWAS. Additionally, major T1D-susceptibility HLA
haplotypes were observed to be less frequent in LADA. Furthermore, contrary to observations in childhood-
onset T1D studies, HLA-B and HLA-A, were not significantly associated with LADA, independent of HLA-
DQB1 and HLA-DRB1 haplotypes. Overall, the genetics of LADA point to a strong T1D component, but a
positive genetic correlation between LADA and T2D is also evident, strongly suggesting LADA has both a
T1D and T2D component. However, it remains unresolved whether LADA is at the genetic intersection of
T1D and T2D or simply a mixture of relatively poorly phenotyped individuals who have either T1D or T2D.
Degree Type
Dissertation
Degree Name
Doctor of Philosophy (PhD)
Graduate Group
Genomics & Computational Biology
First Advisor
Struan Grant
Keywords
adults, autoimmune, diabetes, genetics, LADA
Subject Categories
Bioinformatics | Genetics
This dissertation is available at ScholarlyCommons: https://repository.upenn.edu/edissertations/3276
 
 
GENETIC INSIGHTS INTO LATENT AUTOIMMUNE DIABETES IN ADULTS 
Rajashree Mishra 
A DISSERTATION 
in 
Genomics & Computational Biology 
Presented to the Faculties of the University of Pennsylvania 
in 
Partial Fulfillment of the Requirements for the 
Degree of Doctor of Philosophy 
2019 
 
 
Supervisor of Dissertation       
_________________________      
Struan F.A Grant, Ph.D., Professor of Pediatrics       
 
Graduate Group Chairperson 
__________________________ 
Ben Voight, Ph.D., Associate Professor of Systems Pharmacology and Translational 
Therapeutics and Associate Professor of Genetics 
 
Dissertation Committee  
Marcella Devoto, Ph.D., Professor of Pediatrics 
Ben Voight, Ph.D., Associate Professor of Systems Pharmacology and Translational 
Therapeutics and Associate Professor of Genetics 
Andrew Wells, Ph.D., Associate Professor of Pathology and Laboratory Medicine 
Stephen S. Rich, Ph.D., Professor of Public Health Sciences, University of Virginia 
GENETIC INSIGHTS INTO LATENT AUTOIMMUNE DIABETES IN ADULTS 
COPYRIGHT 
2019 
Rajashree Mishra 
 
This work is licensed under the  
Creative Commons Attribution- 
NonCommercial-ShareAlike 3.0 
License 
 
To view a copy of this license, visit 
https://creativecommons.org/licenses/by-nc-sa/3.0/us/   
  
 iii 
This work is dedicated to my loving parents, brother, and sister. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 iv 
ACKNOWLEDGMENT 
I extend my whole-hearted gratitude to everyone who has supported me in 
my academic endeavors. 
 
This work would not have been made possible without the mentorship and 
guidance of my advisor Struan Grant. Struan, thank you for your constant 
support and push towards excellence. I will always be grateful for the 
opportunities you gave me and your dedication to my development as a 
scientist. You have taught me independence, a strong work-ethic, and 
most importantly how to communicate my work concisely and eloquently. 
It has truly been an honor and privilege to be your first PhD graduate 
student.   
 
To my thesis committee, Marcella Devoto, Ben Voight, Steve Rich, and 
Andrew Wells, thank you for your helpful advice and guidance throughout 
my candidacy. I truly appreciate your time and dedication to my 
development. It’s been an honor to learn from each of your expertise.  
 
To the ‘LADA team’, ‘Bone group’, and co-authors, this work could not 
have been done without you. Special thanks to Diana Cousminer, David 
Leslie, Kenyaita Hodge, and Alessandra Chesi, and special thanks to 
Jonathan Mitchell for providing a quiet and remote space to write. 
 
 v 
To the students, postdocs, faculty, and staff of the Grant Lab and 
Genomics and Computational Biology program, thank you for inspiring me 
every day and providing me with an amazing work and learning 
environment here at Penn/CHOP. Special thanks to Li-San, Maureen, and 
Hannah for their helpful coordination and support throughout my time at 
Penn. 
 
To my close friends, thank you for being my support system throughout 
graduate school. Your encouragement and companionship continue to 
motivate me and keep me in high-spirits. Most importantly, thank you for 
believing in me even when I didn’t believe in myself. 
 
Finally, words cannot describe my appreciation and gratitude towards my 
family. To my parents, Nrusingha and Banita, my brother, Satish, and my 
sister, Biju, thank you for your endless love and support. Your inspiration 
gives me strength to work hard and strive to succeed every day.  
 
 
 
This work was supported by National Institutes of Health R01 DK085212 
grant. 
 
 
 vi 
 
 
 
 
ABSTRACT 
 
GENETIC INSIGHTS INTO LATENT AUTOIMMUNE DIABETES IN ADULTS 
Rajashree Mishra 
Struan F.A. Grant 
‘Latent autoimmune diabetes in adults’ (LADA) is a controversial subtype 
of diabetes characterized by initial insulin independency and the presence 
of diabetes associated autoantibodies. As a result, LADA is often 
misclassified and can represent 5-10% of apparent type 2 diabetes (T2D) 
cases and is potentially more prevalent than childhood-onset type 1 
diabetes (T1D).
 
Despite LADA sharing features with the two better 
characterized classic diabetes subtypes, the genetic etiology of LADA 
remains largely unknown. Once there is a more accurate definition of 
LADA, there will be an improvement in diabetes classification and 
consequently better treatment and therapeutic interventions. The objective 
of this thesis is to understand the genetic basis of LADA in order to bring 
clarity to the current definition of LADA by being the first to leverage 
genome-wide genotype data from a LADA cohort and the subsequent 
application of statistical genetics approaches. These investigations can be 
divided into three parts: 1) the role of T1D and T2D loci in LADA 2) the 
 vii 
first genome-wide association study (GWAS) of LADA, and 3) searching 
for genetic discrepancies between LADA and childhood-onset T1D in the 
human leukocyte antigen (HLA) region. Four out of the five strongest 
associations from the candidate locus study were known T1D loci (HLA, 
PTPN22, INS and SH2B3) and reached genome-wide significance in the 
GWAS meta-analysis. However, a novel independent signal at a known 
T1D locus was also observed to be genome-wide significant, near the 
PFKFB3 gene, which had not been implicated in previous T1D or T2D 
GWAS. Additionally, major T1D-susceptibility HLA haplotypes were 
observed to be less frequent in LADA. Furthermore, contrary to 
observations in childhood-onset T1D studies, HLA-B and HLA-A, were not 
significantly associated with LADA, independent of HLA-DQB1 and HLA-
DRB1 haplotypes. Overall, the genetics of LADA point to a strong T1D 
component, but a positive genetic correlation between LADA and T2D is 
also evident, strongly suggesting LADA has both a T1D and T2D 
component. However, it remains unresolved whether LADA is at the 
genetic intersection of T1D and T2D or simply a mixture of relatively 
poorly phenotyped individuals who have either T1D or T2D.  
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CHAPTER 1. INTRODUCTION 
1.1 Background 
Genetic studies of childhood-onset type 1 diabetes (T1D) and type 2 diabetes 
(T2D) have yielded dozens of loci associated with diabetes risk. However, the 
genetic etiology of latent autoimmune diabetes in adults (LADA) remains 
substantially less well characterized compared to the two classic forms of 
diabetes, thus highlighting a major undeveloped area in the field, including the 
debate on the clinical definition of LADA and its phenotypic heterogeneity. 
Despite being defined as a slowly progressive form of T1D by the World Health 
Organization (American Diabetes Association/ADA, 2018), LADA exhibits clinical 
features of both T1D and T2D, earning the nickname “type 1.5 diabetes.” 
Additionally, existing genetic studies have portrayed LADA as an intersection of 
the two diseases (Tuomi et al., 1999). 
Patients diagnosed with LADA are typically defined by insulin independence for 
at least the first six months after diagnosis plus the presence of circulating 
diabetes-associated pancreatic islet autoantibodies. Diabetes associated 
autoantibodies highly predictive of LADA include glutamic acid decarboxylase 
(GAD) autoantibodies, islet cell autoantibodies (ICA), IA-2 autoantibodies and 
insulin autoantibodies (IAA). In certain populations, notably the Chinese in whom 
the frequency of GAD and IA-2 autoantibody positivity is low, zinc transporter 
(ZnT8) autoantibodies serve as an additional marker that has been shown to 
improve diagnostic sensitivity (Huang et al., 2013).  
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1.2 Motivation and Objective 
Given the initial independence of insulin in patients with LADA, there is a high 
misdiagnosis rate among those with T2D (5-10%), and LADA continues to be 
overlooked in clinical practice with no clear diagnostic guidelines. In fact, the 
majority of patients with adult-onset autoimmune diabetes do not require insulin 
treatment for at least 6 months after diagnosis (Buzzetti, Zampetti, & Maddaloni, 
2017). Despite recent studies that have shown that T1D is as prevalent in adults 
as in children (Thomas et al., 2017), these studies do not directly address LADA. 
The objective of this dissertation is to investigate the genetics of LADA for the 
first time in order to aid in the characterization of this puzzling clinically-defined 
subtype of diabetes. 
1.3 Organization of Dissertation 
The remainder of this chapter will cover the background of LADA, including the 
clinical definition and implications of misdiagnosing individuals, and previous 
genetic studies relevant to LADA. Chapter 2 covers the global prevalence and 
incidence of LADA and highlights the importance of autoantibody screening. The 
remaining chapters highlight the three specific aims of the dissertation. The first 
aim is to investigate the role of T1D and T2D loci in LADA in order to understand 
how LADA compares to these classic forms of diabetes (Chapter 3). The second 
aim is to take a genome-wide approach for understanding the genetics of LADA 
by investigating the heritability (Chapter 4) and performing the first discovery 
genome-wide association (GWAS) of LADA to attempt to identify putatively novel 
signals that are unique to LADA and could aid in the distinguishing of LADA from 
T1D and T2D (Chapter 5). The third aim is to investigate the genetic 
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discrepancies between childhood-onset T1D and LADA within the major 
histocompatibility complex (Chapter 6). Differences within this region between 
the two groups offers great promise to help us understand the progression of 
autoimmune diabetes. Finally, Chapter 7 will summarize the findings from aims 
1-3, provide follow-up analyses and highlight future directions for studying the 
genetics of LADA. 
 
1.4 Autoantibodies and clinical heterogeneity  
The heterogeneity of LADA is evident not only in cases in which autoantibodies 
are present but also in the varying levels of these autoantibodies. The distribution 
of GAD titers across LADA patients has been shown to be bimodal in some 
populations, resulting in two subgroups with distinct characteristics (Buzzetti et 
al., 2017; Maioli et al., 2010; Zhou et al., 2013). However, more detailed analyses 
of bimodality, specifically on untransformed assay signals, should be performed. 
Typically, those with high GAD titer are younger (Turner et al., 1997) with lower 
BMI, lower prevalence of metabolic syndrome (Zinman et al., 2004), higher levels 
of HbA1c, lower C-peptide levels and a higher frequency of other diabetes-
related autoantibodies (Figure 1-1). As a result, this particular subgroup 
resembles T1D more closely than individuals with lower GAD titer; alternatively, 
those with low GAD titer have metabolic presentation and loss of b-cell function 
that resembles a phenotype more closely aligned with T2D (Liu et al., 2015). This 
observation resonates with patterns seen in a cohort of individuals recently 
diagnosed with childhood-onset T1D, where those subjects who were positive for 
a single autoantibody (among those >12 years old) showed an association with 
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the T2D-associated TCF7L2 locus, and had higher C-peptide and lower glucose 
levels in an oral glucose tolerance  test (Redondo et al., 2017; Redondo et al., 
2018). Notably, IA-2 autoantibodies against a specific epitope are associated 
with increased body mass index (BMI) in patients with T2D, and patients positive 
for IA-2 autoantibodies to this epitope have a delayed progression to insulin 
requirement than patients who were solely positive for the GAD autoantibody 
(Buzzetti et al., 2017). These observations have led to two hypothesized 
mechanisms for the onset of LADA, that diabetes can result from either chronic 
inflammatory responses in individuals with higher BMI or through classic T1D 
autoimmune response in leaner individuals (Buzzetti et al., 2017). However, an 
alternative explanation could be that autoantibodies are not necessarily 
pathogenic unless they recognize certain epitopes of an antigen. 
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Figure 1-1 The clinical heterogeneity of diabetes, with LADA situated between T2D 
and late-onset T1D. This image is derived from (Leslie et al., 2008) and current 
knowledge of LADA (Buzzetti et al., 2017; Hawa et al., 2013). Abbreviations: DAA, 
diabetes associated, type 1 diabetes; T2D, type 2 diabetes. 
 
 
1.5 Clinical implications of misdiagnosing LADA cases 
The role of autoantibodies in the pathogenesis of LADA remains crucial for 
identifying patients who should be monitored more closely, especially if they 
require insulin therapy at an early stage. Insulin producing pancreatic b-cells in 
those with LADA tend to be compromised, presumably by the adverse immune 
response. Consequentially, the risk of progression to insulin therapy in patients 
with LADA is higher and earlier than in cases with T2D. If inadequately treated, 
ketoacidosis can result, representing a substantial complication, as it is the most 
common cause of death among pediatric diabetic cases (Tasker & Acerini, 
2014). While the destruction of the b-cell leads to hyperglycemia in T1D, this 
complication is also common in T2D due to insulin insensitivity and pancreatic b-
cell dysfunction or decreased b-cell mass (Parker et al., 2017). 
 
Thus, LADA and T2D are presumed to have two distinct mechanisms for disease 
progression, and therefore should be treated appropriately immediately following 
diagnosis. Studies have indicated that patients with LADA should not be treated 
with sulfonylureas, which is a common treatment for T2D, as these drugs further 
exhaust b-cell reserves, although one caveat is that these studies have had 
limited power (Kobayashi et al., 2002). Agents which augment the incretin 
pathway will be uninformative if C-peptide levels are very low (Dennis et al., 
2018). Therefore, accurate diagnoses are imperative, as the more rapid 
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progression to insulin dependence in misdiagnosed LADA cases could be life-
threatening.  
Several factors are important in making an accurate diagnosis. First, inadequate 
treatment is reflected in higher HbA1c levels in LADA cases than in T2D cases 
(Maddaloni et al., 2015; Zaharieva et al., 2017). A recent study found that the 
rate of deterioration of HbA1c in LADA was double that of patients with antibody-
negative T2D (Donnelly et al., 2018). Furthermore, individuals with LADA have 
higher HbA1c independent of insulin usage (Andersen et al., 2013). Second, co-
morbidities are different, where there is a higher risk of metabolic syndrome and 
cardiovascular disease among T2D cases, although large prospective studies 
are still ongoing in this context (Wod et al., 2018). Recent studies have 
suggested that macrovascular disease is as common in LADA as in T2D. 
However, in LADA there is a higher risk of thyroid and parietal cell autoimmunity, 
leading to a need for either thyroid replacement or vitamin B12 supplementation. 
Finally, LADA patients who are obese and scheduled for bariatric surgery should 
consider avoiding this operation as they are actually at risk of progression to 
insulin therapy independent of their insulin resistance status (De Luca et al., 
2016). 
In particular, the underuse of autoantibody screening has led to the 
underdiagnosis of LADA, hampering the ability to estimate accurate prevalence 
rates and to assess the genetic architecture of the disease. Strikingly, the 
prevalence estimates based on current reports for T1D, T2D and LADA differ 
widely across populations, and this is influenced by genetic, environmental and 
socioeconomic differences, with notable differences between clinic-based or 
population-based studies. There is a need for consistent and thorough, well-
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powered genetic studies in populations of diverse ethnicities to aid in the full 
characterization of the pathogenesis of autoimmune diabetes; however, these 
studies cannot be performed if autoantibody screening is not performed 
immediately after the diagnosis of diabetes. 
1.6 Previous genetic studies of LADA 
The lack of awareness of LADA and the relatively unclear diagnostic criteria 
has hindered progress in understanding the genetics of this common disease. 
However, there have been many genetic studies regarding T1D and T2D, both of 
which have a clear heritable component. The risk for developing T2D is three 
times higher in first-degree relatives of patients with T2D than individuals without 
a family history, while the risk for developing T1D is 15 times more likely in first-
degree relatives (Florez, Hirschhorn, & Altshuler, 2003). A stronger genetic 
similarity between LADA and T1D than between LADA and T2D was supported 
by a recent study based on 378 LADA cases which showed that having family 
history of T1D was associated with a 6-fold increased risk, whereas family history 
of T2D was associated with a 2-fold increased risk of LADA (Hjort et al., 2017). 
This study suggests that the T1D genetic contribution to LADA etiology is greater 
than that of T2D. 
T1D and T2D appear to be due to distinct biological mechanisms, as shown 
by the paucity of overlapping significant loci identified by GWAS (Aylward et al., 
2018; Bradfield et al., 2011). However, some overlapping signals from major 
histocompatibility complex (MHC) loci are beginning to emerge from the most 
recent GWAS of T2D (Mahajan et al., 2018; Ng et al., 2014; Scott et al., 2017), 
potentially due to the presence of unaccounted individuals with autoimmune 
diabetes. The MHC accounts for approximately 50% of the genetic risk for T1D 
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and harbors human leukocyte antigen (HLA) genes which encode highly 
polymorphic antigen-presenting proteins (Todd, 2010).  Risk MHC class II 
haplotypes in combination with an MHC class I chain-related A5 gene 
polymorphism, located in the class III region, has been shown to be a strong 
genetic marker for T1D risk (Gambelunghe et al., 2000). The MHC class I genes 
HLA-A and HLA-B have also been pinpointed through conditional analyses as 
increasing T1D risk(Nejentsev et al., 2007). However, a signal from the HLA-B 
locus has emerged in a GWAS meta-analysis of T2D in African Americans along 
with a signal from the INS-IGF2 locus, which has been strongly implicated in 
LADA (Cervin et al., 2008), further suggesting potential misclassification among 
those diagnosed with T2D.  
Association of T1D and T2D genetic signals in LADA 
Multiple loci are robustly associated with T1D and T2D (Bradfield et al., 2011; 
Ng et al., 2014; Onengut-Gumuscu et al., 2015; Scott et al., 2017). Established 
GWAS-implicated loci for these diseases have been investigated in cohorts of 
European cases diagnosed with LADA (Cervin et al., 2008; Howson et al., 2011). 
Several studies have shown that T2D genetic risk, particularly at TCF7L2, is also 
associated with LADA (Cervin et al., 2008; Howson et al., 2011). There is an 
emerging picture for a role for the TCF7L2 locus in the pathogenesis of 
autoimmune diabetes, where it has been implicated in T1D heterogeneity 
(Redondo et al., 2014). In particular, T1D carriers of the known T2D TCF7L2 risk 
allele tend to have less severe immunological and metabolic phenotypes with an 
age–dependent effect (>12 years at diagnosis being the cut-off above which the 
association was noted) (Redondo et al., 2017). Therefore, it is unclear to what 
extent T2D loci contribute to the onset of LADA, but these recent studies suggest 
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a T2D-like pathophysiological mechanism for a subset of affected individuals. A 
study of diabetes from Hungary (Lukacs et al., 2012) suggested that BMI 
influences the genetic effect on LADA risk, such that the lower the BMI, the 
higher the TCF7L2 genetic effect, as also predicted in a smaller American study 
(Redondo et al., 2014).  
 
Specific HLA haplotypes have been shown to be significantly associated with 
T1D. In particular, the HLA-DR3 and HLA-DR4 haplotypes play a consistent role 
across multiple ethnicities (Desai et al., 2007; Luo et al., 2016; Manan et al., 
2010; Mbanya et al., 2010). Moreover, there is a greater increase in risk for 
patients with DR3/DR4 heterozygosity than those with only the DR3 haplotype. In 
a major Chinese study, protective T1D haplotypes were enriched in LADA 
compared to T1D, while, conversely, susceptibility T1D haplotypes were 
diminished in LADA when compared to T1D (Luo et al., 2016). Perhaps not 
surprisingly, another study in the same Chinese population comparing LADA and 
T2D found that these T1D susceptibility haplotypes had a significantly higher 
frequency in LADA cases (63.9%) than that in either T2D cases (47.1%) or 
controls (43.2%); indeed, the converse was also observed for the frequency of 
protective haplotypes (LADA: 22.8%; T2D: 33.3%; controls: 32.7%) (Zhou et al., 
2013).  
 
Taken together, the genetics studies of LADA thus far have highlighted the HLA 
region and TCF7L2 contribution to LADA. This dissertation further expands these 
studies by investigating not only candidate loci, but also the genome-wide 
genetics of LADA in the largest cohort to date. 
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CHAPTER 2. A GLOBAL PERSPECTIVE OF LADA 
This chapter highlights the prevalence rates reported across the globe and 
addresses the apparent challenges of performing genetic studies for LADA. The 
content of this chapter is published in Mishra R, Hodge KM, Cousminer DL., 
Leslie RD., Grant SFA. "A Global Perspective of Adult Autoimmune Diabetes." 
Trends in Endocrinology and Metabolism (2018). PMID: 30041834.  RM’s 
contribution to the manuscript includes literature review, drafting, critical revision, 
and writing the final version of the manuscript.  
 
2.1 Global prevalence of diabetes 
Diabetes is dramatically on the rise across the globe. Based on the studies 
available, the overall rate of diabetes is approaching epidemic levels, with the 
global prevalence projected to reach 10.4% by 2040, and with 5 million deaths 
reported as of 2015. T2D is by far the most prevalent form of diabetes (Alberti & 
Zimmet, 1998), accounting for approximately 90-95% of total diabetic cases 
world-wide, totaling approximately 400 million adults (Ogurtsova et al., 2017). 
Additionally, an increased rate of obesity and rise in socioeconomic status has 
influenced the rate of T2D (Martinell et al., 2017). In contrast, T1D makes up only 
a small percentage (4-10%) of the total burden of diabetes but has a stronger 
genetic etiology (Eisenbarth et al., 2008; Poulsen et al., 1999) and clear variation 
in prevalence around the world (American Diabetes Association, 2014; Maahs et 
al., 2010). In 2013, worldwide prevalence estimates indicated that there were 
almost 500,000 children under the age of 15 years old with T1D, with the largest 
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populations being in Europe and North America (Maahs et al., 2010). The recent 
increase in T1D incidence in certain areas could be explained by an 
environmental effect, such as the proposed hygiene hypothesis (Bach, 2002). 
However, there is a paucity of well-powered studies which have systematically 
addressed the prevalence of T1D in the under-developed regions of the world. 
Despite the relatively limited studies available, the epidemiological studies 
performed thus far have shown an overall increase in the number of new cases 
per year (incidence rate) especially in young children. However, trends reported 
on T1D are likely only available from countries with well-established public health 
and diabetes research programs. Therefore, there is a need for comparable 
research on T1D in developing countries. Additionally, many of the T1D studies 
represent trends in children, even though age-of-onset can extend to adulthood 
(Maahs et al., 2010; Mayer et al., 2017). Consequently, the prevalence rates 
reported for T1D should be carefully interpreted. 
 
Using genetics to identify T1D cases amongst adults with diabetes 
A recent study (Thomas et al., 2017) demonstrated that T1D is almost as 
common in adulthood as in childhood using genetic risk scores (GRS) in order to 
identify T1D cases in a cohort with adult-onset diabetes. The GRS in this 
particular study was based on data from a cohort of childhood-onset T1D, the 
majority of whom were diagnosed under the age of 16 years. However, 
substantial evidence points towards age-dependent differences in the genetic 
risk to develop autoimmune diabetes. Specifically, the genetic risk to develop 
autoimmune diabetes declines with increasing age-at-diagnosis without a clear 
cut-off, rather in a graded fashion (Frohnert et al., 2017; Pugliese et al., 2016; 
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Steck et al., 2017). Additionally, LADA was not addressed in a recent cohort 
study (Thomas et al., 2017), yet a proportion of diabetes cases genetically 
defined as T1D using a childhood-onset T1D derived GRS did not need insulin at 
diagnosis. Those defined as T1D represented only 22% of the whole cohort on 
insulin treatment and only 66% of that developing ketoacidosis. Therefore, it 
currently remains unclear how to discriminate T1D and LADA. At diagnosis, C-
peptide levels or lack of insulin dependence is commonly used to discriminate 
LADA from T1D; however, there is scope for improvement on how to distinguish 
the two biologically, and that is the motivation for investigating the genetics of 
T1D and LADA.  
2.2 Global prevalence of LADA 
In contrast to T1D and T2D, there have been many fewer studies conducted 
on LADA, especially in ethnicities beyond European ancestral populations, with 
existing studies being somewhat underpowered. Additionally, the validity of 
autoantibody measurements and the application of diagnostic criteria may differ 
significantly across regions, which in turn are likely to influence prevalence 
estimates, leading to overly conservative reports and conclusions. Here, we 
report global trends in LADA and highlight how they compare to the two more 
classic forms of diabetes across populations of European, African, Asian and 
Middle Eastern ancestry.  
 
2.2.1 Prevalence of LADA in populations of European Ancestry  
Approximately 5-12% of cases in European populations with apparent T2D 
are in fact misdiagnosed LADA cases (Barinas-Mitchell et al., 2004; Bosi et al., 
1999; Buzzetti et al., 2007; Hawa et al., 2013; Maioli et al., 2010; Radtke et al., 
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2009; Tuomi et al., 1999; Turner et al., 1997; Wod et al., 2018; Zaharieva et al., 
2017; Zinman et al., 2004) (Table 2-1). In most of these studies, LADA is defined 
by age-of-onset >30 years, with insulin independence for at least 6 months, and 
positivity for at least one autoantibody. However, trends in LADA diagnosis 
across European populations differ even between regions within a given country, 
especially between population-based and hospital clinic-based cohorts. For 
instance, there was a dramatically lower prevalence of LADA in a population-
based study in Northern Italy (0.19%) (Bosi et al., 1999) when compared to a 
much larger study of subjects recruited throughout Italy from hospital clinics 
(6.6%) (Genovese et al., 2006). The reason for this discrepancy is likely due to 
the greater metabolic severity of LADA, such that hospital clinics are more likely 
to be enriched for these cases. However, these observations could also be 
explained by regional variations similar to those reported across Spain, where 
the south of the country has a higher prevalence rate of LADA compared to the 
north (10.9-14.7% vs 5.6-7.2%, respectively) (Soriguer-Escofet et al., 2002). 
These discrepancies could be attributed in part to sample size; however, genetic 
and environmental factors could influence LADA prevalence, an idea that is 
supported by the wide range in diabetes prevalence observed across the globe. 
An unexplored area is the proportion of cases with transient autoantibodies, in 
whom the presentation is autoantibody negative but who otherwise have most of 
the features of LADA. This possibility was highlighted in a recent large (n=14,775 
cases) population-based study in Scandinavia of adult onset diabetes, of which 
6.4% had LADA, but 17.5% had the same features including low C-peptide levels 
but were autoantibody negative (Ahlqvist et al., 2018). 
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Since the vast majority of adult-onset diabetes cases have T2D and the 
estimated prevalence of T2D in populations of European ancestry is 
approximately 10% (Ng et al., 2014), the prevalence of LADA in European 
populations is considerably higher than the previously reported European 
prevalence of T1D (~0.3%) (Dabelea et al., 2014; Maahs et al., 2010). T1D, 
however, is by far the most common type of diabetes in children and adolescents 
and is more frequent in populations of European ancestry (Maahs et al., 2010) 
(Appendix: Supp. Table 2-1).  
 
2.2.2 Prevalence of LADA in populations of African Ancestry 
The majority of well-powered diabetes studies are predominantly of European 
ancestry, despite the African region expecting to have the world’s largest 
proportional increase of adults with diabetes (Ogurtsova et al., 2017). The 
estimated prevalence of diabetes in adults across Africa ranges widely, but is 
overall lower than in other parts of the world (Ogurtsova et al., 2017)(Appendix: 
Supp. Table 2-1). The majority of people in Africa with T2D live in cities, 
although the overall population is predominantly rural, and while those in rural 
areas may have less access to health centers, environmental factors like 
urbanization may also play a major role in susceptibility. In fact, the reported 
prevalence of T2D can vary largely between rural and urban areas (Mbanya et 
al., 2010; Motala et al., 2003). There is also a lack of corresponding studies on 
T1D in Africa, presumably leading to inaccurate incidence/prevalence estimates. 
Additionally, poor healthcare and high mortality rates leave many cases 
unaccounted for in such estimates (Mbanya et al., 2010). 
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Taking T1D/T2D epidemiology in African populations into account, there are 
only a handful of LADA studies performed in that part of the world. It has been 
reported that 10-14% of West Africans with apparent T2D are misdiagnosed 
LADA cases, higher than their European counterparts (8-10%) (Adeleye et al., 
2012; Agyei-Frempong et al., 2008; Ipadeola et al., 2015; Muazu et al., 2016) 
(Table 2-1). However, there may be a lower LADA prevalence in East Africa, 
most obviously in Kenya (5.7%) (Otieno et al, 2008). These findings should be 
interpreted carefully given differences in study design, selection criteria, sample 
size and potential variation in access to healthcare. Additionally, current studies 
have been largely concentrated in West Africa, and therefore further studies 
expanding to regions throughout Africa are still required. Larger population-based 
studies will undoubtedly lead to more accurate comparisons of LADA prevalence 
between populations of European and African ancestry.  
 
2.2.3 Prevalence of LADA in African-American populations 
Limited research exists on the prevalence of LADA in African Americans, as 
the relative scarcity of sample collections continues to be a challenge. There is 
currently only one study of LADA in African Americans, where diabetes-
associated autoantibodies were measured in 295 non-Hispanic black adults, with 
4.7% of subjects being autoantibody positive (Barinas-Mitchell et al., 2004). This 
prevalence estimate was significantly higher than autoantibody positive 
nondiabetic controls (1.3%) and significantly lower than that of autoantibody 
positive non-Hispanic whites (8.6%) in the same study. In this particular analysis, 
there was a higher prevalence of autoantibody positive non-insulin requiring 
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diabetics in non-Hispanic white adults than in non-Hispanic black adults (Table 
2-1). 
With respect to T2D and the difference in prevalence between those with 
European and African ancestry, racial admixture should also be considered. One 
of the highest prevalence rates of T2D has been seen in African Americans 
(18.7%) compared to 10.2% observed in European Americans (Cooke et al., 
2012). This African American prevalence estimate is likely due to socioeconomic 
and behavioral risk factors that have resulted in relatively unhealthy lifestyles and 
higher rates of obesity (Cowie et al., 2006). However, in support of a genetic 
influence, African-European mixed-ancestry individuals have a higher risk of T2D 
compared to those of European ancestry alone (Ng et al., 2014). Indeed, one 
American study, which considered racial admixture, found a significant 
association between African Americans with a higher admixture of African 
ancestry and T2D (Cheng et al., 2012). Although T2D is more prevalent in 
African Americans than Africans (Tull & Roseman, 1995), this increased 
prevalence has been observed in African migrants (Mbanya et al., 2010), 
suggesting a strong impact of environmental factors contributing to the 
progression of T2D.  
Similar to LADA, the T1D prevalence in African Americans is also relatively 
less than in European Americans (approximately 1.62 per 1000 individuals as of 
2009 versus 2.55 per 1000 individuals, respectively) (Dabelea et al., 2014). 
Furthermore, one study observed a higher incidence of T1D among African 
American children living in Allegheny, Pennsylvania (11.8 per 100,000) than in 
Jefferson County, Alabama (4.4 per 100,000) (Tull & Roseman, 1995), where the 
genetic admixture is 21.2% and 17.0%, respectively. These results likely reflect 
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European Americans being at higher risk for childhood-onset T1D than African 
Americans. The trend in LADA diagnoses in racially admixed individuals remains 
unclear, and more studies with larger samples are needed to fully understand the 
epidemiology of LADA in African and African American populations.  
Prevalence of LADA in Asian and Middle Eastern populations 
 LADA studies in other parts of the world, specifically non-European 
populations, will also help determine to what extent discrepancies in prevalence 
are due to genetics. Despite the high prevalence of T2D in populations of Asian 
ancestry, LADA prevalence has been reported to be generally lower in China, 
Japan, Korea and India (2.5-9.2%) than in Europe (Table 2-1) (Hwangbo et al., 
2012; Katulanda et al., 2008; Park et al., 2011; Qi et al., 2011; Sachan et al., 
2015; Takeda et al., 2002; Zhou et al., 2013). In a study of Indian, Malay and 
Chinese populations from Singapore (Ong et al., 2017), GAD autoantibodies 
were more frequent in a European cohort (13.9% vs. 11.4%, 6.0%, 5.8%, 
respectively), while IA-2 antibody positivity was higher in the Asian ethnic groups, 
which has also been shown in an East Indian populations (Kanungo & Sanjeevi, 
2003). A high prevalence of LADA was observed in a small hospital-based study 
in Kerala, India (Unnikrishnan et al., 2004), where 25% of 83 lean patients with 
apparent T2D were positive for GAD autoantibody. Studies based on hospital 
patients, such as this study, are more likely to show a greater frequency of 
autoantibody positive patients given that they have more severe disease, as 
noted above. Overall, countries across Asia have collectively reported a wide 
range of prevalence estimates of LADA compared to European and African 
ancestral groups. Despite the high prevalence of T2D in populations of Asian 
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ancestry, the T1D prevalence and incidence rates are reported to be low 
(Dabelea et al., 2014). Collectively, however, both T1D and LADA have a lower 
prevalence in Asia, with T2D being by far the most prominent form of diabetes.  
 Strikingly, the prevalence of LADA in Middle Eastern countries may be as 
high as 14% (Table 2-1) (Hossein et al., 2015; Maddaloni et al., 2015). However, 
and in contrast, a large cross-sectional population-based study in the United 
Arab Emirates only reported LADA and classic T1D in 2.6% and 0.2%, 
respectively, of 17,072 subjects with adult-onset diabetes (>30 years) (Maddaloni 
et al., 2015). Prevalence rates of adult-onset diabetes therefore vary substantially 
across Northern Africa and the Middle-East. According to the International 
Diabetes Federation, the total number of adults with diabetes in the Middle East 
is also predicted to see a large increase in the prevalence of diabetes over time. 
A high T1D occurrence has recently been reported in the Middle-East 
(Appendix: Supp. Table 2-1), with the incidence rates in Kuwait amongst the 
highest in the world (Ogurtsova et al., 2017; Shaltout et al., 2017). Given these 
strikingly high prevalence estimates in Middle Eastern countries for both T1D and 
T2D, but also potentially for LADA cases, this region would particularly benefit 
from improvements in classification of diabetes subtypes.  
 
As a brief overview of this section, the majority of autoimmune diabetes studies 
have, thus far, been in populations of European ancestry, with only limited 
research that is almost invariably underpowered conducted in other ethnicities. 
Childhood-onset T1D is known to be most prevalent in populations of European 
ancestry, but strikingly the converse can be true for adult-onset autoimmune 
diabetes including LADA. Indeed, the prevalence of LADA varies across Africa, 
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the Middle East and Asia. Unfortunately, many populations affected by this adult-
onset form of autoimmune diabetes frequently have the least access to 
autoantibody screening, hampering efforts to distinguish LADA from T2D. Only 
with proper diagnoses and ascertainment of individuals afflicted with LADA from 
large populations of diverse ancestries can genetic studies be implemented.
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Table 2-1 Prevalence of autoantibody-positive individuals among adults with 
diabetes across different population groups. 
 
 
 
Ethnicity Author/ Year Location 
Type 
of 
study1 
Study 
Size Inclusion 
Age of 
onset2 
Measured 
AA 
# Cases 
positive 
for AA 
Frequency 
of AA 
positivity 
(%) 
African 
Muazu et al. 
(2016) 
Northern 
Nigeria C 200 
Non-insulin requiring T2D 
patients >30 GAD 21 10.5 
Ipadeola et 
al. (2014) 
Southwest 
Nigeria C 160 Individuals with T2D  >30 GAD 19 11.9 
Adeleye et 
al. (2012) 
Southwest 
Nigeria C 235 Individuals with T2D  >30 GAD 33 14 
Agyei et al. 
(2008)  Ghana C 120 
Recently diagnosed (<1 
year) patients with 
diabetes 
>35 GAD 14 11.7 
Otieno et al. 
(2008) Kenya C 124 Individuals with T2D  >40 GAD 7 5.7 
Asian 
Takeda et 
al. (2002) Japan C 4,980 Patients with diabetes >20 GAD 188 3.8 
Qi et al. 
(2010) China P 8,109  
Three step randomized 
sampling procedure from 
population, T2D were 
then identified 
≥15 GAD 46 9.2 
Zhou, et al. 
(2013) China C 4,880  
Individuals with diabetes 
duration of 1 year and no 
ketoacidosis or insulin 
dependence in the first 6 
months after diagnosis.  
≥30 GAD 287 5.9 
Hwangbo et 
al. (2012) Korea C 462 
Individuals with T2D, 
within 5 years from the 
time of study  
>20 GAD 20 4.3 
Park et al. 
(2011) Korea C 884 
Patients with diabetes for 
> 2 months and < 5 
years, and diabetes 
controlled by diet or by 
oral anti-diabetic agents 
for at least (≥) 2 months 
after diagnosis 
35-70 GAD, IA2, 
or ZnT8A 39 4.4 
Katlunda et 
al. 
India C 992 
Individuals with diabetes 
aged ≤45 years.  
16-40 GAD 54 5.4  
Sachan,  et 
al. (2014) India 
C/ 
P 
618 Individuals with T2D  >30 GAD 
and/or IA2 9 2.6 
European 
Turner et al. 
(1997) UK P 3,672 
Individuals recently 
diagnosed with non-
insulin requiring diabetes 
25–65 GAD 
and/or ICA 430 12 
Tuomi,  et 
al.(1999) Finland P 1,122 
Individuals diagnosed 
with non-insulin requiring 
diabetes 
28–83 GAD 
and/or IA-2 104 9.3 
Zinman,  et 
al.(2004) 
USA, 
Europe C 4,357 
Individuals recently 
diagnosed with non-
insulin requiring diabetes 
30–75 GAD 
and/or IA-2 174 4.2 
Buzzetti,  et 
al.(2007) Italy P 4,250 
Participants in NIRAD  
Study with T2D  30–75 
GAD 
and/or IA-2 193 4.5 
Radtke,  et 
al. (2009) Norway P 1,049 
Participants in HUNT 
study with diabetes ≥20 GAD 106 10 
Maioli et al. 
(2010) Sardinia C 5,568 Individuals with T2D  35–70 GAD 276 4.9 
Hawa, et al. 
(2013) Europe C 6,810 Individuals with diabetes  30–70 
GAD 
and/or IA-
2, ZnT8 
598 9.7 
Bosi et 
al.(1999) 
Italy 
(Northen) P 2,076 
Participants in Cremona 
Study, then individuals 
with diabetes were 
identified 
>40 GAD 4 2.8 
Middle 
Eastern 
Maddaloni et 
al. (2015) 
United 
Arab 
Emirates 
C 17,072 
Adult onset diabetes, 
with sufficent data 
available 
30–70 GAD 
and/or IA-2 437 2.6 
Hossein et 
al.(2015) Iran P 500 
Individuals with T2D with 
insulin independency  at 
least first 6 months 
> 35 GAD 71 14.2 
 22 
2.3 Importance of autoantibody screening 
In order to perform well-powered population-based epidemiological and 
genetic studies, more extensive autoantibody screening is crucial for early 
detection of autoimmunity in adult-onset diabetes. The presence of a single 
autoantibody alone, however, cannot be relied on for a categorical diagnosis of 
LADA given the potential for false positive and false negative assay results, as 
well as the variation in observations across racial/ethnic groups (Xiang et al., 
2015). Notably, in a cross-sectional study (Siraj et al., 2016) in Ethiopia 
measuring islet-cell associated antibodies in T1D, T2D and non-diabetic controls, 
IA-2 autoantibodies were absent in all groups, suggesting that the clinical utility of 
IA-2 autoantibodies may be limited in some populations. Furthermore, individuals 
with LADA in China and India also have lower average autoantibody titers, 
especially for GAD and IA-2 autoantibodies, than their European counterparts, 
making LADA much more challenging to diagnose in these populations (Sachan 
et al., 2015; Zhou et al., 2013). In particular, 92.7% of autoantibody positive 
cases in the Action LADA study (Hawa et al., 2013) had GAD autoantibody 
positivity while the remainder of cases were positive for IA-2 autoantibody or 
ZnT8A autoantibodies. However, in the LADA China study, GAD frequency was 
67%, and non-GAD autoantibodies were more prevalent in this Chinese cohort 
(Zhou et al., 2013). Therefore, given that some autoantibodies are less prevalent 
in certain populations, it is crucial to measure more than one marker to capture 
the true frequency of autoimmune diabetes. 
Despite the high frequency of misdiagnosed cases and the availability of 
clinical screening tools for identifying LADA risk, antibody screening is not 
common in practice and is usually limited to only those who are considered to be 
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at very high risk (invariably, lean young adults with high HbA1c (American 
Diabetes Association, 2009)). However, this approach will miss a substantial 
number of cases, and it is challenging to clinically identify patients with LADA, 
because some may be obese, with metabolic syndrome and mild metabolic 
dysfunction. As a consequence of stringent criteria, current standards for high 
risk patients still dismiss true LADA cases (Zinman et al., 2004). Thus, identifying 
at-risk patients through routine autoantibody screening for adult onset 
autoimmune diabetes may substantially decrease the number of misdiagnosed 
cases and could potenitally reduce health care costs. In addition, the 
development of oral therapy used to treat T1D, for example SGLT2 inhibitors 
(sotogliflozin) (Garg et al., 2017), and immune therapy to limit the immune effect 
could be potentially useful in treating LADA. 
 
2.4 Concluding remarks 
Despite the limited number of LADA studies in the ethnicities highlighted in 
this chapter, and the challenges in defining the trait, this diabetes subtype 
appears to be more prevalent than childhood-onset T1D, particularly among 
populations of African ancestry. Additionally, a proportion of cases with T2D are 
misdiagnosed LADA cases irrespective of ancestry, and this misdiagnosis rate is 
perhaps highest in cases of West African ancestry; however, it is unclear whether 
diagnostic practices are significantly different across regions, impacting 
prevalence estimates. Furthermore, the prevalence of autoantibody positivity in 
diabetes cases with non-European ancestry is lower than in European 
populations with misdiagnosis likely due to relatively low levels of GAD 
autoantibodies. Screening programs designed for populations at risk should 
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enable earlier intervention with improved metabolic outcomes, appropriate 
therapy and improved identification of comorbidities (Martinell et al., 2017).  
Finally, genetic studies are particularly needed in African and Asian 
populations to identify ancestry-specific genetic susceptibility loci for autoimmune 
diabetes, most specifically LADA. Of the studies published, sample sizes have 
been relatively small and thus statistically underpowered to fully dissect the 
issues raised in this chapter. In addition to having more power, the collection of 
samples needs to be more representative of the population to gain more clarity 
and accurate prevalence estimates. The polymorphic nature of the MHC region 
means that the frequencies of susceptibility and protective alleles vary widely 
between and within ethnicities, further highlighting the need for population-
specific studies. Future studies should focus on comparing genetic features 
among different subtypes across ethnic groups affected with diabetes in order to 
further improve prognosis, diagnosis and treatment of diabetes, ultimately 
allowing us to move beyond a dependence solely on autoantibodies to make 
such diagnoses. 
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CHAPTER 3. RELATIVE CONTRIBUTION OF T1D 
AND T2D LOCI TO THE GENETIC ETIOLOGY OF 
LADA 
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writing the final version of the manuscript. RM had full access to all the data in 
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3.1 Introduction 
Diabetes is a heterogeneous group of diseases resulting in hyperglycaemia 
due to insulin secretory dysfunction as well as insulin resistance. A substantial 
proportion of type 1 diabetes (T1D) cases present in adulthood, and despite the 
presence of diabetes-associated autoantibodies, the majority of these patients do 
not initially require insulin (Hawa et al., 2013; Maddaloni et al., 2015). The 
manifestation of this ‘latent autoimmune diabetes in adulthood’ (LADA) is 
clinically defined by (i) an adult age of onset, (ii) at least one diabetes-associated 
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autoantibody, and (iii) the lack of requisite insulin treatment for at least 6 months 
after diagnosis. This definition overall represents ~5-10% of all cases of adult-
onset diabetes, potentially the most frequent form of autoimmune diabetes 
(Tuomi et al., 1999; Zhou et al., 2013).  
However, classifying adult-onset autoimmune T1D, including LADA, remains 
challenging. The need for insulin treatment is a clinical decision, while diabetes-
associated autoantibodies are neither pathogenic nor categorical features of 
LADA. Decisions are further confounded by false positives when large numbers 
of patients are screened ( Tuomi et al., 1993). Since LADA has intermediate 
features between T1D and type 2 diabetes (T2D), there are limits to the current 
classification of diabetes. New paradigms are needed to distinguish LADA and 
ensure appropriate disease treatment and management. 
Recently, several studies have used genetic information derived from 
diabetes-associated risk variants across the genome to reclassify diabetes 
(Oram et al., 2016). To date, comprehensive genetic studies of T1D and T2D 
have uncovered dozens of distinct susceptibility loci for each of these two 
diseases (Bradfield et al., 2011; DIAGRAM et al., 2014; Wellcome Trust Case 
Control Consortium, 2007). Initial analyses of T1D loci in relatively small LADA 
cohorts have consistently shown an association with the T1D locus HLA-DQB1, 
which resides in the major histocompatibility complex (MHC) (Desai et al., 2007a; 
Horton et al., 1999; Tuomi et al., 1999), as well as at PTPN22 and INS (Cervin et 
al., 2008; Desai et al., 2006). Similar analyses of T2D loci have suggested an 
association in LADA with the strongest T2D locus harboring TCF7L2 (Cervin et 
al., 2008; Lukacs et al., 2012; Zampetti et al., 2010) and the ZMIZ1 locus (M K 
Andersen et al., 2014). A significant challenge of these studies has been the lack 
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of statistical power due to the small number of LADA patients included. Thus, the 
genetic etiology of LADA remains largely unresolved. 
To quantify the genetic liability to LADA contributed by genetic risk factors for 
T1D and T2D, we amassed the largest LADA cohort to date. By assessing the 
association of these variants in LADA, our objective was to place LADA along the 
etiological diabetes spectrum and reshape our understanding of the relationship 
between LADA and classic diabetes phenotypes. 
 
 
3.2 Methods 
Study populations and antibody testing 
We ascertained 978 LADA cases from two studies, a European Union-funded 
multicenter study (Action LADA) and a German Research Council study (DFG: 
SFB 518, A1), each aimed to identify features of adult-onset autoimmune 
diabetes. A description of the participants and study design has been published 
elsewhere (Hawa et al., 2013). Briefly, for this study, all participants were 
diagnosed with LADA if: aged 30-70 years old, positive for diabetes-associated 
Glutamic Acid Decarboxylase (GAD) autoantibodies, without insulin treatment for 
at least 6 months after diagnosis. These cross-sectional studies included adult-
onset diabetic patients recruited between 2003 and 2007 from Barcelona (Spain), 
Düsseldorf (Germany), London (United Kingdom), Odense (Denmark) and Ulm 
(Germany); two centers recruited patients from a community or primary care 
setting (Düsseldorf and Odense), and the remaining three centers (Barcelona, 
London and Ulm) recruited patients in a hospital setting. The ethics committees 
of all participating centers approved the protocol, and all participants provided 
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written informed consent. Patients were diagnosed with diabetes according to 
standard criteria, with at least two recorded fasting blood glucose measurements 
≥7mmol/L, or 2 hour post-oral glucose blood glucose >10mM. Patients were 
excluded if their data was incomplete, they were pregnant, had renal disease 
(raised creatinine or proteinuria) or an acute illness at the time of testing. An 
attending physician recorded the medication data and risk factors. Serum and 
plasma samples were collected according to standard procedures and stored at -
20°C.  
Samples were tested in two central laboratories (London, UK and Ulm, 
Germany) for serum autoantibodies to glutamic acid decarboxylase (GADA) and 
insulinoma associated antigen-2 (IA2A), using established 
radioimmunoprecipitation assays. Positive results were replicated, reducing false 
positives to <0·2%. Using the Diabetes Antibody Standardization Program (Torn 
et al., 2008) (and unpublished data), we determined the sensitivity and specificity 
of the GADA assays (90%, 93% in London and 86%, 95% in Ulm, respectively) 
and the sensitivity and specificity of IA2A assays (68%, 95% in London and 73%, 
99% in Ulm, respectively).  
Each assay included serially diluted sera from antibody positive 
individuals. The cut-off for positivity was selected arbitrarily based on the 
end point of the standard curve and further confirmed with Quantile-
Quantile probability plots for London (UK) and the 99
th
 centile for Ulm 
(Germany). 
The population-based control cohort comprised non-diabetic children 
of European ancestry, aged 5-20 years old, enrolled in the Bone Mineral 
Density in Childhood Study (BMDCS). Subjects were randomly recruited 
 29 
from five different centers in the US. As previously reported (Kalkwarf et 
al., 2007), enrollment criteria included healthy, normally developing 
children. Each participating center received approval of the study by their 
respective institutional review boards. Participants 18 years old and older 
provided written informed consent. Written informed consent for 
participants younger than 18 years of age was obtained from the parent or 
guardian and assent was obtained from the participants. 
The population-based control cohort comprised 1,057 non-diabetic 
children of European ancestry, aged 5-20 years, enrolled in the Bone 
Mineral Density in Childhood Study (BMDCS). Subjects were randomly 
recruited from five different centers in the US. As previously reported, 
enrollment criteria included healthy, normally developing children. Each 
participating center received approval of the study by their respective 
institutional review boards.  
Since BMDCS consists of European-descent children ascertained from 
the United States, while the LADA cases were adults ascertained from the 
UK and Germany, we also leveraged 2,820 healthy adult British Birth 
Cohort controls from the Wellcome Trust Case Control Consortium 
(WTCCC) (Wellcome Trust Case Control Consortium, 2007) to act as an 
extra set of controls to verify our observations. Principal component 
analysis (PCA) showed that BMDCS controls were well-matched with 
cases despite ascertainment in the United States, while the WTCCC 
controls were stratified (Appendix: Supp. Figure 3-1), principally due to 
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differences in the genotyping arrays used. Thus, BMDCS was used in the 
primary analyses, with verification in the WTCCC cohort. Our study also 
utilized publicly available childhood-onset T1D (n=2,000) and adult-onset 
T2D (n=1,999) from the Wellcome Trust Case Control Consortium; these 
individuals were recruited within England, Scotland and Wales (Wellcome 
Trust Case Control Consortium, 2007).  Individual data from WTCCC is 
available through the Consortium’s Data access committee 
(http://www.wtccc.org.uk).   
 
Genotyping 
LADA samples and BMDCS controls were genotyped on the Illumina 
Infinium II OMNI Express plus Exome BeadChip array (Illuminia, San 
Diego, CA, USA) at the Children’s Hospital of Philadelphia Center for 
Applied Genomics (Philadelphia, PA, USA). WTCCC T1D and T2D cases 
were genotyped on the Affymetrix 500K genotype array. WTCCC control 
samples consisted of 3,000 1958 British Birth Cohort control samples 
genotyped on the Illumina 660K genotyping array. The genomic inflation 
factor for the pruned genome-wide SNPs is 0.966 and the QQ-plot can be 
found in Appendix: Supp. Figure 3-2.  
 
Quality Control and Imputation  
PLINK (Purcell et al., 2007) was used to exclude individuals with 
incorrect gender assignments or whose gender could not be determined 
by genotype, duplicate individuals, and individuals with missing genotype 
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rate >5%. Principal component analysis was used to exclude ethnic 
outliers. Single nucleotide polymorphisms (SNPs) with a call rate <95%, 
minor allele frequency <0.5%, Hardy-Weinberg equilibrium P<10-5 and 
with A/T and G/C alleles were removed. After quality control, genotypes 
were imputed to the 1000 Genome Phase I Integrated Release Version 3 
reference panel. A two-step imputation process was performed using 
SHAPEIT (O’Connell et al., 2014) for haplotype phasing and IMPUTE2 
(Howie et al., 2012) for imputation. All SNPs in this study had imputation 
quality scores >0.40. 
 
Individual candidate SNP association tests 
To investigate the role of previously discovered T1D and T2D variants 
in LADA, we tested 67 T1D SNPs (from Immunobase; 
http://www.immunobase.org and 71 T2D SNPs (from the T2D study led by 
the DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) 
Consortium (DIAGRAM et al., 2014)). Association between each SNP and 
case/control status was assessed using a univariate linear mixed model 
within GEMMA (Zhou & Stephens, 2012). This model accounts for 
population stratification and relatedness using the Wald test and the 
restricted maximum likelihood estimate of ß. We tested each SNP in 
LADA cases versus BMDCS controls and in LADA cases versus T1D or 
T2D cases. Significant associations were called after Bonferroni correction 
for multiple testing. Analysis was performed for all LADA cases (n=978), 
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LADA cases positive for GADA only (n=669), and LADA cases positive for 
both GADA and IA2A (n=309). Approximated odds ratios were calculated 
using µ (intercept) and b (effect size) estimates from the linear mixed 
model, with the formula: OR =
!
"#(%&#) (Zhou & Stephens, 2012). 
 
Genetic risk scores (GRS) 
We calculated two GRS using 69 T1D SNPs and 71 T2D SNPs for 
T1D cases (n=1,990), T2D cases (n=1,960), LADA cases (n=978), LADA 
cases positive for GADA only (n=669), LADA cases restricted on GADA+ 
IA2A+ status (n=309), and BMDCS controls (n=1,057). Weights utilized for 
the scores were derived from published odds ratios (ORs) from T1Dbase 
(t1dbase.org) or a previous publication (Morris et al., 2012), respectively. 
Two SNPs, rs2187668 and rs7454108, were used to infer HLA 
DR3/DR4/DQ8 haplotypes, and additional HLA SNPs tagging HLA-A, 
HLA-B, and DRB1 haplotypes were included (Oram et al., 2016; Winkler 
et al., 2014). rs7111341 and rs11171710 did not have publicly available 
ORs, and rs7202877, implicated in both T1D and T2D (Appendix: Supp. 
Table 3-1), so these were excluded. Each GRS was calculated using 
PLINK by multiplying the number of risk-increasing alleles by the natural 
log of the OR at each locus and summing across risk loci for each 
individual. Logistic regression and receiver operating characteristic (ROC) 
curve analyses evaluated how well these GRS distinguished LADA cases 
from BMDCS controls (using the PredictABEL package (Kundu et al., 
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2011)). We repeated the GRS calculation for GADA+ and IA2+ LADA 
cases and for GADA+, IA2A- LADA cases. Additionally, we combined the 
T1D and T2D SNPs (139 SNPs) and classified LADA and controls for both 
LADA groups. The distributions of the T1D and T2D GRS of the five 
groups were compared using the Wilcoxon rank sum test accounting for 
multiple comparisons (using a Bonferroni correction). Control samples 
were obtained from the WTCCC study, as described above. 
3.3 Results 
T1D loci: 
Four T1D SNPs were significantly associated with LADA and survived 
multiple testing correction (P=0.05/67 loci tested =7.46x10-4; Table 3-1 
and Appendix: Supp. Table 3-2). The strongest association was in the 
MHC region (OR=1.46 P=9.64x10-11). Strong association was also 
observed for variants at PTPN22 (OR=1.47; P=6.38x10-6), SH2B3 
(OR=1.28; P=1.10x10-5), and INS (OR=1.27; P=2.39x10-4). The 
association signal within the MHC region was significantly different 
between LADA and T1D cases (Pdifference=1.26x10-17), with the T1D risk 
allele of rs9272346 (A) less common in LADA than in T1D, but still at a 
higher frequency than in controls. The signals at INS and SMARCE1 also 
yielded significant differences between LADA and T1D (Pdifference=3.88x10-
4 
and 6.54x10
-4
, respectively). The INS signal was more common in LADA 
than in either T1D or controls, while the frequency of the SMARCE1 signal 
was lower in LADA than in T1D but similar to controls.  
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Table 3-1 Association of established T1D loci with LADA. Only T1D variants 
significantly associated with LADA are shown (LADA Association P-value), as well as 
signals significantly different between LADA and T1D (LADA vs. T1D P-value), with a 
significance threshold of p = 7.46 x 10
-4
. The locus reported is the closest gene of interest 
to the signal (a full list of genes is provided in Appendix: Supp. Table 3-2). The risk and 
other alleles reported refer to the alleles in T1D, and the following allele frequencies refer 
to the frequency of the risk allele reported in T1D for LADA, T1D and BMDCS control 
group. Odds ratios of the risk allele reported are derived from the BMDCS control data 
set (n=1,057), the WTCCC T1D (n=1,990), and the LADA cases (n=978).  
 
To further understand the influence of antibody status on the clinical 
classification of LADA, the same analyses were carried out for 669 
GADA+ LADA subjects (Appendix: Supp. Table 3-3). The MHC region 
was the only signal surviving correction for multiple comparison for cases 
against controls, as well as cases versus T1D (OR=1.30; P=6.84x10-5, 
Pdifference=1.99x10-24). 
In the restricted subset of GADA+ IA2A+ LADA cases (n=309), four 
loci were associated (Table 3-2 and Appendix: Supp. Table 3-4). The 
MHC (OR=1.98; P=1.20x10-15), PTPN22 (OR=1.86; P=2.19x10-6), SH2B3 
(OR=1.48; P=5.93x10-6), and INS (rs689; OR=1.44; P=1.90x10-4) signals 
remained strongly associated and had stronger ORs in this constrained 
setting. However, the risk increasing allele at the MHC locus remained 
Locus SNP T1D Alleles Risk/Other 
Risk Allele Frequency LADA Odds Ratio LADA P-value 
LADA vs T1D P-
value 
LADA T1D Control    
MHC rs9272346   A/G 0.686 0.818 0.579 1.455 [1.427-1.483] 9.6x10-11 1.26x10-17 
PTPN22 rs6679677 A/C 0.143 0.17 0.093 1.469 [1.427-1.510] 6.38x10-6 2.61x10-2 
SH2B3 rs17696736 G/A 0.515 0.503 0.44 1.277 [1.250-1.304] 1.10x10-5 0.542 
INS rs689 T/A 0.796 0.741 0.73 1.265 [1.234-1.296] 2.39x10-4 3.88x10-4 
SMARCE1 rs7221109 C/T 0.621 0.687 0.632 0.954 [0.925-0.983] 0.423 6.54x10-4 
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significantly less than that in T1D cases. Two partially independent signals 
near INS (r2=0.278) yielded a significant difference between T1D and 
GADA+ IA2A+ LADA in this restricted dataset, rs689 (Pdifference=1.68x10-6) 
and rs7111341 (Pdifference=2.39x10-4).  
 
Locus SNP T1D Alleles Risk/Other 
Risk Allele Frequency 
LADA Odds Ratio 
LADA P-
value 
LADA vs T1D P-value 
LADA T1D Control 
MHC rs9272346 A/G 0.763 0.818 0.579 1.983 [1.954-2.012] 1.20x10-15 4.01x10-3 
PTPN22 rs6679677 A/C 0.17 0.17 0.093 1.864 [1.819-1.909] 2.19x10-6 0.603 
SH2B3 rs17696736 G/A 0.542 0.503 0.44 1.481 [1.452-1.511] 5.93x10-6 0.180 
INS* rs689 T/A 0.824 0.741 0.73 1.440 [1.407-1.474] 1.90x10-4 1.68x10-6 
INS* rs7111341 C/T 0.812 0.75 0.73 1.360 [1.327-1.394] 1.82x10-3 2.39x10-4 
 
Table 3-2 Association of established T1D loci in LADA subjects positive for both 
GADA and IA2A.Only T1D variants significantly associated with LADA are shown (LADA 
Association P-value), as well as signals significantly different between LADA and T1D 
(LADA vs. T1D P-value). Significance threshold is 7.46x10-4 after correcting for multiple 
comparison. The locus reported is the closest, well-known gene of interest to the signal 
(a full list of genes is provided in Appendix: Supp. Table 3-3). The risk and other alleles 
reported refer to the alleles in T1D, and the following allele frequencies refer to the 
frequency of the risk allele reported in T1D for LADA, T1D and BMDCS control group. 
Odds ratios of the risk allele reported are derived from the BMDCS control data set 
(n=1,057), the WTCCC T1D (n=1,990), and the constrained N LADA cases (n=309). 
*Independent signals (INS signals have a r
2
=0.278) 
 
 
 
T2D loci: 
Only one T2D signal survived correction for multiple comparisons 
(P=0.05/71 loci =7.04x10-4) in LADA cases, the HNF1A locus (OR=1.291; 
P=3.42x10-4; Table 3-3 and Appendix: Supp. Table 3-5). Contrary to 
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previous reports (Cervin et al., 2008; Lukacs et al., 2012; Zampetti et al., 
2010), the T2D risk allele (rs7903146-T) at TCF7L2 was not enriched 
among LADA cases, with a frequency close to that of controls (0.295 vs. 
0.298, respectively); indeed, the TCF7L2 signal was the most significantly 
different signal between LADA and T2D cases (Pdifference=5.21x10-6). In the 
GADA+ restricted set, there were no association signals surviving 
correction for multiple comparisons, and the only signal showing a 
significant difference between LADA and T2D was the depletion of the 
TCF7L2 T allele (Pdifference=5.03x10-4; Appendix: Supp. Table 3-6), where 
the T allele showed modest, albeit non-significant excess when compared 
to controls (OR=1.088). 
 
 
Table 3-3 Association of established T2D loci with LADA. Only T2D variants that 
significantly associated with LADA after correcting for multiple comparison (p<7.04x10
-4
) 
are shown (LADA Association P-value), as well as variants significantly different between 
LADA and T2D (LADA vs. T2D P-value). The locus reported is the closest, well-known 
gene of interest to the signal (a full list of genes is provided in Appendix: Supp. Table 3-
4). The risk and other alleles reported refer to the alleles in T2D, and the following allele 
frequencies refer to the frequency of the risk allele reported in T2D, for LADA, T2D, and 
BMDCS control groups. Odds ratios of the risk allele reported are derived from the 
BMDCS control data set (n=1,057), the WTCCC T2D (n=1,960), and the LADA cases 
(n=978). *Although the control risk allele frequency is greater than the case risk allele 
frequency, the beta calculated from the linear mixed model is adjusted effects after 
controlling for population stratification, resulting in an OR slightly above 1. 
 
In the restricted set of 309 GADA+ IA2A+ LADA subjects, HNF1A 
continued to yield a significant association (OR=1.47; P=2.52x10-4; Table 
Locus SNP 
T2D Alleles 
Risk/Other 
Risk Allele Frequency 
LADA Odds Ratio LADA P-value 
LADA vs T2D P-
value 
LADA T2D Control 
HNF1A rs12427353 G/C 0.831 0.828 0.787 1.291 [1.256-1.326] 3.42x10-4 0.538 
TCF7L2
* 
rs7903146 T/C 0.295 0.376 0.298 1.023 [0.994-1.053] 0.702 5.21x10-6 
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3-4 and Appendix: Supp. Table 3-7). Again, the TCF7L2 locus was 
significantly different between LADA and T2D cases (Pdifference=2.56x10-7), 
with the risk allele frequency even less than that in controls in this 
restricted case set (allele frequency of 0.251 versus 0.298 in LADA and 
controls, respectively). 
Leveraging 2,820 healthy adult British subjects from the WTCCC as 
alternative controls, we observed very consistent results overall 
(Appendix: Supp. Table 3-8 and Supplemental Results) despite the 
array differences for this set.  
 
Table 3-4 Association between established T2D loci in LADA cases positive for 
GAD and IA2 autoantibodies.T2D variants that were significantly associated in LADA 
cases positive for GAD and IA2 autoantibodies (n=309) (LADA Association P-value) are 
shown, as well as signals that were significantly different between LADA and T2D cases 
(LADA vs. T2D P-value). The significance threshold was set to P<7.04x10
-4
 to correct for 
multiple testing. The locus reported is the closest, well-known gene of interest to the 
signal (a full list of genes is provided in Appendix: Supp. Table 3-5). T2D risk allele 
frequencies reported are derived from the BMDCS control data set (n=1,057), the 
WTCCC T2D (n=1,960), and the LADA cases positive for autoantibodies GADA and IA2A 
(n=309). The odds ratios for LADA are shown both GEMMA-corrected (for relatedness 
and batch effects) and uncorrected. 
 
Genetic risk scores 
A high T1D GRS implies a high genetic risk for that disease. Figure 3-
1 shows that the T1D GRS better predicted whether a subject is a LADA 
case or control than the T2D GRS. The areas under the curve (AUC) for 
Locus SNP T2D Alleles Risk/Other 
Risk Allele Frequency 
LADA Odds Ratio LADA P-value LADA vs T2D P-value 
LADA T2D Control 
HNF1A rs12427353 G/C 0.857 0.828 0.787 1.474 [1.438-1.511] 2.52x10-4 5.42x10-2 
ZBED3 rs6878122 A/G 0.744 0.658 0.706 1.216 [1.184-1.249] 3.86x10-2 1.47x10-5 
TCF7L2 rs7903146 T/C 0.251 0.376 0.298 0.852 [0.820-0.883] 8.14x10-2 2.56x10-7 
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the T1D and the T2D GRS were 0.667 and 0.565, respectively (Figure 3-
1A). Thus, when considering adult-onset diabetes patients who do not 
initially require insulin, genetic risk defined for T1D could better identify 
autoimmune diabetes cases than genetic risk defined for T2D. 
This result was more pronounced when considering controls versus 
309 GADA+ IA2A+ LADA cases (Figure 3-1B) (AUC for T1D GRS=0.760, 
T2D GRS=0.496). However, these results were less pronounced for the 
669 GADA+ only LADA cases versus controls (Figure 3-1C) (AUC for 
T1D GRS=0.623, T2D GRS=0.597). The combined effect of genetic risk 
using both T1D and T2D SNPs marginally improved classification of LADA 
cases and controls (AUC=0.673) and classification of GADA+ LADA and 
controls (AUC=0.635). However, there was no improvement of 
classification between GADA+ IA2A+ LADA and controls (AUC=0.755) 
using a combination of T1D-T2D SNPs. To highlight the important role of 
non-HLA loci in discrimination, we calculated T1D GRS without the HLA 
region and an HLA only GRS. Additionally, we tested these five models of 
GRS in discrimination between LADA versus T1D and GADA+ only LADA 
cases versus GADA+IA2A+ LADA cases (Appendix: Supp. Figure 3-3). 
The HLA alone accounts for a strong difference between all LADA cases 
and T1D cases (AUC=0.699), especially between T1D and GADA+ only 
LADA cases (AUC = 0.733). The non-HLA GRS has AUC of 0.655 for 
distinguishing GADA+IA2A+ LADA cases from BMDCS controls.  HLA 
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only GRS has an AUC of 0.737 for distinguishing GADA+IA2A+ LADA 
cases from BMDCS controls, but combining these loci, the AUC is 0.76.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-1 T1D and T2D genetic risk scores tested in LADA cases and controls. 
Weighted genetic risk scores (GRS) for T1D (black) and T2D (red) were calculated by 
summing over all the risk alleles (T1D/T2D SNPs). The scores were tested in A) 978 
LADA cases and 1,057 healthy controls B) 309 autoantibody-positive (GADA, IA2A) 
LADA cases and 1,057 controls C) 669 GADA only autoantibody positive. The ability of 
the GRS to discriminate between cases and controls was assessed by receiver operator 
characteristic (ROC) analysis. The area under the curve (AUC) was 0.667 and 0.565 for 
T1D and T2D, respectively, in the set with all LADA cases, 0.76 for T1D and 0.496 for 
T2D in the GADA, IA2Aautoantibody-positive restricted set, and 0.623 for T1D, 0.597 for 
T2D in the GADA only autoantibody positive restricted set. A combination of T1D and 
T2D SNPs (green) had an AUC of 0.673 for all samples,0.755 for the GADA+ IA2A+ 
restricted set and 0·635 for the GADA only restricted set. 
Figure 1: T1D and T2D genetic risk scores tested in LADA cases and controls. Weighted genetic 
risk scores (GRS) for T1D (black) and T2D (red) were calculated by summing over all the risk alleles 
(T1D/T2D SNPs). The scores were tested in A) 978 LADA cases and 1,057 healthy controls B) 309 
autoantibody-positive (GADA, IA2A) LADA cases and 1,057 controls C) 669 GADA only autoantibody-
positive. The ability of the GRS to discriminate between cases and controls was assessed by receiver 
operator characteristic (ROC) analysis. The area under the curve (AUC) was 0·667 and 0·565 for T1D 
and T2D, respectively, in the set with all LADA cases, 0·76 for T1D and 0·496 for T2D in the GADA, IA2A 
autoantibody-positive restricted set, and 0·623 for T1D, 0·597 for T2D in the GADA only autoantibody-
positive restricted set. A combination of T1D and T2D SNPs (green) had an AUC of 0·673 for all samples, 
0·755 for the GADA+ IA2A+ restricted set and 0·635 for the GADA only restricted set. 
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Comparison of the T1D SNP-GRS distributions among the six groups 
(T1D, T2D, LADA, GADA+ IA2A+ LADA, GADA+ only LADA and controls; 
Figure 3-2A) revealed significant differences between all pairs (P<10-5), 
except T2D versus controls. This observation is expected as T2D cases 
should not harbor a high load of T1D risk alleles. Furthermore, there were 
only nominally significant differences between LADA and GADA+ only 
LADA cases. Of particular note, there was a significant difference in the 
T1D GRS distribution between T1D and GADA+ IA2A+ LADA, highlighting 
genetic differences between LADA restricted on IA2A+ status and T1D 
(P=0.0001). 
Comparison of the distributions of the T2D SNP-GRS (Figure 3-2B) 
revealed significant differences between LADA and T2D cases 
(P=3.50x10-11) and between the GADA+ IA2A+ LADA and T2D cases 
(P=3.50x10-16). These results suggest T2D risk alleles are not enriched in 
LADA, concordant with the results of our single-SNP analyses. However, 
the T2D SNP-GRS distribution was also significantly different between 
LADA and T1D cases (P=6.10x10-11) and controls (P=8.00x10-6). The T2D 
risk allele load, although not as high as for T2D, is still higher than that 
seen in T1D or among the healthy population. We observed a nominally 
significant difference for T2D risk allele load between GADA+ only LADA 
and T2D cases (P=5.60x10-3) and no statistically significant difference 
between GADA+ only LADA and overall LADA cases. 
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Figure 3-2 GRS distributions between T1D cases, T2D cases, LADA cases, LADA 
restricted cases, and controls. The GRS distributions were compared across 
individuals diagnosed with T1D (n=1,990), T2D (n=1,960), LADA (n=978), LADA 
restricted (n=309), LADA GADA+ only (n=669) and BMDCS controls (n=1,057).  (A) 
Violin plots of the distributions of the GRS calculated using the T1D SNPS for the five 
groups. A multiple comparison test (Wilcoxon rank sum test) was performed to calculate 
the significance of pair-wise differences.  (B) Violin plots of the distributions of the GRS 
calculated using the T2D SNPS for the five groups. A multiple comparison test (Wilcoxon 
rank sum test) was performed to calculate the significance of pair-wise differences. We 
include some of the significant P-values to highlight key differences. (***P <10-5, **P 
<0·0001, *P <0·05). 
 
3.4 Discussion  
Defining LADA as a distinct form of T1D has two broad benefits. First, 
it highlights the potential to understand what determines both the degree 
A B 
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and rate of disease progression. Second, it helps define differences 
between adult-onset autoimmune diabetes, including LADA, and T2D in 
terms of co-morbidities and putative therapy (Leslie et al., 2016).  
Leveraging children whose future diabetes risk is unknown represents the 
most conservative setting in which to conduct this study given they serve 
as excellent population-based controls in which to contrast the cases; 
however, the conservative nature of the approach may result in some 
false negative results. 
To shed light on the genetic etiology of LADA, we tested the impact of 
established T1D and T2D risk loci in the largest set of LADA cases 
collected to date. Our study differs from a previous association study with 
GWAS-implicated loci in adult-onset autoimmune diabetes (Howson et al., 
2011); first, our LADA cases are distinguished by the fact that they were 
not treated with insulin upon diagnosis. Furthermore, our study looked at a 
larger set of T1D and T2D loci, as well as comparing their roles in LADA 
against T1D and T2D, including taking population substructure into 
account. As with Howson et al (Howson et al., 2011), we observed 
significant association of the T1D loci PTPN22, INS, HLA, and SH2B3. 
However, we did not observe significant association with the CLEC16A, 
IL2RA, CTLA4 and STAT loci. Despite published data observing the 
association of T2D locus TCF7L2 with a subset of T1D patients (Redondo 
et al., 2017; Redondo et al., 2014), our study did not observe an 
association of this locus with LADA; one possibility could be that we used 
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population-based controls, while previous studies may have used a 
different control strategy where the difference in the risk allele was more 
evident due to its under-representation in relatively disease-free controls. 
Our study goes further by leveraging GRS to offer a further line of 
evidence for the classification of diabetes subtypes, complementing 
standards for clinical decision making and additional standardized 
(antibody) testing, each with their strengths and weaknesses. 
LADA shows the MHC risk found in adult-onset T1D (Howson et al., 
2011) with a reduced genetic susceptibility at this locus compared with 
childhood-onset T1D. Less clear is whether T2D loci play a role in adult-
onset autoimmune diabetes. Our results show that genetic signals 
implicated in T1D or T2D both play a role in LADA, with four T1D loci and 
one T2D locus significantly associated with this form of diabetes. LADA is 
genetically more similar to T1D, especially when cases are constrained on 
both GADA+ and IA2A+, although LADA shares part of its genetic etiology 
with T2D. When constrained on GADA+ only, LADA cases became less 
distinct from T2D, highlighting the importance of IA2A in discriminating 
LADA within the T1D-T2D spectrum. By implication, a GRS derived from 
T1D can discriminate, to a degree, non-insulin requiring adult-onset 
diabetes patients with either autoimmune diabetes or T2D. 
Regarding the loci implicated in T1D, our results are consistent with 
previous studies showing a major role for the MHC, PTPN22 and INS loci 
in LADA (Cervin et al., 2008; Desai et al., 2006, 2007a). Interestingly, the 
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risk allele frequency at INS (rs689) was even more strongly associated 
with LADA than with T1D. Therefore, our data strongly points to common 
insulin-related pathways underpinning autoimmune diabetes irrespective 
of the age at onset of the disease. Given the evidence that age at 
diagnosis is genetically determined (Fava et al., 1998), these loci may play 
a key role in determining the age at disease onset and the rate of disease 
progression. 
While our results suggest LADA is genetically closer to T1D than to 
T2D, we observed an association at one T2D locus, HNF1A, known to be 
associated with T2D and ‘maturity-onset diabetes of the young’; strikingly, 
the HNF1A signal remained significantly associated with LADA even in the 
cohort enriched for both T1D autoantibodies. Nevertheless, the nature of 
the role of HNF1A in LADA is unclear, although any gene compromising 
insulin secretory function could predispose to diabetes. This is the first 
report describing an association between this T2D-associated risk allele 
and LADA, although this locus has been previously implicated in T1D 
(Andersen et al., 2014). Additionally, the strongest T2D-associated locus, 
TCF7L2, has been associated with LADA in a Finnish cohort ( Andersen 
et al., 2014; Lukacs et al., 2012; Zampetti et al., 2010), but in our study, 
the risk allele frequency in LADA was very close to that of controls and 
lower than controls in GADA+ IA2A+ LADA.  Our findings were further 
supported by leveraging healthy adult British controls from the WTCCC 
which provided overall consistent results, including for the HNF1A signal.  
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However, given the borderline association of T2D loci identified and the 
modest power in this single study, these signals must be subjected to 
replication efforts by independent investigators in order to fully validate 
these observations. 
We found that GRS calculated from T1D and T2D-implicated SNPs, 
which distinguished LADA cases from controls, with the T1D GRS 
performing better than the T2D GRS; this difference was particularly 
striking in GADA+ IA2A+ LADA cases. Comparison of GRS between the 
six defined groups placed LADA in-between T1D and T2D but closer to 
T1D. GADA+ IA2A+ LADA was very similar to T1D, primarily because 
such constraint filters out "T2D like" cases and enriches for "T1D like" 
cases. The potential for clinical, immunological, or genetic filters to define 
forms of diabetes is emphasized by the marked overlap in GRS scores, 
even between T1D and controls.  
This study does have limitations. First, GADA+ only LADA cases had a 
T2D-SNP GRS distribution more similar to T2D than controls.  The 
specific association between the T2D risk score and GADA+ only LADA 
cases could be in part due to the fact that approximately 1% of all cases 
are widely considered to be false antibody-positive T2D. Thus, larger 
studies may resolve whether T2D risk alleles play a role in LADA. Indeed, 
this study was underpowered to identify specific associations other than 
for HNF1A. Second, two different genotyping arrays were utilized; thus, to 
correct for potential batch effects due to genotype array differences, 
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population substructure, and relatedness among samples, we used a 
linear mixed model, resulting in highly conservative effect estimates. 
Consequently, it is possible we have missed some true positive 
associations since we robustly controlled for false positive results. 
The current nomenclature to classify diabetes, designating it as ‘T1D’ 
or ‘T2D’, was adopted to foster research and appropriate therapy for 
different phenotypic presentations. The combination of GRS, age at 
diagnosis, clinical phenotype, autoantibody assays, and C-peptide 
estimates as a proxy for insulin secretion, affords a more sophisticated 
approach with the potential to dissect the heterogeneity of diabetes (Oram 
et al., 2016).  This study highlights the uncertainty of the current 
classification of diabetes (Schwartz et al., 2016). These results suggest 
that clinical phenotype alone is insufficient to define the major types of 
diabetes. To better treat the various diabetes subtypes, we need to 
integrate the use of clinical phenotype, metabolic status, immune 
changes, and underlying genetic risk. 
 
3.5 Conclusion 
LADA is genetically closer to T1D than T2D, although the genetic load of 
T1D risk alleles is less than childhood-onset T1D, particularly at the MHC, 
potentially accounting for the later disease-onset. Our results show that 
the genetic spectrum of T1D extends into adult-onset diabetes, where it 
can clinically masquerade as T2D. Furthermore, T2D genetic risk plays a 
small role in LADA, with a degree of evidence for the HNF1A locus, 
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highlighting the potential for GRS to contribute towards defining diabetes 
subtypes. 
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CHAPTER 4. HERITABILITY OF LADA 
4.1 Introduction 
Estimating heritability is central to studying and assessing the risk for genetic 
disease pathogenesis. Heritability is the proportion of phenotypic variance 
attributable to genetic variance (Visscher et al., 2008). Supporting evidence for 
trait heritability has been demonstrated through family (Falconer, 1965) and twin 
studies (Boomsma et al., 2002). For example, if the incidence of a given disease 
is higher among relatives of affected subjects than among individuals from the 
general population, this suggests heritable factors play a role in the disease. 
Additional evidence supporting a detectable genetic component is when 
monozygotic twins show more similarity for a particular disease compared to 
dizygotic twins.  Although twin studies are classical approaches for minimizing 
environmental effects, obtaining sufficiently large sample sizes of family and twin 
material can often be relatively challenging. Additionally, observations from twin 
and family studies alone do not determine heritability estimates. 
 
Alternatively, recent methods have started to leverage high throughput 
microarray genotype data to detect the fraction of phenotypic differences 
explained by the additive contributions from single nucleotide polymorphisms 
(SNPs). Consequently, the estimated heritability by these recent methods is 
represented by the total variance explained by SNPs (‘SNP heritability’). In 
contrast to family and twin studies, individuals are typically unrelated in these 
genotyped datasets. It is also important to note that heritability estimates from 
family studies are represented by narrow-sense heritability, which is phenotypic 
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variance due to any type of additive genetic variation, not just SNPs. On the 
other hand,heritability estimates from twin studies are represented by broad–
sense heritability, which is the proportion of phenotypic variance due to all 
genetic variation (i.e. dominance and epistasis) (Falconer, 1965). Therefore, SNP 
heritability should not be confused with narrow-sense and broad-sense 
heritability, and comparison of heritability estimates reported by different 
approaches should be interpreted cautiously. Three tools capable of SNP 
heritability estimation are: ‘genome-wide complex trait analysis’ (GCTA) (Yang et 
al., 2011), ‘Linkage-Disequilibrium Adjusted Kinships’ (LDAK) (Speed et al., 
2012) and ‘linkage disequilibrium score regression’ (LDSC) (Bulik-Sullivan et al., 
2015).  
 
GCTA and LDAK estimate SNP heritability for a given complex trait from 
individual genotype data, while LDSC requires summary statistics derived from 
genome-wide association studies (GWAS). GCTA assumes a linear mixed 
model, in which SNP effects are normally distributed, along with fixed effects 
such as gender and principal components. A key step in the GCTA model is 
calculating the genetic relationship between pairwise individuals from all the 
autosomal SNPs, with this data stored in a genetic relationship matrix (GRM). 
LDAK is an extension of GCTA, where GRMs (termed kinship matrices in the 
LDAK model) are adjusted for linkage disequilibrium (LD) by adding weights to 
SNPs. Both GCTA and LDAK estimatevariance components using the restricted 
maximum likelihood (REML) method (Patterson & Thompson, 1971). REML is an 
estimation procedure that maximizes the log-likelihood of the linear mixed model 
by estimating the unknown parameter, in this case variance components, from 
the data available. LDSC, on-the-other-hand, assumes a simple polygenic model 
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and estimates heritability by solving the slope of the regression line produced 
when regressing test statistics from GWAS against LD score. Each SNP has an 
LD score which is defined by the sum of its r2 (Pearson’s correlation coefficient) 
with every SNP within a 1cM window.
 
Under the GCTA and LDSC models, two 
SNPs in the same region have the same expected contribution to heritability 
regardless of LD, whereas LDAK models variants in perfect LD as contributing 
less to heritability than two SNPs exhibiting no LD. Both the GCTA and LDSC are 
commonly used, while LDAK is a relatively more recent method. 
 
In this study, GCTA, LDAK, and LDSC were used to estimate SNP heritability for 
latent autoimmune diabetes in adults (LADA) for the first time. LADA is 
commonly referred to as “type 1.5 diabetes” because of its shared features with 
type 1 diabetes (T1D) and type 2 diabetes (T2D). T1D and T2D risk are known to 
be driven by a strong genetic component. In particular, previous studies have 
shown T1D to be more heritable than T2D (88% vs 26%, respectively), with first-
degree relatives of T1D cases at ~15 times greater risk of presenting with the 
disease than the general population, while first degree relatives of individuals 
with T2D are only ~3 times more likely to present with the disease than 
individuals without a family history (Florez et al., 2003; Hyttinen et al., 2003; 
Poulsen et al., 1999). Despite the number of published heritability studies on 
these two classic forms of diabetes, there is currently no report of heritability 
estimates for LADA. Given that LADA shares features of both T1D and T2D, 
LADA heritability estimates are hypothesized to fall somewhere between T1D 
and T2D estimates.  
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4.2 Materials & Methods 
Data 
The raw dataset consisted of 2,843 LADA cases of European ancestry and 1,885 
controls from the Bone Mineral Density Childhood Study (BMDCS). LADA cases 
were from ‘ActionLada+Plus’ (British, American, and German), DIREVA 
(Finnish), BOTNIA (Finnish), ANDIS (Swedish), and SDR (Swedish) (these 
cohorts are further described in Appendix: Supp. Table 5-1).  LADA diagnosis 
criteria was defined by the presence of diabetes-associated autoantibodies and 
the lack of insulin requirement for at least 6 months after diagnosis. Additionally, 
diagnosis criteria included an age at diagnosis greater than 35 years old for all 
cohorts except ActionLada+Plus, where age at diagnosis criteria was between 30 
and 70 years old.  
 
 
 
Quality Control and Imputation 
LADA samples were genotyped on the Illumina Infinium II Omni Express 
BeadChip and Illumina Infinium Core array (Illumina, San Diego, CA, USA). 
BMDCS controls were genotyped on the Illumina Infinium II OmniExpress. Post-
genotyping quality control was performed using PLINK, including removal of 
samples with a call rate less than 95%, ambiguous gender, excess or reduced 
heterozygosity, and related individuals. The threshold for removing individuals 
with relatedness was pi_hat greater than 0.185, which was based on a pruned 
dataset. A correlation-squared threshold of 0.5 and a window of 10Mb was used 
for pruning SNPs. Individuals with divergent ancestry were removed from the 
analysis. At the end, 2,706 LADA cases and 1,254 controls remained. The 
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majority of controls were removed due to divergent ancestry and the remaining 
samples were removed due to relatedness and excess/reduced heterozygosity. 
Monomorphic SNPs were removed, as well as SNPs with minor allele 
frequencies (MAF) less than 5% or missingness rate less than 95%. Majority of 
SNPs were removed when merging all datasets. The Michigan Haplotype 
Reference Consortium (HRC) imputation service (URL) was utilized to perform 
imputation for autosomal SNPs only. Sex chromosomes were not included in this 
analysis.  
 
Post imputation quality control 
Post-imputation quality control consisted of retaining only biallelic autosomal 
SNPs that have a MAF greater than 1% and an information score greater than 
0.99 (high quality SNPs). To ensure reliable heritability estimates, principal 
component analysis was performed and 20 principal components (PCs), 
suggested by the LDAK protocol, were used as covariates to account for 
population stratification during downstream analysis. Gender and significantly 
associated SNPs were also integrated into the model as fixed effects. There 
were 7,478,177 SNPs remaining after post- imputation quality control. 
 
 
Heritability estimated by GCTA  
After quality control, using GCTA, genetic relationships between pairwise 
individuals from all the autosomal SNPs were calculated and stored in a genetic 
relationship matrix (GRM). Finally, a genetic restricted maximum likelihood 
(GREML) algorithm was used to estimate variance component. SNP heritability 
was calculated using the GRM with gender and 20 PCs as covariates. The GCTA 
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tool was downloaded from the GCTA website 
(http://cnsgenomics.com/software/gcta). The disease prevalence of 0.0028 was 
specified, so that GCTA could transform the estimate of variance explained on 
the observed scale to that on the underlying liability scale. The LADA prevalence 
of 0.0028 was derived from T2D prevalence. Specifically, the expected 
proportion of T2D cases that are misdiagnosed LADA cases (8%) was multiplied 
by prevalence for T2D (0.035) (Maahs et al., 2010; Sinnott et al., 2017). 
 
Heritability estimated by LDAK  
LDAK was implemented on the same imputed dataset used in the GCTA 
analysis. After post-imputation quality control, SNP weights were calculated and 
kinships for each chromosome were computed then merged at the end (these 
were the most time-consuming steps post-imputation). To test for cryptic 
relatedness, a test for inflation was performed(Yang et al., 2011). This is done by 
splitting the whole genome into quarters: the first quarter of the genome 
(chromosome 1-3), the second quarter of the genome (chromosome 4-7), the 
third quarter (chromosome 8-11) and the fourth quarter of the genome 
(chromosome 12-22). The inflation estimate was derived by summing the 
heritability estimates for each quarter subtracted by the heritability estimate for 
the whole genome (inflation = (∑ ℎ*+,-+./ )-ℎ*0123", ). Finally, SNP heritability was 
calculated using the kinship matrix with gender, 20 PCs, and top-associated 
SNPs included as fixed effects. LDAK5 program was downloaded from the LDAK 
website (http://dougspeed.com/ldak/).  
 
Heritability estimated by LDSC  
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Summary statistics for unpublished LADA GWAS meta-analysis, as well as 
published T1D GWAS (Bradfield et al., 2011) and T2D GWAS (Morris et al., 
2012) were leveraged to assess LDSC estimates for the three forms of diabetes. 
The dataset used for GCTA and LDAK is a smaller subset of the dataset used in 
this LADA GWAS meta-analysis and therefore LDSC cannot be directly 
compared to GCTA and LDAK estimates. The number of SNPs in the LADA 
summary statistics was 7,813,592. The LDSC v.1.0.0 python package was used 
to calculate heritability estimates for LADA, T1D and T2D, both with and without 
the major histocompatibility complex (MHC) region. Estimates reported for T2D 
with the MHC region removed were obtained from the publicly available LD-Hub 
(Zheng et al., 2017)website (http://ldsc.broadinstitute.org/).  
 
Power analysis 
GCTA-GREML power calculator was used to assess whether we have a 
large enough sample size to detect heritability 
(http://cnsgenomics.com/shiny/gctaPower). The following assumptions 
were used: 2,706 cases and 1,254 controls, a population prevalence of 
0.0028, variance of the SNP-derived genetic relationships of 2 x 10
-5 
and 
type 1 error of 0.05. The prevalence estimate for T2D was 0.0316 in 2012 
(Sinnott et al., 2017). Prevalence continues to increase so assuming a 
T2D prevalence of 0.035 we also assume a 0.0028 prevalence for LADA, 
which is comparable to the T1D prevalence in 2002 (0.00228). Power was 
calculated for varying heritability estimates: 0.35 (GCTA T2D heritability 
estimate from published study), 0.73 (GCTA T1D heritability estimate from 
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published study), 0.54 (average heritability estimate using T1D and T2D 
estimates). 
4.3 Results 
 
Heritability estimates 
LADA heritability estimates calculated by all three methods fell between 
previous estimates for T1D and T2D (Figure 4-1). Heritability estimates 
for LADA according to the LDSC method were 0.392 and 0.256 (with and 
without the MHC region, respectively) (Table 4-1). Indeed, LDSC 
estimates for LADA are greater than the T2D heritability estimates of 
0.167 and 0.087 (with and without the MHC region, respectively) and less 
than the T1D heritability estimates of 0.785 and 0.282 (with and without 
the MHC region, respectively). Similarly, GCTA-estimated heritability for 
LADA (0.533) was lower than what has been reported for T1D (0.73) but 
higher than what has been reported for T2D (0.35; Table 4-2) (Speed et 
al., 2012). GCTA estimates for LADA are comparable to LDAK’s LADA 
heritability estimate of 0.517, which is also lower than LDAK heritability 
estimates for T1D (0.74) and higher than LDAK’s heritability estimates for 
T2D (0.44) (Speed et al., 2012). Population structure can inflate SNP-
based heritability estimates, and after testing for inflation due to population 
structure using LDAK, an inflation estimate of 0.022 suggests that inflation 
due to population structure is responsible for approximately 4.64% of the 
observed LDAK heritability estimates. According to the power calculator 
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provided by GCTA, there was enough power to detect at least a heritability 
of 0.35 (Table 4-3). 
 
 
 
 
 
 
 
Figure 4-1 Comparison of heritability estimates for T1D (blue), LADA (orange), and 
T2D (gray) across three tools: GCTA, LDSC, and LDAK. The asterisk (*) represents 
estimates reported in published data(Speed et al., 2012; Zheng et al., 2017).  
 
  
LDSC with MHC LDSC without MHC 
T1D 0.785 (0.546)  0.282 (0.131) 
LADA 0.328 (0.096)  0.261 (0.072)  
T2D 0.167 (0.017)     0.087 (0.009)* 
 
Table 4-1 Heritability estimates for T1D, LADA, and T2D derived from the LDSC 
method with and without the MHC. The asterisk (*) represents estimates reported in 
published data(Zheng et al., 2017). Standard error for each estimate is represented by 
values within the parentheses.  
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 GCTA  LDAK 
T1D 
0.73 (0.06)* 0.74 (0.08)* 
LADA 
0.533 (0.038) 0.517(0.14) 
T2D 
0.35 (0.06)* 0.44 (0.08)* 
 
Table 4-2 Heritability estimates for T1D, LADA, and T2D across two tools: GCTA 
and LDAK.The asterisk (*) represents estimates reported in published data(Speed et al., 
2012). Stand deviation for each estimate is represented by values within the 
parentheses.  
 
 
Trait heritability (on liability scale, 
2
) POWER SE NCP 
0.35 1 0.0389 80.8545 
0.54 1 0.0739 192.4668 
0.73 1 0.0739 351.7338 
 
Table 4-3 Power calculation for GCTA, using GCTA-GREML to calculate the probability 
of detecting 
2
 > 0, with 0.05 type 1 error, for LADA cases and controls. Standard error 
(SE) of the SNP-heritability (
2
) is shown as well as the non-centrality parameter (NCP) of 
the chi-squared test statistic. NCP is equal to h
4
/SE
2
. 
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4.4 Discussion  
 
Given that LADA appears to be genetically more similar to T1D (Chapter 3 
(Mishra et al., 2017)), yet still share similar clinical features with T2D (adult age 
of onset and initial insulin independency), heritability estimates are predicted to 
fall in the range between T1D and T2D estimates. All three methods, GCTA, 
LDSC, and LDAK, estimated the heritability of LADA to fall between T1D and 
T2D estimates. In general, unreliable heritability estimates could be due to 
various reasons including cryptic relatedness, population structure or sample 
size. According to the power calculator provided by GCTA, there was enough 
power to detect at least a heritability of 0.35 (based on reports for T2D using 
GCTA). Additionally, more stringent thresholds during quality control are crucial 
for reducing cryptic relatedness. After performing stricter QC and including more 
significant PCs, the inflation due to population structure explained 4.64% of the 
heritability estimated by LDAK (0.517).  
 
A major limiting factor for GCTA and LDAK is computational efficiency. 
Imputation and computing SNP weights are the most time-consuming steps of 
the analysis. In addition to the time-consuming steps introduced by GCTA and 
LDAK, solving the mixed models via REML is a memory-consuming part of the 
analysis that we do not encounter when using LDSC (Speed et al., 2017). LDSC 
is less computationally intensive compared to GCTA and LDAK because the 
method only relies on GWAS summary level data and assumes a simple 
polygenic model.  
 
Despite the feasibility and computational efficiency of LDSC, the LDSC method 
estimates the heritability without the MHC region. However, the MHC region 
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contributes up to 50% of the genetic risk of T1D. Additionally, the strongest 
associated signal in LADA and T1D is located in the MHC. The MHC has also 
been implicated in T2D, which could be a true signal or could be due to the 
unaccounted presence of autoimmune diabetes (LADA cases) (Scott et al., 
2017). Thus, the MHC region should be handled more delicately when applying 
these heritability calculations to autoimmune diabetes. If this region is completely 
removed, then careful interpretation is required as SNPs that are highly 
associated with the disease are no longer accounted for in the analysis. When 
implementing LDSC with and without the MHC region, we not only see the role 
the MHC plays in T1D compared to LADA and T2D, but also the MHC region 
introduces more noise to the estimates for T1D and LADA (standard error: 0.546 
and 0.159, respectively). Previous studies have shown that LDSC tends to have 
large standard deviations, and this is likely due to the difference in parameter 
estimation. LDSC uses method of moments whereas GCTA and LDAK use 
maximum likelihood estimators (REML) to estimate parameters (Speed et al., 
2017).   
 
However, a proper comparison between LDSC versus GCTA and LDAK cannot 
be achieved until LDSC is implemented on the same exact dataset used in the 
GCTA and LDAK analysis. Difference in estimates observed between LDSC and 
the two alternative methods could be due to the additional samples in the meta-
analysis. This study can be furthered developed by performing LDSC on the 
same dataset utilized by GCTA and LDAK to properly compare estimates 
between LDSC versus LDAK and GCTA. Additional future steps include 
repeating LDAK and GCTA analysis using a MAF threshold of 5% during post-
imputation quality control to maintain consistency with genotype quality control 
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and leveraging the Wellcome Trust Case Control Consortium T1D/T2D datasets 
and compare results to published datasets to ensure proper implementation and 
analysis of the three methods. 
 
 
4.5 Conclusion  
The SNP heritability estimates for LADA fall between T1D and T2D according to 
heritability estimates derived by all three methods, thus further supporting the 
observations in Chapter 3 and pointing to the concept of ‘type 1.5 diabetes’. 
LDSC was the fastest and most straight-forward tool to implement, however 
exclusion of the MHC results in much lower heritability estimates and more noise, 
especially when studying autoimmune diseases. Across all three methods, it is 
not clear how MHC should be handled; thus, heritability estimates should be 
carefully interpreted.  
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CHAPTER 5. THE FIRST GENOME-WIDE 
ASSOCIATION STUDY OF LADA 
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5.1 Introduction 
The relationship between LADA and both T1D and T2D is not fully 
elucidated and not appropriately encapsulated in the term ‘type 1.5 
diabetes’ (Ahlqvist et al., 2018; Thomas et al., 2017; Tuomi et al., 2014). 
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In many populations, LADA is at least as prevalent as childhood-onset 
T1D (Hawa et al., 2013), but is frequently misdiagnosed as T2D 
(Laugesen et al., 2015; Tuomi et al., 1999) given its presentation in adults 
without need for insulin. As such, subjects with LADA could be present in 
cohort studies for T2D that do not screen out autoantibody-positive cases, 
potentially resulting in the identification of genetic associations for T2D 
that are etiologically related to autoimmunity. Furthermore, LADA has a 
natural history distinct from that of T2D and is likely mismanaged as a 
result (Laugesen et al., 2015). The challenge to define adult autoimmune 
diabetes, including LADA, as distinct from the generality of T2D is acute 
given the increasingly larger datasets assembled to identify additional, 
common genetic risk factors of increasingly smaller effect sizes. Indeed, 
reflecting this concern, recent genome-wide association study (GWAS) 
analyses of T2D have reported associations at T1D-associated regions 
such as HLA-DQA1 in populations of European ancestry (Scott et al., 
2017) and HLA-B and INS-IGF2 in African ancestry populations (Ng et al., 
2014). As such, understanding the genetic etiology of adult autoimmune 
diabetes will not only aid the characterization of this relatively common 
form of diabetes, but will also facilitate our understanding of both T1D and 
T2D. 
To date, the relatively limited candidate gene studies carried out for LADA 
have supported a role for both T1D and T2D risk loci (Andersen et al., 
2014; Andersen et al., 2010; Bakhtadze et al., 2008; Desai et al., 2007a; 
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Hosszúfalusi et al., 2003; Howson et al., 2011; Mishra et al., 2017; Tuomi 
et al., 2014). Most notable from these previous studies is the implicated 
role of the key type 2-associated TCF7L2 locus in the pathogenesis of 
LADA (Andersen et al., 2014; Bakhtadze et al., 2008; Cervin et al., 2008). 
More recently, we constructed genetic risk scores combining known T1D 
and T2D loci and assessed their impact in LADA, and our results 
implicated a role for both sets of loci (Chapter 3 (Mishra et al., 2017)). 
However, no systematic genome-wide appraisal of adult autoimmune 
diabetes has been performed. Therefore, in this study, we performed the 
first GWAS of LADA against population controls and further contrasted 
LADA against T1D and T2D to better understand its genomic signature in 
comparison to these two better characterized forms of diabetes. 
5.2 Methods 
Study subjects  
Cases diagnosed with LADA were included from cohorts of European ancestry 
(Appendix: Supp. Table 5-1), including ‘ActionLada-Plus,’ All New Diabetics In 
Scania (ANDIS), the Botnia Study, Copenhagen LADA (including samples from 
Danish Centre for strategic Research in Type 2 Diabetes (DD2), Vejle Biobank, 
Odense University Hospital (OUH), Copenhagen Insulin and Metformin Therapy 
trial (CIMT), Inter99, and Steno Diabetes Center (SDC)), the Diabetes Registry 
Vasa (DIREVA), GoDARTS, Nord-Trøndelag Health Study (HUNT), and Scania 
Diabetes Registry (SDR). Controls were population-based (including samples 
from the Bone Mineral Density in Childhood Study (BMDCS), Copenhagen 
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controls (with samples from the 1936 Birth Cohort and ADDITION-PRO), 
GoDARTS, HUNT, and the Malmö Diet and Cancer study, DIREVA, and SDR). 
Inclusion and exclusion criteria for LADA, T1D, T2D, and population controls 
varied by cohort (see Appendix: Supp. Table 5-1 and Supplemental Note for 
details). In general, LADA was defined by an age at diagnosis older than 20, 30 
or 35 years, with some cohorts restricting the upper age limit to 70 years; the 
presence of diabetes-associated autoimmune autoantibodies, in particular 
GADA-positivity; and the lack of insulin requirement for 6 months or 1 year after 
diagnosis. In some cases, C-peptide level was also used as a filter.  
 
Genotyping and imputation 
Each respective cohort performed genome-wide genotyping on the Illumina Core 
Exome chip, the Illumina OmniExpressExome BeadChip, or the Affymetrix 6.0 
array. Cases and controls from each study center were matched on the same 
genotyping chip to reduce batch effects. Standard post-genotyping quality control 
was performed, including sample exclusions for ambiguous gender, call rate < 
95%, and any duplicate or related individuals (pi_hat ≥ 0.2), and SNP exclusions 
for monomorphic SNPs, SNPs with MAF < 0.05, and SNPs with missingness rate 
> 0.05. The Haplotype Reference Consortium (HRC) imputation service 
(Michigan imputation server, https://imputationserver.sph.umich.edu/index.html) 
was utilized to perform imputation for autosomal SNPs.  
 
Genome-wide association and meta-analysis: LADA vs. controls, 
LADA vs. T1D, and LADA vs. T2D 
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SNPTEST (Marchini et al., 2007) or EPACTS 
(http://genome.sph.umich.edu/wiki/EPACTS) was used by each respective cohort 
to perform case-control GWAS of LADA (n = 2,634) vs. population controls (n = 
5,947),  LADA (n = 2,454) vs. cases with T1D (n = 968), and LADA (n = 2,779) 
vs. cases with T2D (n = 10, 396), including sex and principal components as 
covariates (see Appendix: Supp. Table 5-1 for cohort-specific covariates).  
After GWAS, filtering was performed centrally to include only SNPs with a MAF > 
0.05, INFO quality score > 0.4, and a Hardy-Weinberg equilibrium P > 1x10-7. 
Meta-analysis was then performed for LADA vs. population controls, LADA vs. 
T1D, and LADA vs. T2D with GWAMA (Magi & Morris, 2010) with two rounds of 
genomic control (Appendix: Supp. Table 5-2; Supp. Figure 5-1 and 5-2). 
Signals in the secondary tier (P = 1 x 10-6 – 5 x 10-8) for the LADA vs. population 
controls analysis were followed up in the GODARTS and HUNT cohorts (LADA, 
n = 345; controls, n = 1,664) and meta-analyzed with the discovery set (total 
LADA, n = 2,979; controls, n = 7,611) to assess whether any novel signals would 
reach genome-wide significance.  
 
Enrichment of directional consistency among T1D/T2D loci in LADA 
To estimate whether the concordance in direction of effects for T1D and T2D loci 
in LADA is significantly different from chance, a binomial test was used assuming 
a null hypothesis of 50% agreement.  
 
Conditional analysis 
Approximate conditional analysis for known T1D-associated loci was carried out 
for the LADA vs controls summary statistics results for the 10p15.1 locus using 
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Genome-wide Complex Trait Analysis (GCTA) (Yang et al., 2011). For this locus, 
LADA vs controls + HUNT summary statistics were conditioned on the following 
T1D-associated SNPs: rs61839660, rs10795791, rs7090530, rs12251307, 
rs41295121, and rs11258747(Barrett et al., 2009; Bradfield et al., 2011; 
Onengut-Gumuscu et al., 2015). For 12q24.3, two of the T1D-associated SNPs 
(rs3184504 (Barrett et al., 2009) and rs653178 (Onengut-Gumuscu et al., 2015) 
were in high LD (r
2
 > 0.9) with our lead SNP, and the MHC, PTPN22, and INS 
loci were not conditioned as the top signals were identified as T1D-associated 
SNPs. 
 
Stratification analysis by GAD autoantibody titer 
Cases with LADA are heterogeneous in terms of GAD autoantibody titer (Buzzetti 
et al., 2007). Therefore, to further understand the genetic landscape of LADA in 
the context of different GAD levels, we stratified cases into tertiles in ActionLADA 
and ANDIS, DIREVA, and SDR. We performed three GWAS, on (1) the top tertile 
with the highest GAD titers (n = 627) vs. population controls (n = 4314); (2) the 
top two tertiles with the highest GAD titers (n = 1012) vs. population controls (n = 
4314); and (3) the bottom tertile with the lowest GAD titers (n = 562) vs. 
population controls (n = 4314).  
  
LD Score Regression 
To test for genetic correlations genome-wide between LADA, T1D (Aylward et 
al., 2018; Bradfield et al., 2011), and T2D (Mahajan et al., 2018; Morris et al., 
2012), we performed LD score (LDSC) regression using the LDSC v.1.0.0 python 
package (Bulik-Sullivan et al., 2015). 
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Pathway analysis 
DEPICT pathway analysis (Pers et al., 2015) was used to perform gene set 
enrichment, tissue enrichment, and gene prioritization analyses. 
 
 
HLA imputation/analysis 
The HLA imputation software SNP2HLA (Jia et al., 2013) was used to impute 
chromosome 6 in ActionLADA-Plus (n = 1,365), Swedish cases with LADA (n = 
794), BMDCS (n = 1,056) and T1D cases from the WTCCC (n = 1,990). HLA 
alleles with 4-digit resolution were imputed. The R package ‘BIGDAWG’ 
(https://cran.r-project.org/web/packages/BIGDAWG) (Pappas et al., 2016) was 
used to test for allele frequency differences for established T1D-associated HLA 
haplotypes between LADA versus T1D, as well as LADA versus BMDCS. 
Haplotypes with frequencies less than 1% across LADA, T1D, and BMDCS were 
removed from the analysis given that rare haplotypes can result in unstable 
variance estimates and unreliable test statistics. 
 
5.3 Results 
Genome-wide association of LADA versus population controls 
We first conducted GWAS in patients with LADA (n = 2,634) versus population-
based controls (n = 5,947) of European ancestry in a discovery meta-analysis 
setting (Appendix: Suppl. Table 5-1; power calculations can be found in Supp. 
Table 5-3). Four signals achieved genome-wide significance (P < 5x10-8), all at 
established T1D risk loci (HLA, PTPN22, INS, and SH2B3; Table 5-1, Appendix: 
 68 
Supp. Figures 5-1 and 5-2). Pathway analysis with DEPICT (Pers et al., 2015) 
for signals at P < 10-5 supported a strong immune role in the pathogenesis of 
LADA (Appendix: Supp. Tables 5-4 and 5-5), with gene set enrichment 
analysis implicating ‘abnormal cytotoxic T cell physiology’ (nominal P = 6.39 x 10-
7
) as well as the ‘mTOR subnetwork’ (P = 6.03 x 10-5) and ‘cell cycle’ (P = 1.67 x 
10
-5
), and immune system tissue types, including ‘natural killer cells’ and ‘T 
lymphocytes’ (nominal P = 0.0079 and 0.0082, respectively). This is consistent 
with previous reports of these cell types playing a role in the pathogenesis of T1D 
and LADA (Radenkovic et al., 2016; Wang et al., 2015).
 
SNP Chr Position (b37) 
Ref/othe
r allele 
Effect allele freq 
(cases/ctrls) 
O
R 95% CI P Gene 
LADA (n =2,634 ) vs. population controls (n = 5,947) 
rs927
3368 
6 
3262647
5 
A/G 0.50/0.28 
3.1
15 
2.855-
3.398 
7.87x1
0-143 
HLA-
DQB
1 
rs247
6601 
1 
1143775
68 
A/G 
0.159/0.1
02 
1.7
17 
1.539-
1.915 
7.21x1
0-22 
PTP
N22 
rs689 11 2182224 T/A 
0.802/0.7
26 
1.4
83 
1.363-
1.613 
1.07x1
0-19 
INS 
rs731
0615 
12 
1118650
49 
C/G 
0.553/0.4
92 
1.2
84 
1.193-
1.383 
4.92x1
0-11 
SH2
B3 
LADA (n = 2,779) vs. T2D cases (n = 10,396) 
rs927
3368 
6 
3262647
5 
A/G 
0.43/0.30
1 
2.4
39 
2.222-
2.676 
3.17x1
0-78 
HLA-
DQB
1 
rs689 11 2182224 T/A 
0.783/0.7
15 
1.4
73 
1.352-
1.605 
9.86x1
0-19 
INS 
rs247
6601 
1 
1143775
68 
A/G 
0.173/0.1
40 
1.5
29 
1.38-
1.693 
4.52x1
0-16 
PTP
N22 
rs318
4504 
12 
1118846
08 
C/T 
0.544/0.5
2 
1.2
4 
1.151-
1.336 
1.77x1
0-08 
SH2
B3 
LADA (n = 2,454) vs. T1D cases (n = 968) 
rs927
3368 
6 
3262647
5 
A/G 
0.415/0.6
5 
0.3
35 
0.256-
0.385 
8.46x1
0-40 
HLA-
DQB
1 
 
Table 5-1 Genome-wide significant signals associated with LADA. We performed 
three genome-wide association approaches, first for LADA versus population controls 
(top panel), then for LADA versus T1D (T1D, middle panel) and LADA versus T2D (T2D, 
lower panel). Odds ratios (ORs) are given for the LADA risk allele except for rs92773368 
in LADA vs. T1D, to illustrate that the T1D risk allele was depleted in LADA. 
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Replication supports a novel locus at PFKFB3 
Using cases with LADA and population samples from an additional two study 
centers, we attempted validation of 13 signals with suggestive association (P < 
5x10
-5
) (Appendix: Supp. Table 5-6). We observed a novel signal at 10p15.1 
between the two established T1D loci at IL2RA and PRKCQ, which achieved 
genome-wide significance (rs1983890-C, OR (95% CI) = 1.16 (1.14-1.32), P = 
3.02 x 10
-8
) (Figure 5-1A and 5-1B). Given that the LADA signal is situated in 
close proximity to known T1D risk loci and was in moderate to low LD with 
established T1D-associated alleles (Appendix: Supp. Table 5-7), we 
conditioned on the T1D SNPs and observed that rs1983890 remained strongly 
associated with LADA (OR (95% CI) = 1.15 (1.13-1.19), P = 4.35 x 10-8) (Figure 
5-1C). This signal reached suggestive association in a study of T1D (P = 1.3 x 
10
-7
) (Bradfield et al., 2011) and as such may not represent a unique LADA 
association. DEPICT gene prioritization analysis identified the gene encoding ‘6-
Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3’ (PFKFB3), the nearest 
gene to the LADA signal, as the most likely functional candidate (Appendix: 
Supp. Table 5-8). 
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Figure 5-1 LocusZoom plots for the PFKFB3 locus. (A) In LADA vs. population 
controls with the addition of replication samples, rs1983890 reached borderline genome-
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wide significance. (B) This signal lies in between two T1D-associated loci at 
10p15.1(Bradfield et al., 2011). (C) When we conditioned on the two known T1D loci, the 
signal in LADA remained. LocusZoom plots were constructed to show the association 
data of SNPs 400kb upstream and downstream of the lead LADA-associated signal at 
rs1983890.   
 
Candidate loci for T1D and T2D 
Some of the loci that were suggestively associated with LADA in this study 
overlapped previously documented T1D associations, including rs11755527 
(BACH2) and rs941576 (DLK1) (Barrett et al., 2009; Bradfield et al., 2011; 
Onengut-Gumuscu et al., 2015), and the T2D association at rs11888640 
(THADA). Taking a candidate gene approach, we extracted 66 established T1D-
associated loci from the LADA vs. population controls meta-analysis and found 
that 17 of these yielded association with LADA after multiple-test correction (P < 
7.6 x 10
-4
, Appendix: Supp. Table 5-9). Taking a similar approach with 65 
established T2D loci, none surpassed the significance threshold; however, at the 
nominal significance level (P < 0.05), eleven T1D and eleven T2D variants were 
associated with LADA, all having the same direction of effect as seen for T1D 
and T2D, respectively, except for the T2D locus CILP2 (rs10401969-T, OR = 
0.820 (0.726-0.927), P = 0.0016; Appendix: Supp. Table 5-10). On the whole, 
both T1D and T2D loci had lower P-values in LADA than expected by chance 
(Appendix: Supp. Figure 5-3).  Approximately 90.6% T1D loci (Appendix: 
Supp. Table 5-9) had directional consistency in LADA (P-value = 4.51 x 10-12) 
and 72.3% of T2D loci (Appendix: Supp. Table 5-10) had directional 
consistency in LADA (P-value = 2.10 x 10-4).  Combining T1D and T2D loci, 
81.4% had directional consistency in LADA (P-value = 1.40 x 10-13).  Therefore, 
we observed a significant enrichment of established T1D and T2D loci having the 
same directional effect in LADA. 
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GWAS of LADA versus T2D and T1D 
Next, we compared LADA with T2D at the genome-wide level. Similar to the 
results of LADA vs. population controls, LADA (n = 2,454) vs. T2D (n = 10,396) 
yielded genome-wide significance for the same four T1D risk loci (Table 5-1). We 
then performed a GWAS of LADA (n = 2,454) vs. T1D (n = 968) to assess 
whether any differences could be detected. Only the HLA region was significantly 
different between T1D and LADA, representing a relative depletion of the lead 
signal in LADA when compared to T1D (rs9273368-A, OR (95% CI) = 0.335 
(0.256-0.385), P = 8.46 x 10-40; Table 5-1). Leveraging the entire genome-wide 
summary statistics, genetic correlation analyses showed that LADA was 
positively correlated with both T1D (with the inclusion of the HLA; rg (SE) = 0.385 
(0.136), P = 0.0047) and T2D (without the HLA; rg (SE) = 0.281 (0.106), P = 
0.008). Genetic correlations were re-calculated using a more recent T1D GWAS 
(Aylward et al., 2018) and T2D GWAS (Mahajan et al., 2018), which also showed 
positive correlation with both T1D (without the HLA; rg (SE) = 0.475 (0.139), P = 
0.0006) and T2D (without the HLA; rg (SE) = 0.371 (0.071), P = 1.84x10-7). 
 
Stratified GWAS of LADA by GAD autoantibody tertile 
Stratifying LADA cases into tertiles resulted in the detection of the same four loci, 
although the magnitude of the associations differed between the top tertile vs. 
population controls, the top 2 tertiles vs. population controls, and the bottom 
tertile vs. population controls (Appendix: Supp. 5-11). As expected, the ORs for 
the leading loci were strongest in the LADA cases with the highest GAD 
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autoantibody titers. For example, rs9273368 (HLA-DQB1) showed the strongest 
association with LADA in the analysis including the top tertile of GAD 
autoantibody titer (OR (95% CI) = 3.30 (2.81-3.88), P = 1.89x10-47) and the 
lowest association in the bottom GAD autoantibody tertile (OR (95% CI) = 2.42 
(2.06-2.85), P = 2.13x10-26). Furthermore, only the HLA-DQB1 locus was 
significantly associated in the LADA cases with the lowest GAD titers, while the 
PTPN22, INS, and SH2B3 loci were only evident among cases with higher GAD 
titers. Furthermore, rs7903146 at TCF7L2 had a slightly higher OR in the group 
with the lowest GAD titer than that with the highest GAD titer (1.09 vs. 1.05, 
respectively). 
 
HLA haplotype analysis 
To further investigate differences in the HLA region between LADA and 
T1D, we imputed this region using SNP2HLA in 2,159 LADA cases from 
the ActionLADA + CHOP + Swedish cohorts and 1,990 patients with T1D 
(WTCCC) and compared the frequencies of the leading T1D-associated 
HLA haplotypes (Appendix: Supp. Table 5-12). After removing 
haplotypes with less than 1% frequency, fifteen known T1D-associated 
HLA haplotypes were tested for association in LADA compared to T1D. 
Eleven T1D haplotypes were significantly different in frequency between 
LADA and T1D cases after correction for multiple testing (P < 0.003), with 
all but four being protective against T1D. The four T1D susceptibility 
haplotypes, HLA-DRB1*0301-DQA1*0501-DQB1*0201, HLA-DRB1*0401-
DQA1*0301-DQB1*0302, HLA-DRB1*0404-DQA1*0301-DQB1*0302, and 
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HLA-DRB1*0405-DQA1*0301-DQB1*0302, had significantly lower 
frequencies in LADA than in T1D. 
 
5.4 Discussion 
Taken collectively, GWAS and HLA haplotype analyses based on established 
associations, along with gene set enrichment analyses, support the hypothesis 
that the strongest genetic risk loci for LADA are shared with T1D, but that 
established T2D alleles also play a weaker role, as evidenced by the enrichment 
of established T2D loci in LADA and the positive genetic correlation between 
LADA and T2D. The strong T1D-like signature seen here in adult autoimmune 
diabetes could be explained by the differing genetic architectures between the 
two main types of diabetes (Timpson et al., 2018), with T1D having multiple low-
frequency risk variants with high odds ratios while T2D has many common risk 
variants with smaller effect sizes. Given these architectural differences, any trait 
with a T1D-like genetic component will detect T1D signals first, and would only 
subsequently detect the T2D signals with increased statistical power (Appendix: 
Supp. Table 5-3).  
Furthermore, this has important implications for genetic studies of T2DX, in 
which misdiagnosed autoimmune diabetes cases are not routinely screened out. 
With increasing sample sizes and the ability to detect additional loci, T2D GWAS 
that are ‘contaminated’ with adult autoimmune cases will inevitably begin to 
detect T1D-associated genetic loci, potentially mis-assigning these loci to T2D 
etiology. 
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  In comparing LADA to the general population, we identified a novel 
independent genome-wide significant signal at the PFKFB3 locus that persisted 
after conditioning on the two nearby T1D-associated signals on chromosome 
10p15. Cumulative evidence for the 10p15 locus suggests it is a complex region 
associated with autoimmune diabetes, given that it already harbors two 
established risk alleles for T1D as well as our signal for LADA. Previous studies 
strongly support PFKFB3 as a plausible biological candidate in diabetes, given its 
gene product’s role as a regulator of glycolysis and insulin signaling (Duran et al., 
2009). In mice, a pair of complementary studies showed that disrupted PFKFB3 
in adipose tissue exacerbated insulin resistance and adipose tissue inflammation 
(Huo et al., 2010), while overexpression of the gene was protective (Huo et al., 
2012). Furthermore, PFKFB3 plays a role in autoimmune diseases; in T cells 
from rheumatoid arthritis patients, PFKFB3 is lost leading to decreased T cell 
glucose consumption and impaired autophagy, which in turn lead to an inability to 
mount a normal immune response and an increase in T cell apoptosis (Weyand 
et al., 2013). Further studies are thus warranted to investigate the role of 
PFKFB3 in LADA, and to determine whether this signal is truly a distinguishing 
feature between adult and childhood-onset autoimmune diabetes.  
Although the lead genome-wide significant loci are shared with those T1D 
risk, they clearly have a diminished impact in LADA. To further investigate the 
differences between LADA and T1D at the HLA region, we performed a 
comparative haplotype analysis that showed a decreased frequency of T1D-
associated risk haplotypes in LADA. This could be partly explained by the 
established age gradient in HLA frequencies seen in T1D patients; however, HLA 
risk genotype frequencies have also been shown to differ between LADA patients 
and T1D patients with age at onset >35 years (Andersen et al., 2010; Luo et al., 
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2016). Future in-depth studies of the differences in HLA risk haplotypes between 
T1D and LADA taking age and ethnicity into account are also warranted.  
In terms of T2D-associated loci, our results differ from previous candidate 
studies. For instance, our previously reported HNF1A locus (Chapter 3 (Mishra 
et al., 2017)) was not observed in this setting. Furthermore, while previous 
studies showed an association for the leading T2D risk locus at TCF7L2 with 
LADA (Andersen et al., 2014; Cervin et al., 2008), our data shows relatively 
limited support of this finding (Appendix: Supp. Table 5-10) (LADA vs. 
population controls, rs7903146-T: OR (95% CI) = 1.107 (1.024-1.20), P = 0.011), 
which may be due to the limited power of our study to detect T2D signals 
(Appendix: Supp. Table 5-2). To understand the evidence supporting the 
previous association, we examined the allele frequencies of the lead variant in 
each contributing cohort. This revealed that the difference in risk allele frequency 
between cases and controls was cohort-specific, with only one case-control set 
(ActionLADA cases vs BMDCS controls) not supporting this association, 
principally due to the higher frequency of the risk allele in the control set 
(Appendix: Supp. Table 5-13). One possibility is that inclusion or exclusion of 
cases with T2D from control cohorts would affect the frequency of the risk allele; 
however, sensitivity analysis with control sets that either excluded or included 
cases with diabetes in Swedish and Danish samples showed the persistence of 
an association (Appendix: Supp. 5-13), although not at the genome-wide 
significance level. Interestingly, a recent study found that the T2D risk allele at 
the key TCF7L2 locus was associated with T1D cases who were older than 12 
years at onset and were positive for only a single autoimmune antibody 
(Redondo et al., 2017). That study provides further evidence for a role for T2D 
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genetic risk in later-onset autoimmune diabetes and resonates with the genome-
wide observations we report here in adults. 
The precise diagnostic criteria used to distinguish LADA from adult-onset 
T1D and T2D remain under debate. These differences in opinion have hindered 
the collection of well-phenotyped, clearly defined LADA cohorts for genetic 
studies, and are reflected in the cohorts we included in this study, e.g. in terms of 
heterogeneous age inclusion thresholds and differences in autoantibody testing. 
In this study, we strove to be inclusive to maximize our sample size and 
statistical power, but we acknowledge that stringent, deeply phenotyped cohorts 
are needed to truly address where adult autoimmune diabetes is placed on the 
diabetes spectrum. Another debate surrounds the idea that LADA cohorts may 
simply be collections of poorly phenotyped cases with adult-onset T1D and T2D, 
and refute the idea that LADA is a unique disease entity. However, GAD assays 
have a specificity of 95–98%, so by implication, some cases with T2D with low-
level GAD can be incorrectly classified as LADA cases; these would, however, 
represent only a very small fraction of cases since the predictive specificity of 
GAD would have been increased by our cohort enrichment as with any biomarker 
assay. Conversely, the small percentage of cases with LADA who do not have 
GAD positivity but have other islet autoantibodies and are misclassified as having 
T2D, could affect the estimate of genetic correlation between LADA and T2D to a 
small degree. Future studies should focus on defining the heterogeneity and 
misdiagnosis rates among patients with LADA. 
Despite these limitations, using the definition of LADA presented here, we 
identified factors which potentially distinguish this form of adult autoimmune 
diabetes from childhood-onset T1D as well as T2D: (1) a novel signal at the 
PFKFB3 locus, and (2) attenuation of T1D-associated HLA risk haplotypes. 
 78 
Overall, we find the presence of both a T1D-like autoimmune genetic component 
and a T2D-like metabolic/anthropometric genetic component consistent with the 
phenotypic features of both main diabetes types, suggesting that LADA as 
defined here is a hybrid of these two major diseases. Our findings promote the 
hypothesis that the polygenic component that contributes susceptibility to T2D 
can act as a modifier to T1D risk, possibly as a ‘second hit’ in individuals who 
have moderate underlying autoimmune susceptibility that is insufficient to trigger 
childhood T1D but greater than that of the general population and sufficient to 
lead to clinical diabetes in adulthood. Taken together, future studies should 
examine the role of body mass index, which is lower in T1D and higher among 
patients with T2D, in adult autoimmune diabetes, as well as further defining the 
role of factors that potentially distinguish adult autoimmune diabetes from T1D 
and T2D. 
 
5.5 Conclusion 
In this first GWAS of LADA, we show that the leading genome-wide 
significant signals point towards LADA as being a late-onset form of T1D, albeit 
with a genetically attenuated potency of key T1D-associated HLA haplotypes, but 
also with a T2D-like genetic component. Further in-depth studies are necessary 
to address how LADA and insulin dependence develops and to study the impact 
of heterogeneity among cases with LADA, as well as a need for functional 
studies to investigate how the glycolytic regulator PFKFB3 is situated at the 
intersection of autoimmune and metabolic diabetes. Furthermore, our LADA 
dataset should act as a resource to help mitigate the unaccounted presence of 
autoimmune diabetes in patients masquerading as T2D, with implications both 
for GWAS and for clinical management. 
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CHAPTER 6. GENETIC DISCRIMINATION 
BETWEEN LADA AND CHILDHOOD-ONSET TYPE 
1 DIABETES WITHIN THE MHC 
 
6.1 Introduction 
 ‘Latent autoimmune diabetes in adults’ (LADA) is characterized by initial insulin 
independency for at least six months after diagnosis and the presence of 
diabetes associated autoantibodies ( Tuomi et al., 1999). Despite such features, 
autoantibody screening is not routinely carried out in routine clinical practice, 
resulting in frequent misdiagnoses. For instance, in a cohort of apparent T2D 
cases, as many as 8-10% can actually represent misdiagnosed autoimmune 
diabetes cases (Hawa et al., 2013; Mishra et al., 2018).  Hence, there is a need 
to identify biomarkers to aid in accurately diagnosing LADA as well as other 
diabetes subtypes (Ahlqvist et al., 2018).   
 
The genetic etiology of LADA was, until recently,  largely unknown (Cousminer et 
al., 2018).  Previous genetic studies have suggested the condition comprised 
both T1D and T2D components either because it is an intermediate form of 
diabetes or because it is a mixture of T2D in a predominantly T1D cohort owing 
to a high false positive detection rate using autoantibodies when screening.  
Since, LADA is currently defined as a slowly progressive form of T1D (American 
Diabetes Association/ADA, 2018), it is crucial to define genetic differences 
between childhood-onset T1D and LADA if we are to clarify the clinical utility of 
identifying adult-onset autoimmune diabetes.   
 
Previous genetic studies in LADA have shown a strong association signal in the 
major histocompatibility complex (MHC), although with diminished effect sizes 
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compared to observations in childhood onset T1D (Cousminer et al., 2018; 
Mishra et al., 2017). The MHC region is located on chromosome 6 and harbors 
over 400 genes, with two main classes, MHC Class I and MHC Class II, which 
together harbor classic human leukocyte antigen (HLA) genes (HLA-A, HLA-B, 
HLA-C and HLA-DRB, HLA-DQA, HLA-DQB, HLA-DPA, and HLA-DPB). The 
HLA encodes cell surface proteins for antigen presentation and accounts for 
approximately 50% of the genetic heritability of T1D, with susceptibility principally 
harbored within the MHC Class II genes HLA-DQB1 and HLA-DRB1. However, in 
addition to Class II genes, previous studies have also pinpointed MHC Class I 
genes in susceptibility to T1D ( Howson et al., 2009; Noble et al., 2002; Valdes et 
al., 2005); in particular, variation within the MHC class I genes HLA-A and HLA-B 
variation has been shown through conditional analysis to further increase T1D 
risk (Nejentsev et al., 2007).  MHC Class I markers have also been shown to be 
associated with younger age-at-diagnosis in T1D, and given the adult-onset 
phenotype of LADA, we hypothesized that this genetic variation will be less 
enriched in LADA.  
 
In this effort, we first attempted to recapitulate the independent effects of MHC 
Class I variants using the SNP2HLA imputation tool followed by stepwise forward 
logistic regression in the same T1D cohort as the previous study (Nejentsev et 
al., 2007). Subsequently, we set out to identify distinguishing features within the 
MHC between childhood-onset T1D from adult-onset LADA, by performing the 
same conditional analysis followed by a replication attempt in a second 
case/control set.	 	
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6.2 Materials & Methods 
 
Study populations 
(I) LADA cases: 1,492 LADA cases were derived from multiple cohorts across 
the United Kingdom, Germany and the United States. Details on the participants 
can be found in Appendix: Supp. Table 6-1. All participants were diagnosed 
with LADA if they fulfilled the following criteria: aged 30-70 years old, tested 
positive for diabetes-associated Glutamic Acid Decarboxylase autoantibodies 
(GADA) and were not on insulin treatment for at least 6 months after diagnosis. 
(II) Controls: The LADA population-based controls comprised of two cohorts 
(n=2,979). The first cohort consisted of 1,296 non-diabetic children and 
adolescents of European ancestry, aged 5-20 years, enrolled in the Bone Mineral 
Density in Childhood Study (BMDCS (Kalkwarf et al., 2007)). The second control 
cohort consisted of 1,683 adults of European ancestry from a Non-Hodgkin 
lymphoma GWAS available in dbGaP (www.ncbi.nlm.nih.gov/projects/gap/cgi-
bin/study.cgi?study_id=phs000818.v2.p1) (Berndt et al., 2013). Details on the 
control cohorts can be found in Appendix: Supp. Table 6-1.  (III) 
Recapitulating a previous study: We also leveraged 3,000 healthy adult British 
Birth Cohort controls, 2,000 individuals with childhood-onset T1D, and 1,999 
individuals with T2D from the Wellcome Trust Case Control Consortium 
(WTCCC) (Wellcome Trust Case Control Consortium, 2007) to recapitulate 
observations found in a previous study (Nejentsev et al., 2007). Individual data 
from the WTCCC is available through the Consortium’s Data Access Committee 
(http://www.wtccc.org.uk). More details on cohort information can be found in 
Appendix: Supp. Table 5-1. (IV) Replication:  A cohort of individuals from 
Sweden were used for further recapitulation and replication, including case 
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subjects with T1D (N = 656), LADA cases (n=823) and population-based controls 
(N=3,218). Details on the participants can be found in Appendix: Supp. Table 6-
1. See flow chart for overview of datasets and workflow (Figure 6-1). 
 
Genotyping 
All samples, except the WTCCC data, were genotyped using the Illumina 
OmniExpress genotyping chip. WTCCC T1D and T2D cases were genotyped 
using Affymetrix 500K and WTCCC controls were genotyped on the Illumina 
1.2M BeadChip. Quality control was performed using PLINK.  Individuals with 
ambiguous sex, genotype missingness >5%, genome-wide heterozygosity (3 
standard deviations from the mean), duplicates and related-individuals were 
excluded (See Appendix: Supp. Table 6-1 for details). Principal component 
(PC) analysis was performed using PLINK, and outliers were removed to exclude 
individuals with non-European ancestry.  Single nucleotide polymorphisms 
(SNPs) with missing rate <5%, minor allele frequency (MAF) <1% and Hardy-
Weinberg equilibrium exact test P-value below 1x10
-5
 were removed before HLA 
imputation.  
 
HLA imputation 
Starting from the genotyped SNPs, we imputed chromosome 6 using the HLA 
imputation software SNP2HLA along with the Type 1 Diabetes Genetics 
Consortium (T1DGC) reference panel (Jia et al., 2013). A marker window size of 
1,000 bp and a posterior probability (gprob) threshold of 0.5 were used.  The 
HLA alleles of LADA cases (n = 1,428) and WTCCC T1D cases (n = 1,985) were 
imputed to both 2-digit resolution and 4-digit resolution for increased coverage 
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and resolution of HLA alleles.  In total, there were 5,698 SNPs, 424 HLA alleles  
and 1,276 HLA amino acids.  In this study, we focused on a subset of SNPs and 
HLA alleles which had a MAF greater than 1% in all three control cohorts (159 
HLA alleles and 5,506 SNPs remained). 
 
 
 
Power calculations 
Power calculations were performed using the Genetic Association Study (GAS) 
Power Calculator (http://csg.sph.umich.edu/abecasis/cats/). Assumptions 
included a multiplicative model, a disease incidence of 0.0036, 1,428 cases and 
2,979 controls and a significance level of 8.83x10
-6
 , based on a Bonferroni 
correction for the 5665 variants tested (Appendix: Supp. Table 6-2). 
 
Recapitulation of a previously published conditional analysis for T1D  
Logistic regression using SNPTEST (Marchini et al., 2007) was used to test all 
HLA alleles and SNPs with MAF >1% in all three control cohorts. Sex and the 12 
broad geographical regions, provided by the WTCCC, were included as 
covariates in the analysis. The analyses were performed in the WTCCC T1D vs 
control datasets using forward stepwise conditional logistic regression until there 
were no significant signals remaining after correction for multiple testing  
 
Conditional analysis in LADA vs population-based controls 
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Conditional logisitic regression was performed using SNPTEST in the LADA vs 
population-based controls, including sex and the first 4 principle components as 
covariates.  
 
Replication 
To further validate MHC Class I independent effects in T1D and lack of MHC 
Class I independent effects in LADA, we implemented approximate conditional 
analyses (COJO) in GCTA (Yang et al., 2012) on summary statistics from the 
Swedish replication cohort. Association analysis was performed using SNPTEST, 
and sex and the first four PCs were used as covariates.  There were 656 cases 
with T1D vs 3,218 population-based controls, and 823 cases with LADA vs 3,211 
population-based controls.  
 
Sensitivity analysis 
We performed sensitivity analysis to determine whether the lack of independent 
T1D-associated signals in MHC Class I genes in LADA cases could be due to a 
lack of power. We randomly sampled 1,428 T1D cases and 714 T1D cases 
(subsets equating to the same size as the LADA cohort and half the size of the 
LADA cohort, respectively) and 2,219 controls to determine whether the T1D-
associated signals could be still be detected. Stepwise conditional logisitic 
regression using SNPTEST was performed as above.  Given the hypothesis that 
LADA is potentially simply a mixture of T1D and T2D cases, we performed a 
further constrained conditional analysis in 714 randomly sampled T1D cases and 
and 714 randomly sampled T2D cases (total n = 1,428 cases) and 2,219 
WTCCC controls.   
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Futher validating independent signals 
PLINK was used to calculate pair-wise linkage disequilibrium between variants to 
further validate that the associated variants were truly independent of each other. 
To confirm independent association of HLA-B*39, the specific HLA-B*39 subtype 
HLA-B*3906 was tested in the WTCCC T1D cases (n = 1985) vs controls (n = 
2219) dataset using the presence of DQB1*0402 and DQB1*0501 as covariates.
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Figure 6-1 Flow Chart of (A) datasets and (B) overall analysis  
A 
B 
Genotype Data 
T1DGC Reference Panel 
SNP2HLA SNPTES
T Condition on 
top signal 
WTCCC 
Controls 
Swedish Population-
based Controls 
Discovery Controls 
Common Variants 
MAF>0.01 
QC 
WTCCC T1D (N=1985) vs 
WTCCC Controls (N =2219)  
LADA (N=1,428) vs Controls 
(N= 2979) 
Replication in Swedish 
Samples 
Swedish T1D (N=656) vs 
Population-based controls  
Swedish LADA (N=823) vs 
Population-based controls 
T1D Cohort 
(Recapitulation) 
LADA Cohort 
(Discovery) 
Reduced Sample Size: 
WTCCC T1D (N=1428) vs WTCCC Controls(N=2219) 
Sensitivity Analyses 
Mixture T1D + T2D: 
T1D (N= 714) + T2D (N = 714) vs WTCCC controls (N= 2219) 
Reduced Sample Size (Half): 
WTCCC T1D (N=714) vs WTCCC Controls(N=2219) 
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6.3 Results 
 
Confirming independent effects of MHC Class I signals in WTCCC 
T1D vs Controls 
Although previous studies  have reported MHC Class I independent effects in 
T1D, those studies used directly HLA-typed cases and controls. Given the cost 
and challenges of direct HLA typing, we elected to  utilize the imputation tool 
SNP2HLA on genotyping data. Furthermore, given this approach differs from the 
Nejensev et al., it was crucial to first ensure that we could recapitulate the 
previously reported T1D observations in the same cohort as previously 
leveraged. Before conditioning, we observed rs3957146  as the strongest 
association signal in the T1D vs WTCCC controls analysis (P = 8.94x10-165; 
Figure 6-2A). rs3957146 is in strong LD with a classical HLA subtype allele, 
HLA-DQB1*0302 (r2 = 0.99).  After conditioning on the top signal, rs3957146, 
and subsequent independent MHC Class II signals (HLA-DQB1*0201 and 
rs9268633), we observed the reported independent significant association of 
MHC Class I variants rs1610649 (HLA-G, P = 6.89x10-23) and HLA-B*39 (P = 
1.06x10
-15
) (Figure 6-2B; Table 6-1). Conditioning on these variants in addition 
to the MHC class II variants, also demonstrated significant association with the 
HLA-A locus (rs94/16/19259852, P=2.04x10-8). Overall, our results were 
consistent with the observations seen in Nejensev, et al. and subsequent studies 
(Howson et al., 2009; Nejentsev et al., 2007).  
 
Conditional analysis in LADA vs population-based controls 
We then went on to perform stepwise conditional analysis in 1,428 LADA cases 
and 2,979 controls. Similar to observations in the T1D vs WTCCC controls 
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dataset, before conditioning on any variants, the strongest association signal in 
LADA vs population-based controls was also rs3957146 (P = 1.80x10-68; Figure 
6-3A). Although we had power to detect HLA-B*39 (Appendix: Supp. Table 6-
2), when conditioning on the most highly significant MHC Class II alleles 
(rs3957146, HLA-DRB1*03, rs9269081, DRB1*0404 and DQB1*0602), there 
were no remaining independent signals in the MHC Class I region reaching 
significance after correction for multiple comparisons (P < 8.83x10-6;Figure 6-
3B). Furthermore, we also noted independent effects in the MHC Class III region 
(rs2143462, P = 8.24x10-8) and the MHC Class II region (HLA-DPA1*02, P = 
1.62x10
-6
  and HLA-DPB1 variant rs3130192, P = 5.32x10-6). Here, HLA-DPB1 
variant is in strong LD with rs2301225 (r
2
=0.85) and is independently associated 
with T1D.  MHC Class I variants were not observed to be independently 
associated with LADA after correcting for multiple comparison (Table 6-2).   
 
Sensitivity analysis in reduced sample of T1D vs controls 
To ensure that power issues in the relatively smaller LADA sample size, when 
compared to the T1D sample, did not explain the lack of significant associations 
in MHC Class I genes, we conducted a sensitivity analysis by systematically 
decreasing the sample size of the T1D vs WTCCC control cohort to match the 
size of the discovery LADA cohort (n= 1428 T1D cases and 2219 controls) and 
performing conditional analysis. Independent significant association signals at 
HLA-G (P = 1.37 x10-17), HLA-B (P = 5.58x10-14) and MUC22 (rs9262545, P = 
3.36x10
-9
; rs9262547, P = 9.69x10-14) were still observed in this reduced T1D 
sample size (Table 6-3), although these signals were missing in the 
comparatively-sized LADA vs controls dataset. Similarily, independent significant 
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association signals at HLA-B (P = 1.26x10-10), HLA-G (P = 0.002), and MUC22 
(rs9262545, P = 1.57x10-5 ) remained after further reducing the T1D cohort size 
to equate with half the LADA cohort size  (Table 6-4). 
 
 
 
Sensitivity analysis in an artificially mixed cohort of T1D and T2D 
cases vs controls 
Another explanation for the lack of independent, significant associations across 
MHC Class I genes in LADA could be due to the possibility that the LADA cohort 
simply represents an approximalty  50/50 mixture of misdiagnosed T1D and T2D 
cases. Therefore, we randomly sampled 714 cases with T1D, 714 cases with 
T2D and 2,219 controls, creating a “mixture” cohort. We performed the same 
conditional analysis described above and observed that the HLA-B, HLA-G and 
two MUCC2 signals in the MHC Class I regions remained independently 
significant in this mixed  cohort, driven by the T1D case subset (Table 6-5).  
 
Replication 
We leveraged summary statistics data from Swedish cohorts to attempt 
replication of our findings. In T1D vs controls, the strongest assocation was 
rs9275206 (P = 6.35X10-89), which is in strong LD with HLA-DQB1*0302 (r2 = 
0.99). After conditioning on rs9275206 and subsequent top signals (Table 6-6), 
we again observed significant association signals at the HLA-G (P = 1.74 x10-10) 
and HLA-B (1.10x10-9) loci . However, as before, when conditional analysis was 
performed in LADA vs controls, there were no such signals across  MHC Class I 
genes, and very sparse signals in the MHC Class II region (Table 6-7).  
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Futher validating HLA*B*39 
It has been shown that the HLA-B*3906 allele is associated with a high risk of 
diabetes only for specific HLA-DR/DQ haplotypes, DRB1*0801-DQB1*0402 and 
DRB1*0101-DQB1*0501 (Baschal et al., 2011). When specifically conditioning on 
these HLA-DR/DQ haplotypes in the WTCCC T1D and control cohort, the 
independent significant association of the more specific HLA-B*3906 subtype still 
remained (OR (95% CI) = 4.57 (3.08-6.80); P = 5.84x10-14). Furthermore, we 
observed a significant association signal at the NOTCH4 (rs397081, P =1.11x10-
10
) locus, the MUC22 locus (rs9262545, P = 7.83x10-11 and rs9262547, P = 
7.17x10
-17
) and the HLA-A locus (rs9259852, P = 5.84x10-14) (Figure 6-2C). 
Notably, rs9259852 is in strong LD with the classic HLA subtype allele, HLA-A*32 
(r
2
=0.96). 
6.4 Discussion 
The main objective of this study was to perform conditional analysis of the 
HLA region in LADA, which has been under explored to date in this disease 
context. The few genetic studies in LADA (Cousminer et al., 2018; Desai et al., 
2007; Luo et al., 2016) only focused on the HLA Class II DRB1 and DQB1 
haplotypes. Such studies,  in populations of both European and Chinese 
ancestry show that T1D risk haplotypes are less frequent in LADA compared to 
childhood-onset T1D cases, whereas T1D protective haplotypes are more 
frequent in LADA, suggesting that LADA is a gentically attentuated form of T1D. 
By extending the analysis of HLA in LADA beyond MHC Class II region, we were 
able to observe further genetic differences between LADA and childhood-onset 
T1D.   
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First, we leveraged the WTCCC T1D and control dataset, as  a positive 
control , with previous studies identifying MHC Class I independent T1D 
associations in the MHC Class I region (Eike et al., 2009; Howson et al., 2009; 
Nejentsev et al., 2007; Noble et al., 2002). Since these studies were reported, 
imputation tools have allowed the analysis of the HLA region more cheaply and, 
in general,  more practically. Before investigating MHC Class II independent 
LADA assocations in the MHC Class I region, given the difference in our 
analytical appraoch, we recapitulated the observations in previous studies 
(Howson et al., 2009; Nejentsev et al., 2007), by leveraging the same WTCCC 
T1D and control datasets. We confirmed that MHC Class I variants are 
significantly associated with T1D, independent of  MHC Class II region using this 
imputation-based approach followed by stepwise conditional logisitic regression. 
The conditional analysis was repeated in the LADA cohort, which consisted of 
cases and population-based controls. Crucially, there were no significant 
independent effects in the MHC Class I region remaining after correction for 
multiple comparisons; furthermore this observation was replicated in a separate 
Swedish cohort of T1D cases, LADA cases and population-based controls.  
Our observations are further supported through a series of sensitivity 
analyses by reducing the size of the WTCCC T1D and control cohort, 
demonstrating that this lack of observation of an MHC Class I independent effect 
in LADA was not due to reduced power. Additionally, motivated by the hypothesis 
that results from our previous genetic studies of LADA (Cousminer et al., 2018) 
can be explained by poor phenotyping of actual T1D and T2D cases, we 
randomly sampled cases from the WTCCC T1D and T2D cohort to create an 
artificial LADA cohort under the assumption that LADA would be a “mixture” of 
actual T1D and T2D cases. In this sensitivity analysis, we still observed the same 
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independent effects of MHC Class I variants, showing that the T1D signature 
remained in the “mixture” cohort, and suggesting that our LADA cohorts do not 
represent a signiifcant proportion of misdiagnosed cases with other forms of 
diabetes. We recognize that T1D cases were sampled from the cohort of 
childhood-onset T1D but that could not account for the argument that, in genetic 
terms, LADA simply represents a mixture of adulthood-onset  T1D and T2D. 
The MHC Class I variant HLA-B*39 is an established locus associated 
with T1D risk (Howson et al., 2009; Nejentsev et al., 2007; Noble et al., 2010). 
More specifically, studies pointed to a strong association with T1D for the 
subtype HLA-B*3906, which is now used in T1D genetic risk scores to predict 
T1D diagnosis (Sharp et al., 2019). It has also been shown that the B*3906 allele 
significantly enhances the risk of T1D when present on specific HLA-DR/DQ 
haplotypes (e.g. DRB1*0801-DQB1*0402 and DRB1*0101-DQB1*0501). The 
frequency of HLA-B*3906 is different among different populations, and here did 
not survive our filter of having a MAF > 1% in the replication control cohort of 
Swedes. Thus, it was excluded in the analyses across the three cohorts.  
However, we confirmed that the HLA-B*3906 allele remained significantly 
associated with T1D after conditioning on the presence of the DRB1*0801-DQB1 
0402 and DRB1*0101-DQB1*0501 haplotypes. Additionally, HLA-B*3906 is 
associated with younger age-at-diagnosis in T1D (Nejentsev et al., 2007; Valdes 
et al., 2005). A recent study using a NOD mouse model showed that HLA-
B*3906 mediates the development of CD8+ T cells required for T1D onset; 
moreover,  in the context of reduced immunological tolerance to insulin, HLA-
B*3906-transgenic NOD mice develop T1D at an accelerated rate (Ali et al., 
2018). The lack of an independent HLA-B*39 association observed in the adult-
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onset phenotype of LADA further confirms the link between HLA-B*39 with 
autoimmune progression with earlier onset of clinical disease.   
HLA-B associations have been confirmed in a previous study (Eike et al., 
2009), as well as associations around HLA-G, which  is expressed in human 
pancreas (Cirulli et al., 2006) and may play a role in autoimmune progression 
(Shiroishi et al., 2003). However, the MHC Class I variant rs1619379, located in 
HLA-G and ~100kb telomeric of HLA-A, may be less informative compared to 
HLA-A variants in predicting T1D risk (Howson et al., 2009). This particular MHC 
Class I variant was independently significant in the downsampled T1D cohort, but 
is in strong linkage disequilibrium with HLA-G variants, rs1610649 and 
rs2735028, which were significantly associated in the full T1D set, the mixture 
cohort consisting of T1D and T2D cases, and the T1D Swedish replication 
cohort. Additionally, the MHC Class I variants located in the MUC22 locus have 
not been replicated in separate cohorts, and likely form haplotypes with HLA 
Class I alleles.  
While our study does not include direct HLA typing, leveraging an 
established HLA imputation method allowed us to investigate HLA associations 
in the largest LADA cohort to date and to directly compare the results to 
oberservations made in a childhood-onset T1D cohort. The imputation method 
SNP2HLA has been commonly used in the field to assess the genetics of 
autoimmune diseases (Hu et al., 2015; Jia et al., 2013; Karnes et al., 2017; 
Sharp et al., 2019). One limitation of this study was that we only tested variants 
with a MAF > 1% in all three control cohorts, which resulted in filtering out many 
informative alleles such as HLA-B*3906. By filtering to include only common 
alleles we limited  potential discrepancies between populations, and were able to 
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replicate our observations across cohorts with different frequencies of known risk 
variants.   
Future studies are warranted to validate these findings in larger cohorts of 
LADA, as well as LADA cohorts directly typed for MHC Class II and MHC Class I 
HLA alleles. Additionally, to futher delineate this putative distinguishing genetic 
feature between LADA and childhood-onset T1D, it will be crucial to investigate 
how the HLA profile of LADA compares to children with T1D  stratified for 
different autoantibody positivity status. Studies have shown that children with 
T1D who are positive for a single autoantibody are more like to show T2D 
features (Redondo et al., 2017;  Redondo et al., 2014), for instance, a significant 
association with T2D GWAS-implicated variants. 
6.5 Conclusion 
Overall, our results point to a key differences in the genetic signature in 
the MHC region, especially Class I markers, between LADA and childhood-onset 
T1D. This study highlights the clinical utility of genetic screening in adult-onset 
autoimmune diabetes, the potential of defining those subjects at risk of rapid loss 
of insulin secretion and the need to consider more tailored approaches to 
immune therapy according to genetic characteristics.  
  
 
 
 
 
Table 6-1 Independent association signals from the conditional analysis in T1D cases vs WTCCC controls. Conditional P-value 
calculated from stepwise regression conditional on all SNP/HLA-Alleles in rows above (first column) in 1985 T1D cases versus 2219 
controls. *Conditional P-value from stepwise regression conditional on all SNPs/HLA-Alleles (column 1) in rows above. Position is base 
pair position according to build 36 of the human genome reference. Shaded rows are variants in the MHC Class I region. Linkage 
disequilibrium (LD) (r2) is between the SNP/HLA allele and most significant (top) classical HLA allele. “P” in the allele column indicates that 
the HLA allele is present and “A” indicates absent.^A*24 did not reach significance after conditioning on all variants in the first column.
SNP/HLA-
Allele  
Locus Position Alleles (Major/Minor) 
Minor Allele Frequency  
Odds Ratio  
(95% CI) 
Single 
Marker P-
value 
Conditional Top 
Classical 
HLA 
allele 
LD 
(r2)   
Cases Controls P-value* Beta Standard Error 
rs3957146 HLA-
DQA2 
32789508 T/C 0.385 0.113 4.91 (4.39- 5.50) 8.94E-165 8.94E-165 1.44 0.05 
DQB1*030
2 0.99 
DQB1*0201 HLA-
DQB1 
32739039 A/P 0.338 0.140 3.13 (2.81-3.49) 1.02E-91 7.98E-153 1.56  0.06 
DQB1*020
1 1.00 
rs9268633 HLA-DRA 32514451 A/G 0.0174 0.197 0.07 (0.06-0.09) 5.94E-132 5.62E-53 -1.46 0.10 DRB1*1501 0.59 
rs1610649 HLA-G 29876896 A/G 0.384 0.418 0.87 (0.79-0.94) 5.59E-04 6.89E-23 -0.61  0.06 B*39  0.00 
B*39 HLA-B 31431272 A/P 0.043 0.016 2.73 (2.07-3.62) 1.82E-12 1.06E-15 1.36 0.17 B*39 1.00 
DRB1*0404 HLA-
DRB1 
32660042 A/P 0.082 0.048 1.75 (1.47-2.09) 5.47E-09 6.17E-15 1.04 0.13 DRB1*0404 1.00 
rs17427599 HLA-
DQB1 
32775342 C/T 0.151 0.245 0.55 (0.49-0.61) 2.16E-23 7.97E-12 -0.59 0.09 DPB1*0402 0.00 
rs2301225 HLA-
DPA1 
33143838 C/T 0.059 0.109 0.51 (0.44-0.60) 1.07E-16 9.56E-12 -0.72  0.11 DPB1*0402 0.96 
rs397081 NOTCH4 32300595 T/C 0.095 0.045 2.22 (1.86-2.65) 2.20E-18 1.11E-10 0.79  0.12 A*3201 0.00 
rs9262545 MUC22 31101041 G/A 0.087 0.119 0.70 (0.61 -0.81) 4.89E-06 7.83E-11 -0.67 0.11 A*3201 0.00 
rs9262547 MUC22 31101206 T/A 0.135 0.119 1.16 (1.02-1.32) 0.034 7.17E-17 1.59 0.19 A*3201 0.00 
rs9259852 HLA-A 30004400 T/C 0.023 0.041 0.55 (0.43-0.72) 3.04E-06 2.04E-08 -1.00  0.18 A*3201 0.96 
rs9269081 HLA-DRA 32549078 C/A 0.110 0.265 0.34 (0.30-0.39) 1.19E-62 1.61E-07 -0.57 0.11 DQB1*0602 0.00 
rs1978029 HLA-
DQB2 
32839688   T/C 0.349 0.463 0.62 (0.57-0.68) 2.53E-22 1.92E-06 -0.36 0.08 ^A*24 0.00 
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Table 6-2 Independent association signals from the conditional analysis in LADA cases vs controls. Conditional P-value calculated 
from stepwise regression conditional on all SNP/HLA-alleles in rows above (first column) in 1428 LADA cases versus 2979 controls. 
Conditional P-value from stepwise regression conditional on all SNPs/HLA-Alleles (column 1) in rows above. Position is base pair position 
according to build 36 of the human genome reference. LD (r2) is between the SNP/HLA allele and the most signficant (top) classical HLA 
allele. “P” in the allele column indicates the HLA allele is present and “A” indicates absent. ^DPB1*0402 did not reach significance after 
conditioning on all variants in the first column.
SNP/HLA-
Allele 
Locus Position Alleles 
(Major 
/Minor) 
Minor Allele 
Frequency  
Odds Ratio 
(95% CI) 
Single 
Marker 
P-value 
Conditional Top 
Classical 
HLA allele 
LD 
(r2) 
Cases Controls P-value* Beta Standard 
Error 
rs3957146 HLA-DQA2 32789508 T/C 0.251 0.101 3.03 (2.63-3.33) 1.80E-68 1.80E-68 1.14 0.06 DQB1*0302 0.99 
DRB1*03 HLA-DRB1 32660042 A/P 0.209 0.118 1.99 (1.76-2.24) 5.31E-35 3.23E-52 1.07 0.07 DRB1*03 1 
rs9269081 HLA-DRA 32549078 C/A 0.179 0.315 0.47 (0.42 -0.53) 1.40E-42 3.54E-16 -0.49 0.06 DQB1*0604 0.01 
DRB1*0404 HLA-DRB1 32660042 A/P 0.037 0.035 1.04 (0.82-1.33) 0.328084 3.08E-11 0.95 0.14 DRB1*0404 1 
DQB1*0604 HLA_DQB1 32739039 A/P 0.059 0.035 1.75 (1.43-2.17) 5.73E-07 1.55E-10 0.81 0.13 DQB1*0604 1 
rs2143462 C6orf10 32443182 C/T 0.221 0.167 1.42 (1.26-1.58) 1.39E-08 8.24E-08 0.47 0.09 DPA1*02 0.01 
DPA1*02 HLA-DPA1 33145064 A/P 0.148 0.186 0.76 (0.67-0.86) 1.23E-04 1.62E-06 -0.34 0.07 DPA1*02 1 
rs3130192 HLA-DPB1 33169908 C/T 0.066 0.103 0.62 (0.52-0.73) 3.96E-08 5.32E-06 -0.42 0.09 ^DPB1*0402 0.85 
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Table 6-3 Independent association signals from the conditional analysis in T1D vs controls in the Swedish replication 
cohort. Conditional P-value calculated from stepwise regression conditional on all SNP/HLA-Alleles in rows above (first column) 
in 656 T1D cases versus 3218 controls. Position is base pair position according to build 36 of the human genome reference. 
Shaded rows denote this signal appeared in the full T1D vs WTCCC dataset. LD (r2) is between the  SNP/HLA allele and top 
classical HLA allele. “P” in the allele column indicates the HLA allele is present and “A” indicates absent. ^DQB1*0503 did not 
reach significance after conditioning on all variants in the first column. 
 
 
 
 
SNP/HLA- 
Allele 
Locus Position  Alleles 
(Major 
/Minor) 
Frequency Odds Ratio  
(95% CI) 
Single 
Marker P-
value 
Conditional Top Classical  
HLA allele 
LD (r2) 
Cases Controls P-value* Beta Standard 
Error 
rs9275206 HLA-DQA1 32765543 A/G 0.393 0.147 3.70 (3.33-4.34) 6.35E-89 6.35E-89 1.57 0.08 DQB1*0302 0.99 
DQB1*0201 HLA-DQB1 32739039 A/P 0.312 0.129 3.07 (2.67-3.52) 2.17E-58 1.96E-135 1.98 0.08 DQB1*0201 1.00 
DQB1*0602 HLA-DQB1 32739039 A/P 0.005 0.138 0.03 (0.02-0.07) 2.41E-43 1.85E-40 -1.26 0.09 DQB1*0602 1.00 
rs9269081 HLA-DRA 32549078 C/A 0.076 0.262 0.23(0.19-0.29) 1.60E-45 1.99E-30 -0.82 0.07 DRB1*0401 0.06 
rs3129871 HLA-DRA 32514320 C/A  0.095 0.335 0.21(0.17-0.25) 1.27E-65 3.33E-22 -0.63 0.07 DRB1*0401 0.06 
rs9784758 TAP2 32896489 T/C 0.212 0.091 2.70(2.27-3.13) 2.02E-34 1.03E-23 0.97 0.10 DRB1*0401 0.11 
rs805294 LY6G6C 31796196 C/T 0.530 0.359 2.01(1.78-2.27) 6.41E-30 8.02E-20 0.55 0.06 B*39 0.00 
rs707919 LY6G5B 31749118 T/C  0.333 0.310 1.11(0.98-1.27) 0.04 5.61E-16 0.42 0.05 DRB1*0401 0.13 
rs3130192 HLA-DPB1 33169908 C/T 0.049 0.107 0.43(0.33-0.56) 6.17E-10 8.83E-15 -0.77 0.10 DPB1*0402 0.88 
rs11969522 PSMB9 32967803 G/C 0.081 0.033 0.44 (0.39-0.49) 5.98E-16 6.45E-13 -1.10 0.15 B*39 0.00 
rs9275425 HLA-DQB1 32778852 C/A 0.487 0.293 2.22(2.04-2.56) 1.33E-40 2.54E-12 0.37 0.05 B*39 0.01 
rs1053924 PRRT1 32228693 G/A  0.144 0.305 0.38(0.32-0.45) 1.16E-32 8.02E-11 -0.43 0.07 B*39 0.00 
B*39 HLA-B 31431272 A/P 0.034 0.013 2.75(1.90-3.98) 6.80E-09 1.74E-10 1.54 0.24 B*39 1.00 
rs2735028 HLA-G 29893517 G/A 0.319 0.335 0.93(0.82-1.05) 0.315203 1.10E-09 -0.39 0.06 A*0101 0.42 
rs3104407 HLA-DQA2 32790430 A/G 0.244 0.457 0.38(0.33-0.44) 5.10E-45 3.01E-10 -0.36 0.06 DRB1*0401 0.12 
rs3104406 HLA-DQA2 32790421 G/A 0.143 0.339 0.33(0.28-0.38) 2.23E-39 9.71E-11 -0.37 0.06 DQB1*0301 0.11 
rs2239803 HLA-DRA 32519811 G/A 0.543 0.436 1.54(1.37-1.72) 3.33E-13 3.67E-09 0.32 0.05 DQB1*0503 0.01 
rs3117099 BTNL2 32466248 C/T  0.361 0.246 1.73(1.53-1.97) 3.29E-17 7.95E-11 0.35 0.05 DQB1*0604 0.06 
rs549182 NOTCH4 32313023 G/A 0.040 0.017 2.44(1.75-3.41) 9.09E-09 1.37E-06 0.97 0.20 DQB1*0503 0.01 
rs3135392 HLA-DRA 32517220 G/T  0.446 0.417 1.13(1.00-1.27) 0.04 3.23E-07 0.15 0.03 DRB1*0401 0.15 
rs3132132 HLA-DMB 33009912 G/A  0.082 0.116 0.68(0.55-0.84) 6.15E-04 1.81E-06 -0.46 0.10 DRB1*0401 0.01 
rs3129727 HLA-DQA2 32787668 C/T  0.001 0.021 0.04(0.01-0.26) 1.44E-06 7.31E-06 -1.09 0.24 ^DQB1*0503 0.99 
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Table 6-4 Independent association signals from the conditional analysis in LADA vs controls in the Swedish replication 
cohort. Conditional P-value calculated from stepwise regression conditional on all SNP/HLA-Alleles in rows above (first column) 
in 823 LADA cases versus 3211 controls. “P” in the allele column indicates the HLA allele is present and “A” indicates absent. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SNP/HL
A- 
Allele 
Locus Positio
n 
Allele (Major 
/Minor) 
Frequency Odds Ratio  
(95% CI) 
Single 
Marker  
P-value 
Conditional Top Classical HLA 
allele 
LD 
(r2) Case
s 
Contro
ls 
P-
value* 
Bet
a 
Standa
rd 
Error 
rs31298
82    
HLA-
DRA 
325175
08 
A/G 0.223 0.378 0.47(0.42-
0.54) 
3.51E-10 3.51E-
10 
-
0.8
4 
0.13 HLA_DRB1_15 0.2
0 
rs25965
60  
MICA 314632
97 
A/G 0.586 0.747 0.48 (0.43-
0.53) 
3.67E-08 4.19E-
07 
-
0.6
7 
0.13 HLA_DQB1_0201 0.3
5 
98 
 
 
 
 
 
 
 
 
Table 6-5 Independent association signals from the conditional analysis in the downsampled cohort of T1D cases vs 
controls. Conditional P-value calculated from stepwise regression conditional on all SNP/HLA-alleles in rows above (first column) 
in 1428 T1D cases versus 2219 controls. Shaded rows denote that this MHC Class I signal appeared in the full T1D vs WTCCC 
dataset but not in LADA vs control set. *rs1619379 is in LD with rs1610649 (r2=0.822), which is consistent in the full T1D vs 
WTCCC dataset. “P” in the allele column indicates the HLA allele is present and “A” indicates absent. ^C*07 did not reach 
significance after conditioning on all variants in the first column. 
 
 
SNP/HLA- 
Allele 
Locus Position Allele (Major 
/Minor) 
Frequency Odds Ratio  
(95% CI) 
Single 
Marker  
P-value 
Conditional  Top 
Classical  
HLA allele 
LD  
 
(r2) Case
s 
Control
s 
P-value* Bet
a 
Standar
d Error 
rs3957146 HLA-
DQA2 
3278950
8 
T/C 0.390 0.113 5.02 (4.45-
5.66) 
2.98E-157 2.98E-
157 
1.5
7 
0.06 DQB1*0302 0.9
9 
DQB1*02
01 
HLA-
DQB1 
3273903
9 
A/P 0.338 0.140 3.14 (2.80-
3.528) 
7.33E-81 3.27E-
136 
1.6
7 
0.07 DQB1*0201 1.0
0 
rs9268633 HLA-DRA 3251445
1 
G/A 0.020 0.197 12.3 (9.34-
16.17) 
6.40E-102 2.02E-37 1.3
5 
0.11 DQB1*0602  0.5
3 
rs1619379 HLA-G 2989321
4 
G/A 0.398 0.432 0.87 (0.79-
0.95) 
0.002 1.37E-17 -
0.5
6 
0.07 DRB1*0404 0.0
0 
DRB1*040
4 
HLA-
DRB1 
3266004
2 
A/P 0.083 0.048 1.78 (1.47-
2.15) 
1.54E-08 9.91E-13 0.9
8 
0.14 DRB1*0404 1.0
0 
B*39 HLA-B 3143127
2 
A/P 0.043 0.016 2.79 (2.08-
3.75) 
5.09E-12 5.58E-14 1.4
3 
0.19 B*39 1.0
0 
rs2301225 HLA-
DPA1 
3314383
8 
C/T 0.057 0.109 0.49 (0.41-
0.59) 
1.60E-14 3.96E-12 -
0.8
1 
0.12 DPB1*0402 0.9
6 
rs9267665 C2 3197883
5 
C/T 0.082 0.030 2.92 (2.35-
3.64) 
1.86E-21 1.73E-09 0.8
8 
0.15 DQB1*0602 0.0
0 
rs9269081 HLA-DRA 3254907
8 
C/A 0.110 0.265 0.34 (0.30-
0.39) 
1.60E-54 1.79E-13 -
0.8
0 
0.11 DQB1*0602 0.3
1 
rs9262545 MUC22 3110104
1 
G/A 0.087 0.119 0.70 (0.60-
0.82) 
8.07E-06 3.36E-09 -
0.6
7 
0.11 A*24 0.0
0 
rs9262547 MUC22 3110120
6 
T/A 0.133 0.119 1.13 (0.98-
1.31) 
0.16388 9.69E-14 1.6
4 
0.22 B*14 0.0
0 
rs549182 NOTCH4 3231302
3 
G/A 0.074 0.020 3.93 (3.05-
5.06) 
5.59E-28 1.20E-06 1.3
3 
0.27 B*14 0.0
0 
rs2853928 HLA-C 3136549
0 
G/T 0.372 0.295 1.42 (1.28-
1.57) 
3.22E-11 1.26E-06 0.4
8 
0.10 C*07 0.7
9 
99 
 
 
 
 
 
Table 6-6 Independent association signals from the conditional analysis in a sample of randomly selected T1D and T2D cases vs 
controls. Conditional P-value calculated from stepwise regression conditional on all SNP/HLA-alleles in rows above (first column) in 714 
T1D cases + 714 T2D cases versus 2219 controls. Shaded rows highlight the MHC Class I signals that appear in the full T1D vs WTCCC 
conditional analysis. “P” in the allele column indicates that the HLA allele is present and “A” indicates absent. ^B*39 did not reach 
significance after conditioning on all variants in the first column. 
 
 
 
 
 
 
 
 
 
 
 
 
 
SNP/HLA-
Allele 
Locus Position Allele (Major /Minor) Allele Frequency Odds Ratio 
(95% CI) 
Single 
Marker P-
value 
Conditional  Top 
Classical 
HLA allele 
LD 
(r2) 
Cases Controls P-value Beta Standard 
Error 
rs3957146 HLA-DQA2 32789508 T/C 0.256 0.112 2.72 (2.40-3.09) 1.16E-52 1.16E-52 0.99 0.07 DQB1*0302 0.99 
rs2187668 HLA-DQA1 32713862 G/A 0.234 0.140 1.88 (1.66-2.12) 2.71e-27  1.03E-38 0.89 0.07 DRB1*0301 0.99 
DRB1*0404 HLA-DRB1 32660042 A/P 0.059 0.049 1.22 (0.99-1.51) 0.075 2.11E-10 0.85 0.13 DRB1*0404 1.00 
rs1619379 HLA-G 29893214 G/A 0.400 0.430 0.88(0.800.97) 0.014 1.60E-07 -
0.30 
0.06 B*39 0.00 
rs9262545 MUC22 31101041 G/A 0.083 0.119 0.67 (0.57-0.79) 3.43E-07 6.42E-07 -
0.44 
0.09 B*39 0.00 
rs9262547 MUC22 31101206 T/A 0.117 0.118 0.99 (0.85-1.14) 0.548 3.03E-16 1.63 0.20 B*39 0.00 
HLA_B_39 HLA-B 31431272 A/P 0.030 0.015 1.99 (1.44-2.77) 4.73E-05 2.61E-06 0.88 0.19 ^B*39 1.00 
100 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-2 Conditional analysis in 1,985 T1D cases and 2,219 WTCCC controls. A) Logistic regression analysis without conditioning 
on MHC Class II alleles. B) Logistic regression analysis conditioning on MHC Class II alleles. C) Logistic regression analysis conditioning 
on MHC Class II and MHC Class I signals. 
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Figure 6-3 Conditional analysis in 1,428 LADA cases and 2,979 WTCCC controls. A) Logistic regression analysis without conditioning 
on MHC Class II alleles. B) Logistic regression analysis conditioning on MHC Class II alleles. 
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CHAPTER 7. FUTURE DIRECTIONS 
7.1 Brief Summary  
While the genetic risk scores and heritability calculations both suggested 
LADA genetically resides between T1D and T2D, principally T1D GWAS-
implicated loci including the MHC region, PTPN22, INS, and SH2B3, were shown 
to be significantly associated with LADA in both the candidate locus association 
study and the GWAS meta-analysis. The GWAS also highlighted a novel signal 
at the PFKFB3 locus, which had never been reported in previous T1D and T2D 
GWAS, and could be associated with older age of onset of autoimmune diabetes. 
Additionally, the MHC association with LADA is attenuated compared to T1D, 
with established T1D risk haplotypes less frequent in LADA, and conversely 
protective T1D haplotypes more frequent.  When looking further into the HLA 
region in LADA, contrary to observations in childhood-onset T1D, we did not 
observe independent effects of MHC Class I variants, particularly the HLA-B*39 
allele, which is consistent with previous studies. Despite the significant role T1D 
genetics plays in LADA, there is also a positive genetic correlation between 
LADA and T2D, and significant enrichment of directional consistency for T2D loci 
in LADA. However, it remains unclear whether these results are at least partially 
explained by T2D individuals mistakenly classified as “affected with LADA”, and 
the studies presented in this dissertation have yet to fully answer this outstanding 
question due to the challenges outlined below. 
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7.2 Limitations 
The limitations of our genetic efforts in LADA include the lack of power to 
detect most T2D signals that would reach genome-wide significance. If our 
hypothesis of a T2D component of LADA holds, the T2D loci with relatively 
weak effect sizes should emerge in a larger cohort given the contrasting 
genetic architecture between T1D and T2D (Timpson et al., 2018). 
Additionally, there is a possibility of misdiagnosed individuals in our LADA 
cohort and in the T1D and T2D reference cohorts, which was a major 
challenge in all of our analyses. Another limitation is the reference T1D 
and T2D GWAS that were utilized in our studies. For instance, Bradfield et 
al used T2D cases as part of their controls in a T1D GWAS, which 
resulted in conservative effects sizes that were used in our initial T1D 
GRS calculations. Given that T2D genetic studies do not screen for 
autoantibodies and T1D-associated loci have started to emerge in these 
studies (Mahajan et al., 2018; Ng et al., 2014; Scott et al., 2017), it is also 
very possible that our analyses using T2D GWAS data may have been 
confounded by poor phenotyping. Moving forward, one of our key 
conclusions is that T2D genetic studies must exclude cases positive for 
diabetes associated autoantibodies. Additionally, we did not have 
consistent access across the cohorts to important clinical data such as 
age of onset, time to insulin and BMI, and systematically collecting this 
information will be crucial for future studies. 
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7.3 Is LADA simply a mixture of T1D and T2D? 
 
 In the first attempt to answer this question, different proportions of T1D 
and T2D cases were randomly sampled from the WTCCC dataset to represent 
an “artificial” model of a possible LADA cohort and the distributions of T1D and 
T2D GRS were compared to the distribution of T1D and T2D GRS in LADA 
(n=978) (Figure 7-1A and 7-1B). GRS were calculated using 69 T1D loci and 71 
T2D GWAS from Chapter 3 (Appendix: Supp. Table 3-1). Wilcoxon rank sum 
test was used to perform a pairwise comparison amongst the six groups (10% 
T1D cases/90% T2D cases, 25% T1D cases/75% T2D cases, 50% T1D 
cases/50% T2D cases, 75% T1D cases/25% T2D cases, 100% T1D cases and 
LADA cases). The T1D GRS distribution for the 50% T1D and 50% T2D mixture 
cohort appeared to be nearly identical to the T1D GRS distribution for LADA (P = 
1.00).  
This cocktail analysis was repeated after increasing the LADA sample 
size to 2,735 cases and using 30 T1D loci and their respective odds ratio from 
Oram et al for T1D GRS (Oram et al., 2016) and 403 T2D loci from the most 
recent T2D GWAS (Mahajan et al., 2018) for the T2D GRS(Figure 7-1C and 7-
1D). In this analysis, we still saw an identical distribution of T1D GRS between 
50/50 T1D/T2D GRS mixture and LADA, which was consistent with the initial 
T1D GRS cocktail analysis. However, contrary to the initial T2D GRS cocktail 
analysis using 71 SNPs, the T2D GRS distribution of LADA was near identical to 
the T2D GRS distribution of the 75% T1D/25% T2D mixture. This observation 
was also seen using the same 403 SNP-derived T2D GRS in the 978 LADA 
cases, which highlights how crucial T2D GWAS references will be for future 
work. Differences between the two T2D cocktail analyses could be explained by 
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the potential increase in influence of the misdiagnosis rate resulting in T1D loci 
(i.e. HLA, INS) emerging in the recent T2D GWAS. 
To assess whether there is a correlation between the T1D genetics and T2D 
genetics for an individual with LADA, we plotted the T2D GRS against the T1D 
GRS in LADA (n=2,735), controls (WTCCC controls and BMDCS, N=4,286), 
WTCCC T1D (N=1,995), WTCCC T2D (N=1,971), and different mixtures of T1D 
and T2D cases. We observed a negative correlation between the T2D GRS and 
T1D GRS for LADA (Figure 7-2A); however, this is also seen when randomly 
sampling different proportions of T1D and T2D cases (Figure 7-2B). While the 
use of T1D and T2D whole-genome polygenic risk scores could be more 
informative, without a cleaner reference T2D GWAS dataset, we still may not 
fully answer whether the T2D genetic component of LADA is explained by “T2D 
contaminates” in the cohort.  
A future approach to investigate this outstanding question is to leverage the 
summary statistics from the T1D, T2D and LADA GWAS. Therefore, future T2D 
GWAS removing individuals positive for diabetes associated autoantibodies will 
be imperative. By leveraging summary statistics data, two potential hypotheses 
can be tested: 1) LADA is simply a form of T1D with low penetrance and 2) LADA 
is a mixture of T1D and T2D cases. The first hypothesis can be tested by 
estimating parameters that will obtain a ‘low penetrant T1D model’ that best fits 
the association summary statistics based on the LADA GWAS. The second 
hypothesis can be tested by estimating the proportion of T1D cases + T2D cases 
that will obtain a model that best fits the data observed from the LADA GWAS. 
We can further improve this study by leveraging samples from the Type 1 
Diabetes Genetic Consortium and the UK Biobank, using strict criteria for T1D 
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and T2D cases. A potential result from this study would be identifying a model 
that best fits LADA, however it may not explain the observations we see in the 
LADA GWAS. This would suggest a genetic signature unique to LADA. The 
model that best fits LADA should clinically and biologically make sense as well.
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Figure 7-1 GRS distribution of varying proportions of T1D and T2D cases (A) 
Compared to T1D GRS in LADA (n=978) (B) Compared to T2D GRS in LADA (n=978)  
(C) Compared to Oram et al T1D GRS in LADA (n=2,735) (D) Compared to updated T2D 
GRS  in LADA (n=2,735)  
T1D Proportion 
T1D GRS 
n.s 
T1D Proportion 
T2D GRS 
n.s 
A n.s B 
n.s 
T1D Proportion 
n.s C D 
T1D Proportion 
10% 25% 50% 75% 100% LADA 10% 25% 50% 75% 100% LADA 
10% 25% 50% 75% 100% LADA 10% 25% 50% 75% 100% LADA 
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Figure 7-2 T2D GRS plotted against T1D GRS in LADA (n=2,735), controls (N=4,286), 
T1D (N=1,995), T2D (N=1,971), and different mixtures of T1D and T2D cases. 
 
 
 
 
7.4 Follow-up on genetic markers involved in autoimmune diabetes 
 
The presence of autoantibodies and the T1D genetic component of LADA has a 
lot of power to discriminate LADA from T2D. However, our work has also pointed 
to potential genetic discriminators of LADA and childhood-onset T1D, that can 
help shed light on the progression of autoimmune diabetes. For instance, the 
novel independent LADA-associated variant, located between two known signals 
at a T1D locus, points to an interesting functional candidate, ‘6-Phosphofructo-2-
Kinase/Fructose-2,6-Biphosphatase 3’ (PFKFB3), that links immune and 
metabolic traits. PFKFB3 is a known regulator of glycolysis and insulin signaling 
in T2D and inflammation and autophagy in autoimmune diseases. While our 
LADA GWAS was the first to report this novel signal, the variant subsequently 
reached genome-wide association in a recent T1D study (Aylward et al., 2018). 
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One explanation for why this signal has not been reported before could be lack of 
power for prior T1D studies. However, another explanation, particularly for 
(Bradfield et al., 2011), could be the inclusion of WTCCC T2D cases in the 
control group. Thus, the novel variant is not a unique marker for LADA, however 
it is possible that this variant could be associated with older age of onset and is 
thus more amenable for detection in a LADA setting; therefore, future genetic 
studies of autoimmune diabetes in all ages should further investigate this variant 
and its role in the progression of autoimmune diabetes.  
Additionally, genetic variation in the MHC Class I region may also point to 
potential discriminators between LADA and childhood-onset T1D. Particularly, 
HLA-B*3906 has been shown in previous studies to be associated with early age 
of onset, and our lack of observation of an independent effect of this signal in 
LADA confirms this relationship. It is also possible that T1D variants, which we 
had power to detect in our LADA GWAS but did not reach genome-wide 
significance in the study, could also mediate the progression of autoimmune 
diabetes. Identifying variants associated with early onset of T1D or conversely 
delay in progression of T1D, and functionally following up on their involvement in 
insulin production and beta cell autoimmunity will be an interesting future 
direction from this work.   
7.5 Towards precision medicine in diabetes 
While some scientists and clinicians believe LADA is simply a mixture of T1D and 
T2D, some believe LADA is part of a diabetes continuum with childhood-onset 
T1D on one end of the spectrum and T2D on the other end of the spectrum. Our 
genetic studies of LADA, as well as childhood-onset T1D studies, have 
supported the hypothesis of an interplay between T1D and T2D genetics. 
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Additionally, individuals can have both T1D and T2D, which has been termed  
“double diabetes” (Pozzilli et al., 2011). Atypical cases such as double diabetes, 
and “Flatbush diabetes” demonstrate that diabetes definitions are certainly not 
clear cut and is extremely heterogenous. The extent of heterogeneity within T2D 
alone has been demonstrated in previous clustering analyses (Ahlqvist et al., 
2018; Udler et al., 2018).  As a result of this phenotypic heterogeneity, 
misclassification may have confounded genetic studies of diabetes which makes 
it more challenging to understand the genetics and pathogenesis. Large scale 
genetic data combined with patient data that includes BMI, C-peptide levels, 
HbA1c, insulin treatment, time to insulin, age of diagnosis, and autoantibody titre 
will help to further move forward the field of precision medicine in diabetes.  
 
7.6 Conclusion 
 
By conducting the first genome-wide systematic appraisal of LADA, we have 
demonstrated that the genetic etiology of this relatively common diabetes 
subtype is largely similar to the genetic etiology of T1D, suggesting that LADA is 
an age-related extension of the childhood-onset T1D pathogenesis. Although 
there was clear evidence of a T2D genetic component, further studies are 
required to investigate the extent to which these observations are due to poor 
phenotyping. Finally, we did not find strong evidence for novel genetic variants 
unique to LADA so one of our conclusions is that LADA is very unlikely to be a 
separate diseases entity, although some MHC signatures may act as a 
discriminator from T1D. Our genetic efforts in LADA have moved the field forward 
by sparking the debate surrounding the definition of LADA and highlighting the 
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need for a better classification system for diabetes. Additionally, this work has 
highlighted the potential utility of genetics in identifying and monitoring high risk 
patients with adult-onset autoimmune diabetes, thus leading to better and more 
refined treatment and therapeutic interventions. 
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Chapter 2: A Global Perspective of LADA Supplemental Table 
 
 
Region County 
2015 
National 
prevalence 
of diabetes 
% 
[uncertainty 
interval] 
Approximate 
number of 
Adults with 
diabetes 
[aged 20-79]  
Approximate 
number of 
children 
with type 1 
diabetes 
[aged 0-14]  
Basis of 
estimate 
[OGTT, 
extrapolation, 
other1] 
Africa 
Nigeria 1.9 [1.4 - 4.6]  1,564,700 14,400 Extrapolation 
Ghana 1.9 [1.5 - 4.7]  266,200 N/A Extrapolation 
Kenya 2.2 [1.2 -10.2]  478,000 N/A OGTT 
Ethopia 2.9 [1.7 - 7.6]  1,333,200 578 Extrapolation 
Middle 
East 
Iran 8.5 [6.6 -11.5]  4,602,200 
                                                                                      
3,100  
Other 
Saudi 
Arabia 17.6 [13.5 -19.6]  3,487,300 
                                                                                    
16,100  OGTT 
United 
Arab 
Emirates 
14.6 [13.0 - 17.1]  1,086,300 N/A OGTT 
Asia 
India 8.7 [7.0 - 10.6]  69,188,600 70,000 OGTT 
Sri 
Lanka 
8.5[6.1 - 12.9] 1,161,700 N/A OGTT 
China 10.6 [9.6 - 12.9]  109,649,100 30,500 OGTT 
Republic 
of Korea 8.7 [6.9 - 11.2]  3,369,000 400 Other 
Japan 7.6 [6.5 - 10.1]  7,202,200 2,500 Other 
North 
America USA 12.8 [12.1 - 13.5]  29,251,600 84,100 OGTT 
Europe 
UK 6.2 [5.4 - 8.5]  2,858,600 19,800 OGTT 
Finland 9.0 [6.7 - 11.0]  360,000 4,400 OGTT 
Italy 7.9 [7.1 - 9.2]  3,507,700 6,800 OGTT 
Sweden 6.3 [5.2 - 9.5]  446,900 4,400 OGTT 
Norway 7.8 [5.9 - 9.7]  289,600 1,900 Extrapolation 
Spain 10.4 [8.2 - 14.7]  3,576,100 8,800 OGTT 
Turkey 12.5 [11.2 - 14.9]  6,339,000 9,600 OGTT 
Supp. Table 2-1. National prevalence of diabetes in 2015  
This data is derived from the International Diabetes Federation(Ogurtsova et al., 2017)for 
highlighted countries in Chapter 1.
1
Other includes 'Fasting blood glucose', 'Self-reported', 
'Medical record or clinical diagnosis', and 'HbA1c';  OGTT = oral glucose tolerance test.
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Chapter 3: RELATIVE CONTRIBUTION OF T1D AND T2D LOCI 
TO THE GENETIC ETIOLOGY OF LADA 
Supplemental Results 
 
 
Given our primary control cohort consisted of European-descent children 
ascertained from the United States, while the LADA cases were adults 
ascertained from the UK and Germany, we also leveraged 2,820 healthy 
adult British controls from the WTCCC and, overall, observed consistent 
results (Appendix: Supp. Table 3-8), despite the array differences for this 
control set, as outlined in the Methods section. The T1D signals at the 
MHC (OR=1.18, P=1.01x10-4), PTPN22 (OR=1.33; P=3.86x10-6), SH2B3 
(OR=1.16; P=9.35x10-5), and INS (rs689; OR=1.24; P=1.27x10-6) 
remained strongly associated and were directionally consistent.  Similar 
observations were also seen when comparing the MHC 
(Pdifference=1.26x10-17), INS (rs689; Pdifference= 3.88x10-4), and SMARCE1 
(Pdifference= 6.54x10-4) loci in the LADA cases vs the WTCCC T1D cases. 
While the HNF1A association weakened, it did remain significantly 
associated (OR=1.11; P=0.036) while the TCF7L2 signal remained 
significantly differently associated in LADA cases vs T1D cases 
(Pdifference=5.21x10-6). 
When constrained on GADA+ only LADA cases, the signal at the MHC 
was no longer significantly associated while TCF7L2 remined non-
significant for cases vs WTCCC controls; however, they both remained 
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significantly different between LADA cases vs T1D cases 
(Pdifference=1.99x10-24 and 5.03x10-4, respectively).  Furthermore, when 
constrained on LADA cases positive for GADA+ and IA2A+ antibodies, the 
T1D association signals remained all significant, although not all were 
significantly different from T1D, i.e. MHC (OR=1.59, P=3.34x10-9, 
Pdifference=4.01x10-3), PTPN22 (OR=1.86; P=1.88x10-7, Pdifference= N.S), 
SH2B3 (OR=1.32; P=1.95x10-4, Pdifference= N.S), and INS (rs689; 
OR=1.48; P=2.07x10-6 , Pdifference=1.68x10-6) showing again that this set 
of LADA cases is overall more similar to T1D cases. The HNF1A signal 
remained significantly associated in these restricted LADA cases 
(OR=1.27; P=0.011), while the ZBED3 and TCF7L2 loci continued to be 
significantly different in LADA cases vs T1D cases (Pdifference=1.47x10-5 
and 2.56x10-7, respectively).
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T1D SNPS Gene 
Odds 
Ratio 
Weight 
Effect 
Allele 
rs2187668, 
rs7454108 
DR3/DR4-DQ8  48.18 3.87  
DR3/DR3  21.12 3.05  
DR4-DQ8/DR4-DQ8  21.98 3.09  
DR4-DQ8/X  7.03 1.95  
DR3/X  4.53 1.51  
rs1264813 HLA_A_24  1.54 0.43 T 
rs2395029 HLA_B_5701  2.51 0.92 T 
rs3129889 HLA_DRB1_15 14.88 2.7 A 
rs10272724 IKZF1, FIGNL1, DDC, GRB10 1.15 0.14 T 
rs10492166 CD69 1.15 0.14 G 
rs10509540 RNLS 1.14 0.13 T 
rs10517086 SLC34A2, SEL1L3, SMIM20, RBPJ, CCKAR, TBC1D19 1.09 0.09 A 
rs10795791 IL2RA, RBM17 1.16 0.15 G 
rs11170466 ITGB7 1.19 0.17 T 
rs11203203 UBASH3A 1.14 0.13 A 
rs113010081 CCR5 1.19 0.17 T 
rs11571316 CTLA4, ICOS 1.22 0.2 G 
rs11755527 BACH2 1.13 0.12 G 
rs11954020 IL7R 1.11 0.1 G 
rs12148472 CHRNB4, ADAMTS7, MORF4L1, CTSH, RASGRF1 1.20 0.18 T 
rs12453507 FBXL20, MED1, CDK12, NEUROD2, PPP1R1B, STARD3, TCAP, 
PNMT, PGAP3, ERBB2, MIEN1, GRB7, IKZF3, ZPBP2, GSDMB, 
ORMDL3, LRRC3C, GSDMA, PSMD3, CSF3, MED24, THRA 
1.11 0.1 G 
rs12708716 CLEC16A,CIITA, DEXI,  RMI2, SOCS1, TNP2, PRM3, PRM2, PRM1, 
CTD-3088G3.8 
1.23 0.21 A 
rs12908309 RASGRP1 1.19 0.17 G 
rs1456988 C14orf64 1.12 0.11 G 
rs1538171 CENPW 1.12 0.11 G 
rs1615504 DOK6, CD226 1.13 0.12 T 
rs1738074 RSPH3, TAGAP 1.09 0.09 C 
rs17696736 SH2B3,NAA25, CUX2, FAM109A, ATXN2, BRAP, ACAD10, RP11-
162P23.2 (ENSG00000257767), ALDH2, MAPKAPK5, TMEM116, 
ERP29, TRAFD1, HECTD4, RPL6, PTPN11, RPH3A 
1.34 0.29 G 
rs193778 CLEC16A,CIITA, DEXI,  RMI2, SOCS1, TNP2, PRM3, PRM2, PRM1, 
CTD-3088G3.8 
1.14 0.13 G 
rs1990760 GCG, FAP, IFIH1, GCA, KCNH7 1.15 0.14 T 
rs2281808 SIRPD, RP4-576H24.4 (ENSG00000260861), SIRPB1, SIRPG 1.11 0.1 C 
rs2304256 ICAM1, ICAM4, ICAM5, ZGLP1, FDX1L, FDX1L, CTD-2369P2.12, 
RAVER1, ICAM3, TYK2, CDC37, PDE4A, KEAP1, S1PR5 
1.16 0.15 C 
rs3024493 MAPKAPK2, IL10, IL19, IL20 1.22 0.2 C 
rs3825932 CHRNB4, ADAMTS7, MORF4L1, CTSH, RASGRF1 1.16 0.15 T 
rs402072 DACT3, PRKD2, STRN4, FKRP, SLC1A5 1.15 0.14 T 
rs4763879 CD69, KLRB1, CLEC2D, CLECL1 1.09 0.09 A 
rs478222 DNMT3A,CENPO, ADCY3, DNAJC27, EFR3B, POMC 1.15 0.14 A 
rs4849135 ACOXL,LINC00116, LIMS3, LIMS3L, RGPD6, BUB1, ACOXL 1.12 0.11 G 
rs4948088 COBL 1.30 0.26 C 
rs5753037 NF2, CABP7, ZMAT5, UQCR10, ASCC2, MTMR3, HORMAD2, LIF, 
OSM 
1.11 0.1 T 
rs597325 BACH2 1.19 0.17 G 
rs601338 FUT2,SULT2B1, FAM83E, SPACA4, RPL18, SPHK2, DBP, CA11, 
NTN5, MAMSTR, RASIP1, IZUMO1, FUT1, FGF21 
1.34 0.29 A 
rs602662 FUT2,SULT2B1, FAM83E, SPACA4, RPL18, SPHK2, DBP, CA11, 
NTN5, MAMSTR, RASIP1, IZUMO1, FUT1, FGF21 
1.12 0.11 A 
rs61839660 IL2RA, RBM17, PFKFB3 1.62 0.48 C 
rs6476839 GLIS3 1.12 0.11 T 
rs6679677 PTPN22, PHTF1 1.82 0.6 A 
rs6691977 KIF14, DDX59, CAMSAP2, GPR25, C1orf106 1.13 0.12 C 
rs689 INS,IGF2, INS-IGF2,TH 2.39 0.87 T 
rs6920220 TNFAIP3 1.12 0.11 A 
rs705705 IKZF4,PMEL, CDK2, RAB5B, SUOX,  RPS26, ERBB3, RP11-603J24.9, 
PA2G4, RPL41, ZC3H10, ESYT1, MYL6B, MYL6, SMARCC2, RNF41, 
NABP2, SLC39A5, ANKRD52, COQ10A, CS, RP11-977G19.10, 
CNPY2, PAN2, IL23A, STAT2, APOF 
1.25 0.22 C 
rs7090530 IL2RA, RBM17, PFKFB3 1.22 0.2 A 
rs7221109 CCR7, SMARCE1, KRT222, KRT222, KRT24 1.05 0.05 C 
rs72727394 RASGRP1, C15orf53 1.15 0.14 T 
 117 
 
 
rs72928038 BACH2 1.20 0.18 A 
rs7804356  SKAP2, C7orf71, HOXA1, HOXA2, HOXA3, HOXA4, HOXA5, HOXA6, 
HOXA7, HOXA9 
1.14 0.13 T 
rs7928968 INS,IGF2, INS-IGF2,TH 1.25 0.22 T 
rs911263 RAD51B, ZFP36L1 1.12 0.11 T 
rs924043 WDR27, C6orf120, PHF10, TCTE3, ERMARD, DLL1, FAM120B, 
PSMB1, TBP, PDCD2 
1.19 0.17 C 
rs9272346 MHC 5.58 1.72 A 
rs9585056 UBAC2, GPR18, GPR183, TM9SF2 1.12 0.11 C 
rs9924471 SBK1, NPIPB6, EIF3CL, NPIPB7, CLN3, CLN3, APOBR, IL27, NUPR1, 
CCDC101, SULT1A2, SULT1A1, NPIPB8, EIF3C, NPIPB9, ATXN2L, 
TUFM, SH2B1, ATP2A1, RABEP2, CD19, NFATC2IP, SPNS1, LAT 
1.25 0.22 A 
rs10877012 CYP27B1 1.22 0.2 G 
rs11258747 PRKCQ 1.45 0.37 G 
rs1465788 RAD51B, ZFP36L1 1.16 0.15 C 
rs229541 IL2RB, C1QTNF6, SSTR3, RAC2 1.12 0.11 A 
rs2542151 PTPN2 1.30 0.26 G 
rs2611215 TMEM192, KLHL2, MSMO1, CPE, TLL1 1.19 0.17 A 
rs6827756 KIAA1109, ADAD1, IL2, IL21 1.13 0.12 T 
rs694739 BAD,MACROD1, FLRT1, STIP1, FERMT3, TRPT1, NUDT22, DNAJC4, 
VEGFB, FKBP2, PPP1R14B, PLCB3, GPR137, KCNK4, TEX40, 
ESRRA, TRMT112, PRDX5, CCDC88B, RPS6KA4 
1.05 0.05 A 
rs722988 ITGB1, NRP1 1.11 0.1 C 
rs941576 DLK1 1.14 0.13 A 
rs9653442 AFF3 1.11 0.1 C 
Type 2 
Diabetes SNP 
Gene Odds 
Ratio 
Weight Effect 
Allele 
rs7903146 TCF7L2 1.40 0.34 T 
rs17791513 TLE4 1.21 0.19 A 
rs7756992 CDKAL1 1.20 0.18 G 
rs10811661 CDKN2A/B 1.19 0.17 T 
rs3802177 SLC30A8 1.16 0.15 G 
rs2261181 HMGA2 1.16 0.15 T 
rs1111875 HHEX/IDE 1.15 0.14 C 
rs10203174 THADA 1.15 0.14 C 
rs9936385 FTO 1.13 0.12 C 
rs6878122 ZBED3 1.13 0.12 G 
rs4430796 HNF1B 1.13 0.12 G 
rs4402960 IGF2BP 1.13 0.12 T 
rs17168486 DGKB 1.13 0.12 T 
rs1552224 ARAP1 (CENTD2) 1.13 0.12 A 
rs10401969 CILP2 1.13 0.12 C 
rs849135 JAZF1 1.12 0.11 G 
rs12427353 HNF1A 1.12 0.11 G 
rs7593730 RBMS1 1.11 0.1 C 
rs10830963 MTNR1B 1.11 0.1 G 
rs7612463 UBE2E2 1.11 0.1 C 
rs516946 ANK1 1.11 0.1 C 
rs17106184 FAF1 1.11 0.1 G 
rs1359790 SPRY2 1.11 0.1 G 
rs13233731 KLF14 1.11 0.1 G 
rs11063069 CCND2 1.11 0.1 G 
rs10923931 NOTCH2 1.11 0.1 T 
rs7955901 TSPAN8 1.09 0.09 C 
rs4458523 WFS1 1.09 0.09 G 
rs2943640 IRS1 1.09 0.09 C 
rs243088 BCL11A 1.09 0.09 T 
rs163184 KCNQ1 1.09 0.09 G 
rs12899811 PRC1 1.09 0.09 G 
rs12571751 ZMIZ1 1.09 0.09 A 
rs11717195 ADCY5 1.09 0.09 T 
rs11634397 ZFAND6 1.09 0.09 G 
 
rs10842994 
KLHDC5 1.09 0.09 C 
rs7845219 TP53INP1 1.08 0.08 T 
rs7178572 HMG20A 1.08 0.08 G 
rs702634 ARL15 1.08 0.08 A 
rs6813195 TMEM154 1.08 0.08 C 
rs6808574 LPP 1.08 0.08 C 
rs5215 KCNJ11 1.08 0.08 C 
rs2075423 PROX1 1.08 0.08 G 
rs12970134 MC4R 1.08 0.08 A 
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rs9505118 SSR1/RREB1 1.07 0.07 A 
rs6795735 ADAMTS9 1.07 0.07 C 
rs4812829 HNF4A 1.07 0.07 A 
rs4275659 MPHOSPH9 1.07 0.07 C 
rs2796441 TLE1 1.07 0.07 G 
rs2334499 DUSP8 1.07 0.07 T 
rs8108269 GIPR 1.06 0.06 G 
rs7163757 C2CD4A 1.06 0.06 C 
rs11257655 CDC123 1.06 0.06 T 
rs7041847 GLIS3 1.05 0.05 A 
rs459193 ANKRD55 1.05 0.05 G 
rs10278336 GCK 1.05 0.05 A 
rs780094 GCKR 1.04 0.04 C 
rs3923113 GRB14 1.04 0.04 A 
rs2028299 AP3S2 1.04 0.04 C 
rs831571 PSMD6 1.03 0.03 C 
rs16861329 ST64GAL1 1.03 0.03 C 
rs7403531 RASGRP1 1.02 0.02 T 
rs3786897 PEPD 1.02 0.02 A 
rs1802295 VPS26A 1.02 0.02 T 
rs9470794 ZFAND3 1.01 0.01 T 
rs6723108 TMEM163 1.01 0.01 T 
rs6467136 GCC1 1.01 0.01 A 
 
Supp. Table 3-1. Established SNPs for GRS Calculation 
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Supp. Table 3-2. LADA (n= 978) vs T1D and BMDCS controls testing T1D candidae 
loci
RSID Locus Chr T1D Alleles 
Risk/Other 
Risk Allele Frequency LADA Odds Ratio LADA P-
value 
LADA vs 
T1D P-
value 
LADA T1D Control 
rs9272346 MHC 6 A/G 0.686 0.818 0.579 1.455 [1.427-1.483] 9.64E-11 1.26E-17 
rs6679677 PTPN22 1 A/C 0.143 0.17 0.093 1.469 [1.427-1.510] 6.38E-06 2.61E-02 
rs17696736 SH2B3 12 G/A 0.515 0.503 0.44 1.277 [1.250-1.304] 1.10E-05 5.42E-01 
rs689 INS,IGF2 11 T/A 0.796 0.741 0.73 1.265 [1.234-1.296] 2.39E-04 3.88E-04 
rs597325 BACH2 6 G/A 0.646 0.647 0.583 1.192 [1.164-1.220] 2.11E-03 5.06E-01 
rs7804356 SKAP2 7 T/C 0.791 0.768 0.751 1.217 [1.185-1.249] 2.77E-03 5.87E-02 
rs11954020 IL7R 5 G/C 0.438 0.415 0.387 1.174 [1.146-1.202] 5.44E-03 2.03E-01 
rs4505848 KIAA1109 4 G/A 0.36 0.363 0.321 1.160 [1.131-1.189] 1.23E-02 7.92E-01 
rs9585056 UBAC2 13 C/T 0.246 0.266 0.22 1.174 [1.142-1.206] 1.54E-02 3.44E-02 
rs11755527 BACH2 6 G/C 0.481 0.5 0.43 1.139 [1.112-1.166] 1.75E-02 2.36E-01 
rs229541 IL2RB 22 A/G 0.436 0.468 0.412 1.136 [1.108-1.164] 2.81E-02 6.70E-02 
rs1538171 CENPW 6 G/C 0.514 0.475 0.472 1.127 [1.099-1.155] 3.64E-02 1.38E-01 
rs402072 DACT3 19 T/C 0.861 0.862 0.841 1.173 [1.134-1.212] 4.41E-02 6.13E-01 
rs12908309 RASGRP1 15 G/A 0.779 0.78 0.76 1.142 [1.107-1.176] 5.96E-02 3.07E-01 
rs9653442 AFF3 2 C/T 0.485 0.502 0.454 1.109 [1.082-1.137] 6.53E-02 2.71E-01 
rs7928968 INS,IGF2 11 T/A 0.259 0.267 0.232 1.144 [1.108-1.180] 6.72E-02 4.27E-01 
rs72928038 BACH2 6 A/G 0.193 0.21 0.168 1.162 [1.122-1.202] 6.74E-02 9.66E-03 
rs601338 FUT2 19 A/G 0.451 0.456 0.507 0.905 [0.878-0.932] 7.33E-02 8.10E-01 
rs6476839 GLIS3 9 T/A 0.448 0.435 0.413 1.096 [1.067-1.124] 1.14E-01 5.32E-01 
rs911263 RAD51B 14 T/C 0.706 0.74 0.691 1.091 [1.062-1.121] 1.49E-01 2.38E-01 
rs602662 FUT2 19 G/A 0.523 0.518 0.513 1.084 [1.057-1.111] 1.49E-01 5.72E-01 
rs2542151 PTPN2 18 G/T 0.148 0.202 0.166 0.897 [0.860-0.934] 1.53E-01 2.58E-03 
rs4763879 CD69 12 A/G 0.397 0.392 0.376 1.085 [1.056-1.113] 1.58E-01 8.13E-01 
rs694739 BAD,  11 A/G 0.64 0.639 0.608 1.085 [1.056-1.113] 1.64E-01 7.21E-01 
rs941576 DLK1 14 A/G 0.574 0.602 0.56 1.084 [1.055-1.112] 1.64E-01 3.81E-01 
rs10509540 RNLS 10 T/C 0.741 0.75 0.716 1.086 [1.056-1.116] 1.76E-01 7.69E-01 
rs4849135 ACOXL 2 G/T 0.73 0.727 0.717 1.076 [1.045-1.107] 2.42E-01 9.59E-01 
rs10877012 CYP27B1 12 T/G 0.336 0.313 0.311 1.071 [1.042-1.101] 2.48E-01 2.91E-01 
rs3024493 MAPKAPK2 1 C/A 0.855 0.856 0.839 1.088 [1.050-1.125] 2.73E-01 7.29E-01 
rs4948088 COBL 7 C/A 0.965 0.962 0.958 1.158 [1.087-1.229] 3.11E-01 8.67E-01 
rs11571316 CTLA4 2 G/A 0.602 0.623 0.588 1.060 [1.032-1.088] 3.14E-01 2.43E-01 
rs7111341 INS,IGF2 11 C/T 0.757 0.75 0.73 1.063 [1.032-1.094] 3.35E-01 6.90E-01 
rs72727394 RASGRP1 15 T/C 0.195 0.223 0.185 1.071 [1.036-1.107] 3.39E-01 5.47E-02 
rs6691977 KIF14 1 C/T 0.213 0.219 0.207 1.065 [1.032-1.098] 3.56E-01 5.00E-01 
rs1456988 C14orf64 14 G/T 0.276 0.301 0.26 1.060 [1.029-1.091] 3.57E-01 3.37E-01 
rs1465788 RAD51B 14 C/T 0.735 0.733 0.728 1.059 [1.027-1.090] 3.70E-01 8.25E-01 
rs1615504 DOK6 18 T/C 0.492 0.504 0.473 1.051 [1.023-1.080] 3.90E-01 3.12E-01 
rs7221109 CCR7 17 C/T 0.621 0.687 0.632 0.954 [0.925-0.983] 4.23E-01 6.54E-04 
rs12148472 CHRNB4 15 T/C 0.879 0.899 0.884 0.935 [0.893-0.978] 4.40E-01 1.64E-02 
rs1738074 RSPH3 6 C/T 0.607 0.568 0.585 1.045 [1.017-1.073] 4.43E-01 2.67E-02 
rs6920220 TNFAIP3 6 A/G 0.22 0.248 0.205 1.053 [1.019-1.087] 4.53E-01 1.21E-01 
rs1990760 GCG 2 T/C 0.633 0.651 0.618 1.043 [1.015-1.071] 4.59E-01 6.66E-01 
rs2611215 TMEM192 4 A/G 0.175 0.173 0.165 1.054 [1.018-1.091] 4.81E-01 7.07E-01 
rs61839660 IL2RA 10 C/T 0.91 0.923 0.899 1.064 [1.017-1.111] 5.19E-01 2.09E-03 
rs7090530 IL2RA 10 A/C 0.605 0.645 0.611 0.964 [0.936-0.993] 5.34E-01 1.12E-02 
rs2281808 SIRPD 20 C/T 0.677 0.666 0.659 1.037 [1.007-1.067] 5.47E-01 5.34E-01 
rs722988 ITGB1 10 C/T 0.391 0.401 0.387 1.035 [1.006-1.063] 5.55E-01 6.23E-01 
rs113010081 CCR5 3 T/C 0.887 0.901 0.882 1.052 [1.008-1.097] 5.77E-01 2.05E-01 
rs5753037 NF2 22 T/C 0.381 0.415 0.375 1.032 [1.004-1.060] 5.83E-01 4.47E-01 
rs2304256 ICAM1 19 C/A 0.729 0.73 0.722 1.033 [1.003-1.064] 5.98E-01 8.94E-01 
rs11203203 UBASH3A 21 A/G 0.389 0.401 0.371 1.031 [1.002-1.059] 6.01E-01 3.78E-01 
rs705705 IKZF 12 C/G 0.341 0.386 0.331 1.031 [1.002-1.061] 6.12E-01 1.82E-01 
rs478222 DNMT3A 2 A/T 0.564 0.628 0.581 0.971 [0.943-1.000] 6.17E-01 5.05E-02 
rs11171710 IKZF4 12 A/G 0.458 0.397 0.447 1.025 [0.998-1.053] 6.58E-01 1.90E-02 
rs7202877 CTRB2 16 G/T 0.111 0.115 0.106 1.038 [0.995-1.082] 6.72E-01 2.50E-01 
rs11258747 PRKCQ 10 G/T 0.77 0.761 0.77 1.028 [0.996-1.061] 6.73E-01 6.77E-01 
rs12708716 CLEC16A 16 A/G 0.637 0.702 0.633 1.024 [0.996-1.052] 6.84E-01 5.55E-03 
rs10795791 IL2RA 10 G/A 0.434 0.456 0.418 1.022 [0.994-1.049] 7.06E-01 4.83E-02 
rs3825932 CHRNB4 15 T/C 0.311 0.29 0.309 1.023 [0.993-1.053] 7.06E-01 2.23E-01 
rs10517086 SLC34A2 4 A/G 0.303 0.326 0.305 1.021 [0.991-1.050] 7.33E-01 4.80E-01 
rs10492166 CD69 12 G/A 0.508 0.549 0.506 1.019 [0.991-1.046] 7.40E-01 2.10E-02 
rs9924471 SBK1 16 A/G 0.18 0.18 0.176 1.019 [0.983-1.055] 7.97E-01 7.30E-01 
rs193778 CLEC16A 16 G/A 0.239 0.284 0.244 1.015 [0.983-1.047] 8.17E-01 5.64E-02 
rs11170466 ITGB7 12 T/C 0.06 0.056 0.058 0.978 [0.921-1.035] 8.46E-01 4.86E-01 
rs924043 WDR27 6 C/T 0.852 0.867 0.856 0.989 [0.949-1.029] 8.94E-01 3.16E-01 
rs12453507 FBXL20 17 G/C 0.524 0.541 0.522 1.005 [0.977-1.034] 9.28E-01 8.88E-01 
rs10272724 IKZF1 7 T/C 0.73 0.749 0.733 1.000 [0.969-1.031] 9.99E-01 6.14E-02 
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RSID Locus Chr T1D 
Alleles 
Risk/Other 
Risk Allele Frequency LADA Odds Ratio LADA P-
value 
LADA vs 
T1D P-
value 
LADA T1D Control 
rs9272346 MHC 6 A/G 0.651 0.818 0.579 1.296 [1.266-1.326] 6.84E-05 1.99E-24 
rs17696736 SH2B3 12 G/A 0.503 0.503 0.44 1.226 [1.197-1.256] 1.23E-03 0.99 
rs6679677 PTPN22 1 A/C 0.131 0.170 0.093 1.383 [1.336-1.429] 1.27E-03 0.01 
rs9585056 UBAC2 13 C/T 0.256 0.266 0.22 1.244 [1.209-1.279] 3.48E-03 0.25 
rs597325 BACH2 6 G/A 0.646 0.647 0.583 1.207 [1.177-1.237] 3.67E-03 0.56 
rs11954020 IL7R 5 G/C 0.444 0.415 0.387 1.191 [1.160-1.221] 0.01 0.17 
rs689 INS,IGF2 11 T/A 0.782 0.741 0.73 1.208 [1.175-1.241] 0.01 0.01 
rs229541 IL2RB 22 A/G 0.446 0.468 0.412 1.169 [1.138-1.199] 0.02 0.14 
rs4505848 KIAA1109 4 G/A 0.363 0.363 0.321 1.170 [1.139-1.201] 0.02 0.79 
rs1538171 CENPW 6 G/C 0.518 0.475 0.472 1.156 [1.126-1.186] 0.02 0.15 
rs7804356  SKAP2 7 T/C 0.781 0.768 0.751 1.166 [1.132-1.201] 0.04 0.31 
rs402072 DACT3 19 T/C 0.861 0.862 0.841 1.185 [1.143-1.226] 0.06 0.59 
rs601338 FUT2 19 A/G 0.446 0.456 0.493 0.888 [0.858-0.918] 0.06 0.95 
rs11755527 BACH2 6 G/C 0.474 0.5 0.43 1.119 [1.090-1.148] 0.07 0.14 
rs10877012 CYP27B1 12 T/G 0.344 0.313 0.311 1.120 [1.089-1.152] 0.09 0.17 
rs12908309 RASGRP1 15 G/A 0.779 0.78 0.76 1.137 [1.100-1.175] 0.11 0.43 
rs602662 FUT2 19 G/A 0.528 0.518 0.487 1.104 [1.074-1.133] 0.12 0.74 
rs2542151 PTPN2 18 G/T 0.149 0.202 0.166 0.887 [0.847-0.927] 0.16 1.20E-03 
rs3024493 MAPKAPK2 1 C/A 0.857 0.856 0.839 1.118 [1.077-1.158] 0.20 0.84 
rs7928968 INS,IGF2 11 T/A 0.251 0.267 0.232 1.112 [1.073-1.152] 0.21 0.22 
rs941576 DLK1 14 A/G 0.574 0.602 0.56 1.085 [1.055-1.116] 0.21 0.39 
rs2611215 TMEM192 4 A/G 0.187 0.173 0.165 1.110 [1.070-1.149] 0.22 0.42 
rs12148472 CHRNB4 15 T/C 0.873 0.899 0.884 0.887 [0.842-0.933] 0.22 2.36E-03 
rs4763879 CD69 12 A/G 0.394 0.392 0.376 1.078 [1.048-1.108] 0.25 0.81 
rs4948088 COBL 7 C/A 0.967 0.962 0.958 1.206 [1.130-1.283] 0.25 0.83 
rs7090530 IL2RA 10 A/C 0.591 0.645 0.611 0.927 [0.897-0.958] 0.26 2.88E-03 
rs72928038 BACH2 6 A/G 0.184 0.21 0.168 1.110 [1.066-1.153] 0.27 3.33E-03 
rs6476839 GLIS3 9 T/A 0.44 0.435 0.413 1.070 [1.040-1.101] 0.30 0.94 
rs10509540 RNLS 10 T/C 0.738 0.75 0.716 1.073 [1.041-1.105] 0.31 0.63 
rs5753037 NF2 22 T/C 0.386 0.415 0.375 1.063 [1.033-1.093] 0.34 0.82 
rs1456988 C14orf64 14 G/T 0.274 0.301 0.26 1.067 [1.033-1.100] 0.37 0.24 
rs9653442 AFF3 2 C/T 0.472 0.502 0.454 1.057 [1.028-1.087] 0.38 0.11 
rs6920220 TNFAIP3 6 A/G 0.22 0.248 0.205 1.061 [1.024-1.097] 0.45 0.12 
rs11171710 IKZF4 12 A/G 0.466 0.397 0.447 1.049 [1.019-1.079] 0.45 4.31E-03 
rs4849135 ACOXL 2 G/T 0.724 0.727 0.717 1.054 [1.021-1.087] 0.46 1.00 
rs694739 BAD 11 A/G 0.626 0.639 0.608 1.049 [1.018-1.079] 0.47 0.32 
rs1465788 RAD51B 14 C/T 0.734 0.733 0.728 1.052 [1.019-1.085] 0.48 0.96 
rs10492166 CD69 12 G/A 0.515 0.549 0.506 1.044 [1.015-1.074] 0.49 0.13 
rs722988 ITGB1 10 C/T 0.396 0.401 0.387 1.041 [1.010-1.072] 0.54 0.75 
rs11258747 PRKCQ 10 G/T 0.774 0.761 0.77 1.042 [1.007-1.077] 0.58 0.47 
rs924043 WDR27 6 C/T 0.845 0.867 0.856 0.951 [0.908-0.994] 0.59 0.13 
rs72727394 RASGRP1 15 T/C 0.194 0.223 0.185 1.045 [1.007-1.083] 0.59 0.05 
rs2281808 SIRPD 20 C/T 0.656 0.666 0.659 0.965 [0.934-0.997] 0.60 0.66 
rs7202877 CTRB2 16 G/T 0.114 0.115 0.106 1.053 [1.006-1.100] 0.61 0.31 
rs7111341 INS,IGF2 11 C/T 0.731 0.75 0.73 0.970 [0.937-1.003] 0.67 0.23 
rs113010081 CCR5 3 T/C 0.888 0.901 0.882 1.044 [0.996-1.092] 0.68 0.15 
rs1990760 GCG 2 T/C 0.629 0.651 0.618 1.027 [0.997-1.057] 0.68 0.67 
rs6691977 KIF14 1 C/T 0.208 0.219 0.207 1.030 [0.994-1.066] 0.71 0.31 
rs10795791 IL2RA 10 G/A 0.418 0.456 0.418 0.976 [0.946-1.006] 0.71 0.01 
rs1738074 RSPH3 6 C/T 0.601 0.568 0.585 1.024 [0.993-1.054] 0.72 0.08 
rs1615504 DOK6 18 T/C 0.488 0.504 0.473 1.023 [0.993-1.054] 0.73 0.22 
rs61839660 IL2RA 10 C/T 0.905 0.923 0.899 1.037 [0.987-1.087] 0.74 3.47E-03 
rs193778 CLEC16A 16 G/A 0.236 0.284 0.244 1.023 [0.989-1.058] 0.76 0.11 
rs10272724 IKZF1 7 T/C 0.726 0.749 0.733 0.979 [0.946-1.013] 0.77 0.06 
rs911263 RAD51B 14 T/C 0.69 0.74 0.691 1.016 [0.984-1.048] 0.82 0.05 
rs3825932 CHRNB4 15 T/C 0.309 0.29 0.309 1.016 [0.984-1.049] 0.82 0.24 
rs11203203 UBASH3A 21 A/G 0.385 0.401 0.371 1.013 [0.983-1.044] 0.84 0.38 
rs7221109 CCR7 17 C/T 0.624 0.687 0.632 0.989 [0.958-1.021] 0.87 4.39E-03 
rs2304256 ICAM1 19 C/A 0.724 0.73 0.722 1.009 [0.976-1.041] 0.90 0.74 
rs12453507 FBXL20 17 G/C 0.517 0.541 0.522 0.992 [0.962-1.023] 0.91 0.73 
rs9924471 SBK1 16 A/G 0.174 0.18 0.824 0.992 [0.953-1.031] 0.92 0.48 
rs705705 IKZF4 12 C/G 0.331 0.386 0.331 0.994 [0.962-1.026] 0.93 0.09 
rs10517086 SLC34A2 4 A/G 0.3 0.326 0.305 1.006 [0.974-1.038] 0.93 0.20 
rs12708716 CLEC16A 16 A/G 0.632 0.702 0.633 1.004 [0.973-1.034] 0.96 0.01 
rs11571316 CTLA4 2 G/A 0.587 0.623 0.588 1.002 [0.972-1.032] 0.97 0.10 
rs478222 DNMT3A 2 A/T 0.574 0.628 0.581 1.002 [0.971-1.033] 0.98 0.11 
rs11170466 ITGB7 12 T/C 0.061 0.056 0.058 0.998 [0.936-1.060] 0.99 0.38 
Supp. Table 3-3. LADA cases positive for GADA only (n= 669) vs T1D and BMDCS 
controls testing T1D candidate loci
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Supp. Table 3-4. LADA cases positive for GADA and IA2A (n= 309) vs T1D and BMDCS 
controls testing T1D candidate loci 
 
 
RSID Locus Chr T1D Alleles 
Risk/Other 
Risk Allele Frequency LADA Odds Ratio LADA P-
value 
LADA vs 
T1D P-
value 
LADA T1D Control 
rs9272346 MHC 6 A/G 0.763 0.818 0.579 1.983 [1.954-2.012] 1.20E-15 4.01E-03 
rs6679677 PTPN22 1 A/C 0.17 0.17 0.093 1.864 [1.819-1.909] 2.19E-06 6.03E-01 
rs17696736 SH2B3  12 G/A 0.542 0.503 0.44 1.481 [1.452-1.511] 5.93E-06 1.80E-01 
rs689 INS,IGF2 11 T/A 0.824 0.741 0.73 1.440 [1.407-1.474] 1.90E-04 1.68E-06 
rs7111341 INS,IGF2 11 C/T 0.812 0.75 0.73 1.360 [1.327-1.394] 1.82E-03 2.39E-04 
rs7804356  SKAP2 7 T/C 0.814 0.768 0.751 1.354 [1.320-1.388] 2.27E-03 1.22E-02 
rs2281808 SIRPD 20 C/T 0.723 0.666 0.659 1.276 [1.244-1.308] 9.17E-03 9.53E-03 
rs694739 BAD 11 A/G 0.672 0.639 0.608 1.253 [1.223-1.283] 1.06E-02 3.07E-01 
rs911263 RAD51B 14 T/C 0.739 0.74 0.691 1.265 [1.233-1.297] 1.09E-02 6.27E-01 
rs72928038 BACH2 6 A/G 0.213 0.21 0.168 1.367 [1.324-1.410] 1.31E-02 4.29E-01 
rs9653442 AFF3 2 C/T 0.515 0.502 0.454 1.235 [1.205-1.264] 1.37E-02 5.59E-01 
rs11571316 CTLA4 2 G/A 0.634 0.623 0.588 1.238 [1.208-1.268] 1.48E-02 5.03E-01 
rs11755527 BACH2 6 G/C 0.495 0.5 0.43 1.229 [1.200-1.258] 1.54E-02 6.10E-01 
rs7928968 INS,IGF2 11 T/A 0.276 0.267 0.232 1.292 [1.253-1.331] 2.32E-02 5.67E-01 
rs597325 BACH2 6 G/A 0.646 0.647 0.583 1.216 [1.186-1.246] 2.68E-02 6.67E-01 
rs10795791 IL2RA 10 G/A 0.469 0.456 0.418 1.200 [1.171-1.229] 3.39E-02 6.80E-01 
rs6476839 GLIS3 9 T/A 0.465 0.435 0.413 1.188 [1.158-1.219] 5.29E-02 2.04E-01 
rs4505848 KIAA1109 4 G/A 0.354 0.363 0.321 1.161 [1.130-1.192] 1.01E-01 9.74E-01 
rs705705 IKZF4  12 C/G 0.364 0.386 0.331 1.158 [1.126-1.190] 1.14E-01 7.76E-01 
rs11954020 IL7R 5 G/C 0.424 0.415 0.387 1.149 [1.118-1.179] 1.18E-01 5.20E-01 
rs4763879 CD69 12 A/G 0.405 0.392 0.376 1.139 [1.108-1.169] 1.48E-01 7.25E-01 
rs61839660 IL2RA 10 C/T 0.921 0.923 0.899 1.223 [1.173-1.273] 1.66E-01 2.66E-01 
rs1738074 RSPH3 6 C/T 0.62 0.568 0.585 1.119 [1.089-1.148] 1.93E-01 1.26E-02 
rs402072 DACT3 19 T/C 0.861 0.862 0.841 1.168 [1.127-1.209] 1.93E-01 7.25E-01 
rs10509540 RNLS 10 T/C 0.748 0.75 0.716 1.123 [1.090-1.155] 2.19E-01 9.90E-01 
rs478222 DNMT3A 2 A/T 0.542 0.628 0.581 0.896 [0.865-0.927] 2.24E-01 1.32E-02 
rs7221109 CCR7 17 C/T 0.615 0.687 0.632 0.898 [0.867-0.928] 2.27E-01 1.96E-03 
rs4849135 ACOXL 2 G/T 0.744 0.727 0.717 1.122 [1.090-1.155] 2.28E-01 6.52E-01 
rs2542151 PTPN2 18 G/T 0.147 0.202 0.166 0.877 [0.838-0.916] 2.50E-01 4.07E-02 
rs1615504 DOK6 18 T/C 0.499 0.504 0.473 1.106 [1.076-1.136] 2.50E-01 6.01E-01 
rs6691977 KIF14 1 C/T 0.223 0.219 0.207 1.124 [1.089-1.160] 2.58E-01 8.94E-01 
rs9924471 SBK1  16 A/G 0.193 0.18 0.176 1.133 [1.095-1.172] 2.65E-01 7.40E-01 
rs1990760 GCG 2 T/C 0.642 0.651 0.618 1.100 [1.070-1.130] 2.69E-01 7.60E-01 
rs12908309 RASGRP1 15 G/A 0.778 0.78 0.76 1.124 [1.087-1.160] 2.69E-01 3.31E-01 
rs1538171 CENPW 6 G/C 0.505 0.475 0.472 1.099 [1.069-1.128] 2.76E-01 4.97E-01 
rs2304256 ICAM1 19 C/A 0.739 0.73 0.722 1.107 [1.074-1.140] 2.92E-01 3.85E-01 
rs12708716 CLEC16A 16 A/G 0.647 0.702 0.633 1.093 [1.063-1.124] 3.15E-01 9.47E-02 
rs7090530 IL2RA 10 A/C 0.636 0.645 0.611 1.089 [1.059-1.119] 3.32E-01 9.76E-01 
rs1456988 C14orf64 14 G/T 0.278 0.301 0.26 1.097 [1.065-1.130] 3.32E-01 7.46E-01 
rs2611215 TMEM192 4 A/G 0.149 0.173 0.165 0.898 [0.858-0.938] 3.57E-01 2.38E-01 
rs72727394 RASGRP1 15 T/C 0.198 0.223 0.185 1.103 [1.065-1.140] 3.75E-01 1.82E-01 
rs11203203 UBASH3A 21 A/G 0.396 0.401 0.371 1.079 [1.049-1.109] 3.82E-01 9.08E-01 
rs941576 DLK1 14 A/G 0.574 0.602 0.56 1.079 [1.049-1.109] 3.84E-01 6.79E-01 
rs601338 FUT2 19 A/G 0.461 0.456 0.493 0.935 [0.906-0.964] 4.30E-01 7.86E-01 
rs3024493 MAPKAPK2 1 C/A 0.85 0.856 0.839 1.087 [1.047-1.126] 4.73E-01 7.16E-01 
rs924043 WDR27 6 C/T 0.866 0.867 0.856 1.084 [1.041-1.127] 5.19E-01 7.56E-01 
rs229541 IL2RB 22 A/G 0.414 0.468 0.412 1.057 [1.026-1.089] 5.39E-01 2.07E-02 
rs12148472 CHRNB4 15 T/C 0.893 0.899 0.884 1.085 [1.038-1.131] 5.48E-01 8.32E-01 
rs10517086 SLC34A2 4 A/G 0.309 0.326 0.305 1.054 [1.023-1.085] 5.61E-01 9.95E-01 
rs1465788 RAD51B 14 C/T 0.736 0.733 0.728 1.056 [1.023-1.090] 5.76E-01 9.36E-01 
rs11171710 IKZF4 12 A/G 0.44 0.397 0.447 0.953 [0.923-0.983] 5.78E-01 3.13E-01 
rs6920220 TNFAIP3 6 A/G 0.218 0.248 0.205 1.059 [1.023-1.095] 5.85E-01 2.27E-01 
rs602662 FUT2 19 G/A 0.513 0.518 0.487 1.045 [1.016-1.074] 6.04E-01 6.69E-01 
rs12453507 ERBB2  17 G/C 0.538 0.541 0.522 1.041 [1.011-1.072] 6.48E-01 7.67E-01 
rs9585056 UBAC2 13 C/T 0.227 0.266 0.22 1.045 [1.010-1.080] 6.68E-01 2.18E-02 
rs3825932 CHRNB4 15 T/C 0.314 0.29 0.309 1.041 [1.009-1.074] 6.70E-01 3.32E-01 
rs10272724 IKZF1  7 T/C 0.738 0.749 0.733 1.025 [0.992-1.058] 8.00E-01 3.56E-01 
rs193778 CLEC16A 16 G/A 0.244 0.284 0.244 1.024 [0.990-1.059] 8.10E-01 1.62E-01 
rs10492166 CD69 12 G/A 0.49 0.549 0.506 0.981 [0.951-1.010] 8.20E-01 1.82E-02 
rs11170466 ITGB7 12 T/C 0.06 0.056 0.058 0.965 [0.904-1.026] 8.42E-01 9.89E-01 
rs722988 ITGB1 10 C/T 0.379 0.401 0.387 1.016 [0.985-1.046] 8.59E-01 5.64E-01 
rs11258747 PRKCQ 10 G/T 0.764 0.761 0.77 0.989 [0.954-1.024] 9.11E-01 8.21E-01 
rs10877012 CYP27B1 12 T/G 0.32 0.313 0.311 1.007 [0.976-1.038] 9.39E-01 5.86E-01 
rs5753037 NF2 22 T/C 0.371 0.415 0.375 0.994 [0.964-1.024] 9.45E-01 2.26E-01 
rs4948088 COBL 7 C/A 0.96 0.962 0.958 1.007 [0.933-1.081] 9.74E-01 3.03E-01 
rs113010081 CCR5 3 T/C 0.886 0.901 0.882 0.998 [0.951-1.046] 9.91E-01 1.85E-01 
rs7202877 CTRB2 16 G/T 0.105 0.115 0.106 1.001 [0.954-1.048] 9.94E-01 3.51E-01 
 122 
 
 
RSID Locus Chr T2D Alleles 
Risk/Other 
Risk Allele Frequency LADA Odds 
Ratio 
LADA P-
value 
LADA vs T2D P-
value LADA T2D Control 
rs12427353 HNF1A 12 G/C 0.831 0.828 0.787 
1.291 [1.256-
1.326] 3.42E-04 5.38E-01 
rs849135 JAZF1 7 G/A 0.526 0.529 0.485 
1.165 [1.137-
1.193] 7.99E-03 8.10E-01 
rs6723108 TMEM163 2 T/G 0.617 0.521 0.553 
1.149 [1.121-
1.177] 1.58E-02 2.21E-03 
rs11634397 ZFAND6 15 G/A 0.683 0.679 0.653 
1.152 [1.123-
1.181] 1.67E-02 9.25E-01 
rs8108269 GIPR 19 G/T 0.338 0.31 0.292 
1.153 [1.123-
1.183] 1.96E-02 1.70E-01 
rs7178572 HMG20A 15 G/A 0.702 0.73 0.73 
0.870 [0.839-
0.900] 2.58E-02 8.38E-02 
rs12970134 MC4R 18 A/G 0.28 0.291 0.247 
1.151 [1.120-
1.181] 2.59E-02 5.59E-01 
rs16861329 ST64GAL1 3 C/T 0.882 0.872 0.861 
1.186 [1.145-
1.226] 3.92E-02 3.61E-01 
rs1111875 HHEX/IDE 10 C/T 0.625 0.634 0.59 
1.115 [1.087-
1.142] 5.36E-02 3.24E-01 
rs17106184 FAF1 1 G/A 0.91 0.918 0.895 
1.191 [1.146-
1.237] 6.00E-02 6.55E-01 
rs2943640 IRS1 2 C/A 0.662 0.675 0.634 
1.118 [1.089-
1.148] 6.58E-02 8.53E-01 
rs163184 KCNQ1 11 G/T 0.497 0.49 0.463 
1.104 [1.077-
1.132] 8.09E-02 6.43E-01 
rs10923931 NOTCH2 1 T/G 0.117 0.117 0.106 
1.161 [1.119-
1.204] 8.48E-02 9.67E-01 
rs6813195 TMEM154 4 C/T 0.74 0.737 0.718 
1.110 [1.079-
1.141] 1.03E-01 6.24E-01 
rs7041847 GLIS3 9 A/G 0.535 0.516 0.505 
1.097 [1.068-
1.125] 1.12E-01 2.24E-01 
rs5215 KCNJ11 11 C/T 0.382 0.382 0.362 
1.097 [1.068-
1.125] 1.15E-01 4.90E-01 
rs17168486 DGKB 7 T/C 0.187 0.172 0.163 
1.120 [1.085-
1.156] 1.17E-01 3.41E-01 
rs4430796 HNF1B 17 G/A 0.512 0.479 0.484 
1.092 [1.064-
1.121] 1.26E-01 2.51E-02 
rs10811661 CDKN2A/B 9 T/C 0.851 0.858 0.831 
1.120 [1.082-
1.157] 1.39E-01 6.04E-01 
rs10203174 THADA 2 C/T 0.887 0.897 0.871 
1.136 [1.094-
1.178] 1.40E-01 9.93E-02 
rs11063069 CCND2 12 G/A 0.21 0.223 0.221 
0.911 [0.878-
0.944] 1.65E-01 2.69E-01 
rs10886471 GRK5 10 T/C 0.469 0.477 0.489 
0.927 [0.899-
0.954] 1.78E-01 3.66E-01 
rs11717195 ADCY5 3 T/C 0.783 0.777 0.77 
1.096 [1.062-
1.130] 1.84E-01 3.07E-01 
rs391300 SRR 17 C/T 0.632 0.638 0.61 
1.079 [1.051-
1.107] 1.88E-01 7.14E-01 
rs780094 GCKR 2 C/T 0.571 0.618 0.6 
0.928 [0.900-
0.956] 1.88E-01 3.15E-02 
rs7403531 RASGRP1 15 T/C 0.221 0.229 0.204 
1.091 [1.058-
1.124] 1.97E-01 3.29E-01 
rs1802295 VPS26A 10 T/C 0.302 0.321 0.322 
0.925 [0.895-
0.956] 2.12E-01 1.21E-01 
rs17584499 PTPRD 9 T/C 0.212 0.17 0.193 
1.084 [1.051-
1.118] 2.35E-01 1.54E-03 
rs516946 ANK1 8 C/T 0.767 0.782 0.754 
1.080 [1.048-
1.112] 2.42E-01 7.69E-02 
rs3786897 PEPD 19 A/G 0.608 0.578 0.589 
1.070 [1.041-
1.098] 2.48E-01 6.75E-02 
rs2261181 HMGA2 12 T/C 0.115 0.109 0.101 
1.111 [1.066-
1.155] 2.54E-01 9.26E-01 
rs4275659 MPHOSPH9 12 C/T 0.715 0.735 0.694 
1.072 [1.042-
1.102] 2.55E-01 8.06E-01 
rs3923113 GRB14 2 A/C 0.646 0.656 0.632 
1.062 [1.034-
1.091] 3.03E-01 1.76E-01 
rs7955901 TSPAN8 12 C/T 0.461 0.487 0.438 
1.058 [1.031-
1.086] 3.11E-01 1.29E-01 
rs3802177 SLC30A8 8 G/A 0.684 0.706 0.699 
0.941 [0.911-
0.971] 3.23E-01 5.96E-02 
rs4458523 WFS1 4 G/T 0.611 0.614 0.59 
1.056 [1.028-
1.084] 3.36E-01 9.89E-01 
rs7163757 C2CD4A 15 C/T 0.573 0.59 0.588 
0.950 [0.923-
0.978] 3.65E-01 3.76E-02 
rs6878122 ZBED3 5 A/G 0.718 0.658 0.706 
1.051 [1.021-
1.081] 4.20E-01 8.81E-04 
rs17791513 TLE4 9 A/G 0.946 0.952 0.939 
1.096 [1.037-
1.154] 4.45E-01 6.81E-01 
rs459193 ANKRD55 5 G/A 0.753 0.771 0.741 
1.050 [1.018-
1.082] 4.55E-01 1.43E-01 
rs13233731 KLF14 7 G/A 0.544 0.538 0.527 
1.043 [1.015-
1.072] 4.67E-01 9.79E-01 
rs7593730 RBMS1 2 C/T 0.793 0.811 0.796 
1.052 [1.018-
1.085] 4.68E-01 4.54E-01 
rs2075423 PROX1 1 G/T 0.643 0.678 0.653 
0.959 [0.930-
0.988] 4.75E-01 2.41E-01 
rs10842994 KLHDC5 12 C/T 0.803 0.814 0.794 
1.050 [1.016-
1.083] 4.84E-01 4.23E-01 
rs1359790 SPRY2 13 G/A 0.746 0.741 0.736 
1.043 [1.011-
1.075] 5.16E-01 5.07E-01 
rs243088 BCL11A 2 T/A 0.494 0.492 0.485 
1.036 [1.008-
1.064] 5.32E-01 4.08E-01 
rs10401969 CILP2 19 C/T 0.077 0.088 0.067 
1.069 [1.016-
1.122] 5.37E-01 7.38E-02 
rs11257655 CDC123 10 T/C 0.194 0.236 0.213 
0.962 [0.927-
0.997] 5.85E-01 9.13E-02 
rs7756992 CDKAL1 6 G/A 0.306 0.316 0.289 
1.033 [1.003-
1.062] 5.96E-01 6.09E-01 
rs2796441 TLE1 9 G/A 0.607 0.582 0.601 
1.031 [1.003-
1.058] 5.97E-01 4.85E-02 
rs7202877 BCAR1 16 T/G 0.889 0.914 0.894 
0.963 [0.920-
1.007] 6.72E-01 4.14E-02 
 123 
 
 
rs4812829 HNF4A 20 G/A 0.836 0.837 0.831 
1.033 [0.995-
1.070] 6.74E-01 3.23E-01 
rs7612463 UBE2E2 3 C/A 0.887 0.894 0.89 
0.963 [0.918-
1.007] 6.75E-01 1.19E-01 
rs10830963 MTNR1B 11 G/C 0.292 0.27 0.29 
0.974 [0.944-
1.005] 6.76E-01 2.28E-01 
rs10278336 GCK 7 A/G 0.58 0.577 0.579 
1.024 [0.996-
1.053] 6.82E-01 3.21E-01 
rs12899811 PRC1 15 G/A 0.324 0.315 0.306 
1.024 [0.994-
1.053] 6.98E-01 9.54E-01 
rs7903146 TCF7L2 10 T/C 0.295 0.376 0.298 
1.023 [0.994-
1.053] 7.02E-01 5.21E-06 
rs9936385 FTO 16 C/T 0.4 0.454 0.394 
1.022 [0.994-
1.050] 7.09E-01 1.80E-03 
rs6795735 ADAMTS9 3 C/T 0.571 0.618 0.575 
0.982 [0.955-
1.009] 7.45E-01 1.26E-02 
rs9505118 SSR1/RREB1 6 A/G 0.595 0.612 0.592 
1.018 [0.989-
1.046] 7.60E-01 1.91E-01 
rs831571 PSMD6 3 C/T 0.829 0.81 0.827 
1.023 [0.986-
1.059] 7.64E-01 1.74E-01 
rs7845219 TP53INP1 8 T/C 0.515 0.525 0.515 
0.983 [0.955-
1.011] 7.65E-01 3.86E-01 
rs4402960 IGF2BP 3 T/G 0.305 0.351 0.314 
0.983 [0.952-
1.013] 7.82E-01 1.01E-02 
rs12571751 ZMIZ1 10 A/G 0.544 0.583 0.549 
0.988 [0.960-
1.015] 8.27E-01 1.02E-02 
rs2334499 DUSP8 11 T/C 0.409 0.418 0.41 
1.011 [0.983-
1.039] 8.52E-01 1.93E-01 
rs6467136 GCC1 7 A/G 0.479 0.472 0.477 
1.008 [0.981-
1.036] 8.85E-01 7.75E-01 
rs9470794 ZFAND3 6 T/C 0.908 0.911 0.908 
1.014 [0.966-
1.061] 8.89E-01 3.93E-01 
rs2028299 AP3S2 15 C/A 0.284 0.297 0.291 
0.995 [0.965-
1.026] 9.42E-01 7.89E-01 
rs1552224 
ARAP1 
(CENTD2) 11 A/C 0.851 0.849 0.85 
1.005 [0.967-
1.043] 9.45E-01 8.96E-01 
rs702634 ARL15 5 A/G 0.306 0.289 0.299 
0.997 [0.967-
1.027] 9.56E-01 5.92E-01 
rs6808574 LPP 3 C/T 0.621 0.604 0.613 
1.003 [0.975-
1.031] 9.60E-01 7.07E-01 
Supp. Table 3-5. LADA (n= 978) vs T2D and BMDCS controls testing T2D candidate 
loci
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RSID Locus Chr T2D Alleles 
Risk/Other 
Risk Allele Frequency LADA Odds Ratio LADA P-value LADA 
vs 
T2D 
P-
value 
LADA T2D Control 
rs1111875 HHEX/IDE 10 C/T 0.643 0.634 0.59 1.205 [1.175-1.234] 3.63E-03 0.75 
rs12970134 MC4R 18 A/G 0.291 0.291 0.247 1.216 [1.183-1.249] 0.01 0.97 
rs12427353 HNF1A 12 G/C 0.818 0.828 0.787 1.224 [1.187-1.260] 0.01 0.72 
rs11634397 ZFAND6 15 G/A 0.69 0.679 0.653 1.184 [1.153-1.215] 0.01 0.80 
rs16861329 ST64GAL1 3 C/T 0.886 0.872 0.861 1.251 [1.208-1.294] 0.02 0.29 
rs849135 JAZF1 7 G/A 0.527 0.529 0.485 1.168 [1.138-1.198] 0.02 0.97 
rs7178572 HMG20A 15 G/A 0.699 0.73 0.73 0.851 [0.818-0.884] 0.02 0.08 
rs4458523 WFS1 4 G/T 0.628 0.614 0.59 1.143 [1.113-1.173] 0.04 0.31 
rs6723108 TMEM163 2 T/G 0.613 0.521 0.553 1.144 [1.114-1.174] 0.04 
4.27E-
03 
rs3786897 PEPD 19 A/G 0.625 0.578 0.589 1.143 [1.112-1.173] 0.04 0.02 
rs11717195 ADCY5 3 T/C 0.796 0.777 0.77 1.162 [1.126-1.199] 0.06 0.18 
rs8108269 GIPR 19 G/T 0.336 0.31 0.292 1.142 [1.110-1.175] 0.06 0.26 
rs10203174 THADA 2 C/T 0.89 0.897 0.871 1.200 [1.154-1.246] 0.06 0.18 
rs6813195 TMEM154 4 C/T 0.748 0.737 0.718 1.141 [1.107-1.175] 0.07 0.39 
rs10811661 CDKN2A/B 9 T/C 0.86 0.858 0.831 1.170 [1.130-1.211] 0.07 0.64 
rs163184 KCNQ1 11 G/T 0.498 0.49 0.463 1.124 [1.094-1.154] 0.07 0.39 
rs17106184 FAF1 1 G/A 0.913 0.918 0.895 1.207 [1.158-1.256] 0.07 0.57 
rs5215 KCNJ11 11 C/T 0.386 0.382 0.362 1.112 [1.081-1.142] 0.11 0.41 
rs391300 SRR 17 C/T 0.638 0.638 0.61 1.109 [1.078-1.139] 0.11 0.98 
rs4430796 HNF1B 17 G/A 0.517 0.479 0.484 1.108 [1.078-1.138] 0.12 0.03 
rs17584499 PTPRD 9 T/C 0.217 0.17 0.193 1.130 [1.094-1.167] 0.12 
9.54E-
04 
rs10923931 NOTCH2 1 T/G 0.12 0.117 0.106 1.164 [1.118-1.209] 0.12 0.91 
rs2943640 IRS1 2 C/A 0.656 0.675 0.634 1.108 [1.076-1.140] 0.13 0.47 
rs516946 ANK1 8 C/T 0.775 0.782 0.754 1.116 [1.082-1.151] 0.14 0.22 
rs1359790 SPRY2 13 G/A 0.76 0.741 0.736 1.104 [1.070-1.139] 0.18 0.75 
rs10401969 CILP2 19 C/T 0.085 0.088 0.067 1.172 [1.115-1.228] 0.19 0.35 
rs7903146 TCF7L2 10 T/C 0.315 0.376 0.298 1.088 [1.056-1.119] 0.21 
5.03E-
04 
rs3923113 GRB14 2 A/C 0.65 0.656 0.632 1.081 [1.050-1.112] 0.24 0.36 
rs2261181 HMGA2 12 T/C 0.114 0.109 0.101 1.129 [1.080-1.177] 0.25 0.95 
rs780094 GCKR 2 C/T 0.573 0.618 0.6 0.929 [0.899-0.959] 0.25 0.04 
rs17791513 TLE4 9 A/G 0.949 0.952 0.939 1.168 [1.105-1.231] 0.25 0.81 
rs17168486 DGKB 7 T/C 0.181 0.172 0.163 1.100 [1.061-1.139] 0.25 0.53 
rs13233731 KLF14 7 G/A 0.551 0.538 0.527 1.077 [1.047-1.108] 0.26 0.47 
rs10886471 GRK5 10 T/C 0.47 0.477 0.489 0.932 [0.903-0.962] 0.27 0.36 
rs10830963 MTNR1B 11 G/C 0.282 0.27 0.29 0.932 [0.899-0.965] 0.32 0.64 
rs7955901 TSPAN8 12 C/T 0.464 0.487 0.438 1.061 [1.032-1.090] 0.34 0.16 
rs4275659 MPHOSPH9 12 C/T 0.715 0.735 0.694 1.065 [1.033-1.097] 0.36 0.56 
rs11063069 CCND2 12 G/A 0.214 0.223 0.221 0.932 [0.897-0.968] 0.36 0.43 
rs7041847 GLIS3 9 A/G 0.527 0.516 0.505 1.060 [1.029-1.090] 0.37 0.40 
rs7756992 CDKAL1 6 G/A 0.312 0.316 0.289 1.059 [1.027-1.091] 0.40 0.79 
rs9470794 ZFAND3 6 T/C 0.915 0.911 0.908 1.095 [1.044-1.147] 0.41 0.65 
rs1802295 VPS26A 10 T/C 0.304 0.321 0.322 0.944 [0.912-0.977] 0.42 0.25 
rs7403531 RASGRP1 15 T/C 0.218 0.229 0.204 1.064 [1.029-1.100] 0.42 0.22 
rs3802177 SLC30A8 8 A/G 0.31 0.294 0.301 1.055 [1.022-1.087] 0.45 0.11 
rs4812829 HNF4A 20 G/A 0.841 0.837 0.831 1.068 [1.027-1.109] 0.45 0.37 
rs243088 BCL11A 2 T/A 0.496 0.492 0.485 1.040 [1.010-1.070] 0.54 0.41 
rs12899811 PRC1 15 G/A 0.329 0.315 0.306 1.042 [1.010-1.073] 0.55 0.87 
rs12571751 ZMIZ1 10 A/G 0.564 0.583 0.549 1.040 [1.009-1.070] 0.55 0.14 
rs2334499 DUSP8 11 T/C 0.409 0.418 0.41 1.040 [1.009-1.070] 0.55 0.30 
rs7593730 RBMS1 2 C/T 0.793 0.811 0.796 1.048 [1.011-1.084] 0.55 0.49 
rs9936385 FTO 16 C/T 0.402 0.454 0.394 1.039 [1.008-1.069] 0.56 
1.18E-
03 
rs6795735 ADAMTS9 3 C/T 0.567 0.618 0.575 0.964 [0.934-0.993] 0.56 0.01 
rs10278336 GCK 7 A/G 0.586 0.577 0.579 1.038 [1.008-1.069] 0.57 0.27 
rs831571 PSMD6 3 C/T 0.835 0.81 0.827 1.047 [1.008-1.086] 0.59 0.07 
rs7202877 BCAR1 16 T/G 0.886 0.914 0.894 0.950 [0.902-0.997] 0.61 0.04 
rs7612463 UBE2E2 3 C/A 0.886 0.894 0.89 0.955 [0.907-1.003] 0.65 0.17 
rs4402960 IGF2BP 3 T/G 0.315 0.351 0.314 1.029 [0.997-1.062] 0.68 0.05 
rs702634 ARL15 5 A/G 0.711 0.711 0.701 1.027 [0.994-1.060] 0.71 0.88 
rs2028299 AP3S2 15 C/A 0.291 0.297 0.291 1.026 [0.993-1.059] 0.72 0.69 
rs2796441 TLE1 9 G/A 0.609 0.582 0.601 1.023 [0.992-1.053] 0.73 0.14 
rs11257655 CDC123 10 T/C 0.196 0.236 0.213 0.975 [0.937-1.012] 0.75 0.12 
rs6467136 GCC1 7 A/G 0.472 0.472 0.477 0.980 [0.950-1.010] 0.75 0.60 
rs1552224 
ARAP1 
(CENTD2) 11 A/C 0.848 0.849 0.85 0.975 [0.934-1.016] 0.77 0.73 
rs9505118 SSR1/RREB1 6 A/G 0.592 0.612 0.592 1.016 [0.986-1.047] 0.81 0.17 
rs7163757 C2CD4A 15 C/T 0.583 0.59 0.588 0.988 [0.958-1.018] 0.85 0.15 
rs7845219 TP53INP1 8 T/C 0.524 0.525 0.515 1.009 [0.980-1.039] 0.88 0.45 
rs6808574 LPP 3 C/T 0.62 0.604 0.613 1.009 [0.979-1.040] 0.89 0.65 
rs459193 ANKRD55 5 G/A 0.748 0.771 0.741 1.008 [0.974-1.043] 0.91 0.13 
rs6878122 ZBED3 5 A/G 0.706 0.658 0.706 0.995 [0.963-1.028] 0.95 0.01 
rs10842994 KLHDC5 12 C/T 0.797 0.814 0.794 1.004 [0.968-1.041] 0.96 0.27 
rs2075423 PROX1 1 G/T 0.66 0.678 0.653 0.999 [0.968-1.030] 0.99 0.56 
Supp. Table 3-6.  LADA cases positive for GADA only (n= 669) vs T2D and BMDCS 
controls testing T2D candidate loci
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RSID Locus Chr T2D Alleles 
Risk/Other 
Risk Allele Frequency LADA Odds Ratio LADA P-
value 
LADA vs 
T2D P-
value 
LADA T2D Control 
rs12427353 HNF1A 12 G/C 0.857 0.828 0.787 1.474 [1.438-1.511] 2.52E-04 5.42E-02 
rs8108269 GIPR 19 G/T 0.341 0.31 0.292 1.221 [1.189-1.253] 3.25E-02 1.77E-01 
rs6878122 ZBED3 5 A/G 0.744 0.658 0.706 1.216 [1.184-1.249] 3.86E-02 1.47E-05 
rs2943640 IRS1 2 C/A 0.674 0.675 0.634 1.209 [1.177-1.241] 4.04E-02 9.59E-01 
rs6723108 TMEM163 2 T/G 0.625 0.521 0.553 1.193 [1.164-1.223] 4.20E-02 6.22E-03 
rs7041847 GLIS3 9 A/G 0.554 0.516 0.505 1.188 [1.157-1.218] 5.27E-02 1.68E-01 
rs7903146 TCF7L2 10 T/C 0.251 0.376 0.298 0.852 [0.820-0.883] 8.14E-02 2.56E-07 
rs12571751 ZMIZ1 10 A/G 0.503 0.583 0.549 0.866 [0.836-0.895] 9.35E-02 1.02E-03 
rs2075423 PROX1 1 G/T 0.608 0.678 0.653 0.867 [0.837-0.898] 1.11E-01 1.14E-02 
rs7403531 RASGRP1 15 T/C 0.228 0.229 0.204 1.174 [1.138-1.209] 1.22E-01 7.04E-01 
rs849135 JAZF1 7 G/A 0.523 0.529 0.485 1.141 [1.112-1.171] 1.30E-01 9.02E-01 
rs17168486 DGKB 7 T/C 0.199 0.172 0.163 1.170 [1.131-1.208] 1.63E-01 1.92E-01 
rs4402960 IGF2BP 3 T/G 0.283 0.351 0.314 0.876 [0.843-0.908] 1.65E-01 4.11E-03 
rs7163757 C2CD4A 15 C/T 0.55 0.59 0.588 0.893 [0.864-0.922] 1.87E-01 4.06E-02 
rs11063069 CCND2 12 G/A 0.201 0.223 0.221 0.877 [0.841-0.912] 1.98E-01 3.36E-01 
rs459193 ANKRD55 5 G/A 0.764 0.771 0.741 1.133 [1.099-1.167] 2.09E-01 6.51E-01 
rs10842994 KLHDC5 12 C/T 0.816 0.814 0.794 1.141 [1.104-1.177] 2.15E-01 8.39E-01 
rs702634 ARL15 5 A/G 0.659 0.711 0.701 0.895 [0.863-0.927] 2.31E-01 1.05E-01 
rs163184 KCNQ1 11 G/T 0.497 0.49 0.463 1.104 [1.074-1.133] 2.47E-01 5.68E-01 
rs1802295 VPS26A 10 T/C 0.296 0.321 0.322 0.899 [0.867-0.932] 2.59E-01 2.46E-01 
rs9470794 ZFAND3 6 T/C 0.892 0.911 0.908 0.851 [0.801-0.900] 2.64E-01 1.80E-01 
rs17106184 FAF1 1 G/A 0.905 0.918 0.895 1.165 [1.117-1.213] 2.73E-01 5.08E-01 
rs3802177 SLC30A8 8 G/A 0.672 0.706 0.699 0.910 [0.878-0.942] 3.13E-01 8.75E-02 
rs7178572 HMG20A 15 G/A 0.707 0.73 0.73 0.910 [0.877-0.943] 3.26E-01 2.48E-01 
rs11257655 CDC123 10 T/C 0.189 0.236 0.213 0.900 [0.863-0.937] 3.29E-01 1.22E-01 
rs2028299 AP3S2 15 C/A 0.269 0.297 0.291 0.911 [0.878-0.944] 3.34E-01 2.02E-01 
rs4275659 MPHOSPH9 12 C/T 0.714 0.735 0.694 1.092 [1.060-1.124] 3.49E-01 7.39E-01 
rs10923931 NOTCH2 1 T/G 0.11 0.117 0.106 1.134 [1.088-1.181] 3.52E-01 9.38E-01 
rs780094 GCKR 2 C/T 0.566 0.618 0.6 0.923 [0.894-0.953] 3.55E-01 1.77E-01 
rs4458523 WFS1 4 G/T 0.574 0.614 0.59 0.930 [0.900-0.959] 3.97E-01 1.20E-01 
rs1359790 SPRY2 13 G/A 0.717 0.741 0.736 0.925 [0.892-0.958] 4.21E-01 8.02E-02 
rs7845219 TP53INP1 8 T/C 0.495 0.525 0.515 0.933 [0.903-0.963] 4.24E-01 3.70E-01 
rs10886471 GRK5 10 T/C 0.468 0.477 0.489 0.935 [0.906-0.965] 4.32E-01 5.75E-01 
rs3786897 PEPD 19 A/G 0.57 0.578 0.589 0.935 [0.905-0.965] 4.47E-01 5.84E-01 
rs16861329 ST64GAL1 3 C/T 0.872 0.872 0.861 1.097 [1.055-1.140] 4.50E-01 6.59E-01 
rs10830963 MTNR1B 11 G/C 0.314 0.27 0.29 1.070 [1.037-1.103] 4.77E-01 4.90E-02 
rs5215 KCNJ11 11 C/T 0.374 0.382 0.362 1.065 [1.034-1.095] 4.85E-01 9.76E-01 
rs11634397 ZFAND6 15 G/A 0.668 0.679 0.653 1.062 [1.032-1.093] 4.97E-01 4.43E-01 
rs10401969 CILP2 19 C/T 0.06 0.088 0.067 0.888 [0.828-0.948] 4.99E-01 2.40E-02 
rs4430796 HNF1B 17 G/A 0.5 0.479 0.484 1.060 [1.029-1.090] 5.09E-01 3.44E-01 
rs6467136 GCC1 7 A/G 0.492 0.472 0.477 1.054 [1.024-1.083] 5.41E-01 8.66E-01 
rs2261181 HMGA2 12 T/C 0.115 0.109 0.101 1.084 [1.036-1.133] 5.69E-01 5.69E-01 
rs10203174 THADA 2 C/T 0.879 0.897 0.871 1.065 [1.021-1.109] 6.21E-01 1.05E-01 
rs11717195 ADCY5 3 T/C 0.757 0.777 0.77 0.951 [0.915-0.987] 6.29E-01 6.77E-01 
rs1111875 HHEX/IDE 10 C/T 0.587 0.634 0.59 0.960 [0.931-0.990] 6.35E-01 9.02E-03 
rs243088 BCL11A 2 T/A 0.489 0.492 0.485 1.041 [1.011-1.070] 6.41E-01 4.54E-01 
rs6813195 TMEM154 4 C/T 0.723 0.737 0.718 1.044 [1.011-1.077] 6.52E-01 8.01E-01 
rs516946 ANK1 8 C/T 0.751 0.782 0.754 1.037 [1.004-1.071] 7.08E-01 9.86E-02 
rs10278336 GCK 7 A/G 0.567 0.577 0.579 0.968 [0.937-0.998] 7.09E-01 6.17E-01 
rs3923113 GRB14 2 A/C 0.639 0.656 0.632 1.033 [1.003-1.064] 7.14E-01 2.16E-01 
rs391300 SRR 17 C/T 0.618 0.638 0.61 1.032 [1.002-1.061] 7.20E-01 5.31E-01 
rs7593730 RBMS1 2 C/T 0.794 0.811 0.796 1.039 [1.002-1.075] 7.23E-01 4.01E-01 
rs7612463 UBE2E2 3 C/A 0.887 0.894 0.89 0.953 [0.904-1.001] 7.31E-01 3.48E-01 
rs7955901 TSPAN8 12 C/T 0.456 0.487 0.438 1.028 [0.999-1.057] 7.47E-01 8.39E-02 
rs12970134 MC4R 18 A/G 0.257 0.291 0.247 1.032 [0.998-1.066] 7.50E-01 1.88E-01 
rs6795735 ADAMTS9 3 C/T 0.579 0.618 0.575 1.027 [0.997-1.056] 7.57E-01 2.46E-01 
rs4812829 HNF4A 20 G/A 0.826 0.837 0.831 0.970 [0.931-1.010] 7.97E-01 5.08E-01 
rs831571 PSMD6 3 C/T 0.817 0.81 0.827 0.974 [0.935-1.012] 8.13E-01 9.28E-01 
rs1552224 ARAP1 (CENTD2) 11 A/C 0.859 0.849 0.85 1.025 [0.983-1.066] 8.40E-01 3.23E-01 
rs17584499 PTPRD 9 T/C 0.202 0.17 0.193 1.020 [0.984-1.056] 8.49E-01 1.43E-01 
rs2796441 TLE1 9 G/A 0.602 0.582 0.601 1.015 [0.986-1.045] 8.61E-01 2.25E-01 
rs9505118 SSR1/RREB1 6 A/G 0.602 0.612 0.592 1.015 [0.985-1.045] 8.65E-01 6.60E-01 
rs6808574 LPP 3 C/T 0.623 0.604 0.613 1.009 [0.980-1.039] 9.14E-01 8.13E-01 
rs10811661 CDKN2A/B 9 T/C 0.832 0.858 0.831 1.011 [0.972-1.049] 9.26E-01 3.70E-01 
rs9936385 FTO 16 C/T 0.396 0.454 0.394 1.008 [0.978-1.037] 9.30E-01 2.42E-02 
rs12899811 PRC1 15 G/A 0.314 0.315 0.306 0.995 [0.964-1.026] 9.56E-01 9.26E-01 
rs13233731 KLF14 7 G/A 0.529 0.538 0.527 1.004 [0.974-1.034] 9.66E-01 2.41E-01 
rs2334499 DUSP8 11 T/C 0.409 0.418 0.41 0.997 [0.967-1.027] 9.75E-01 2.40E-01 
rs7756992 CDKAL1 6 G/A 0.294 0.316 0.289 1.001 [0.969-1.033] 9.89E-01 7.67E-01 
rs7202877 BCAR1 16 T/G 0.895 0.914 0.894 0.999 [0.952-1.046] 9.94E-01 2.00E-01 
rs17791513 TLE4 9 A/G 0.939 0.952 0.939 1.001 [0.941-1.062] 9.94E-01 3.10E-01 
Supp. Table 3-7. LADA cases positive for GADA and IA2A (n= 309) vs T2D and 
BMDCS controls testing T2D candidate loci 
 
 
A) MHC, PTPN22, SH2B3, INS, SMARCE1 association replicated in 978 LADA cases and 2,820 WTCCC healthy British controls  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B)  MHC, PTPN22, SH2B3, and INS association replicated in 309 LADA cases positive for autoantibodies GADA and IA2 and 2,820 
WTCCC healthy British controls 
 
 
 
 
 
 
 
 
 
 
 
 
 
Locus SNP T1D Alleles Risk/Other 
Risk Allele Frequency 
LADA Odds Ratio LADA P-value LADA vs T1D P-value 
LADA T1D Control 
MHC rs9272346 A/G 0.763 0.818 0.620 1.591 [1.577-1.604] 3.34x10-9 4.01x10-3 
PTPN22 rs6679677 A/C 0.17 0.17 0.097 1.855 [1.834-1.875] 1.88x10-7 0.603 
SH2B3 rs17696736 G/A 0.542 0.503 0.44 1.316 [1.303-1.329] 1.95x10-4 0.180 
INS rs689 T/A 0.824 0.741 0.712 1.479 [1.465-1.494] 2.07x10-6 1.68x10-6 
INS rs7111341 C/T 0.812 0.75 0.734 1.272 [1.258-1.287] 4.05x10-3 2.39x10-4 
SMARCE1 rs7221109 C/T 0.621 0.687 0.648 1.010[0.995-1.025] 0.810 6.54x10-4 
Locus SNP T1D Alleles Risk/Other 
Risk Allele Frequency 
LADA Odds Ratio LADA P-value LADA vs T1D P-value 
LADA T1D Control 
MHC rs9272346   A/G 0.686 0.818 0.620 1.177[1.161-1.192] 1.01x10-4 1.26x10-17 
PTPN22 rs6679677 A/C 0.143 0.17 0.097 1.329[1.306-1.352] 3.86x10-6 2.61x10-2 
SH2B3 rs17696736 G/A 0.515 0.503 0.44 1.162[1.148-1.177] 9.35 x10-5 0.542 
INS rs689 T/A 0.796 0.741 0.712 1.235[1.219-1.252] 1.27x10-4 3.88x10-4 
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 C) HNF1A and TCF7L2 association replicated in 978 LADA cases and 2,820 WTCCC healthy British controls 
 
 
 
 
 
 
 
 
 
 
 
 
D) HNF1A, ZBED3, and TCF7L2 association replicated in 309 LADA cases positive for autoantibodies GADA and IA2 and 2,820 
WTCCC healthy British controls 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supp. Table 3-8. Follow-up analysis of significant T1D and T2D loci in LADA using WTCCC controls  
Locus SNP T2D Alleles Risk/Other 
Risk Allele Frequency 
LADA Odds Ratio LADA P-value LADA vs T2D P-value 
LADA T2D Control 
HNF1A rs12427353 G/C 0.831 0.828 0.807 1.111 [1.092-1.129] 3.57x10-2 0.538 
TCF7L2 rs7903146 T/C 0.295 0.376 0.300 0.988 [0.972-1.004] 0.702 5.21x10-6 
Locus SNP T2D Alleles Risk/Other 
Risk Allele Frequency 
LADA Odds Ratio LADA P-value LADA vs T2D P-value 
LADA T2D Control 
HNF1A rs12427353 G/C 0.857 0.828 0.807 1.274 [1.258-1.290] 1.05x10-2 5.42x10-2 
ZBED3 rs6878122 A/G 0.744 0.658 0.658 1.132 [1.118-1.146] 0.123 1.47x10-5 
TCF7L2 rs7903146 T/C 0.251 0.376 0.300 0.851 [0.837-0.865] 4.62x10-2 2.56x10-7 
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Supp. Figure 3-1. Principle Component Analyses.   
A) 978 LADA cases (red) vs 1,057 BMDCS controls (blue), and B) 978 
LADA cases (red) vs 2,820 WTCCC controls (blue). 
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Supp. Figure 3-2. Quantile-quantile plot 
Quantile-quantile plot of pruned markers used for PCs (no HLA signals) 
for LADA cases and BMDCS controls. The genomic inflation factor is 
0.966.   
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Supp. Figure 3-3. ROC plots 
Extended set of ROC plots including Non-HLA and HLA only GRS 
also tested in LADA vs T1D and GADA+ only LADA vs GADA+IA2A 
LADA. Weighted genetic risk scores (GRS) for T1D  GRS (black), 
T1D without HLA GRS (blue) , HLA only GRS (cyan), T2D GRS (red) 
and both T1D and T2D GRS (green) were calculated and tested in A) 
978 LADA cases and 1,057 healthy controls B) 669 GADA only 
autoantibody- positive and 1,057 healthy controls C) 309 
autoantibody-positive (GADA, IA2A) LADA and 1,057 controls D) 978 
LADA and 1,990 WTCCC T1D cases E) 669 GADA only 
autoantibody- positive LADA and 1,990 WTCCC T1D F) 309 
autoantibody- positive (GADA, IA2A) LADA and 1,990 WTCCC T1D. 
The T2D GRS predict GADA+ only LADA from GADA+IA2A+ LADA 
and LADA from T1D, resulting in T2D GRS performance dropping 
below the y=x line. 
 
 
 
 
Chapter 5: THE FIRST GENOME-WIDE ASSOCIATION STUDY IN LADA – SUPPLEMENTARY 
MATERIAL  
 
Supplemental Tables 
Cohort Population  N 
Age 
(mean, 
range) 
% 
Male/Female 
GADA 
measurement 
 method, notes 
Genotyping chip Genotyping QC Imputation panel and service Imputation QC 
ActionLada (LADA) British, 
German 
1051 
 
 
  
47.7, 
46.99-
48.47 
M57%/F37% 
* 6% missing 
info  
In House RIA Illumina Infinium II Omni Express Individuals with ambiguous sex, genotype missingness > 5%, and relatedness (pi_hat 
> 0.2) were excluded. PCA was performed to exclude individuals of non-European 
ancestry. 
HRC r1.1.2016 (Michigan) SNP missing call rate <95%, SNP missing 
rate <95%, MAF <0.05, non-European 
individuals 
ActionLada 'Plus' 
(LADA) 
American 
and British 
441 55.33 
years 
(25 
years-88 
years) 
55.6%/44.1% RIA at Northwest 
Lipid, Metabolism, 
and Diabetes 
Research 
Laboratories, 
Seattle Washington 
Illumina Infinium II Omni Express Individuals with ambiguous sex, genotype missingness > 5%, and relatedness (pi_hat 
> 0.2) were excluded. PCA was performed to exclude individuals of non-European 
ancestry. 
HRC r1.1.2016 
(Michigan) 
SNP missing call rate <95%, SNP missing 
rate <95%, MAF <0.05, non-European 
individuals 
Bone Mineral Density 
in Childhood Study 
(population controls) 
American of 
diverse 
ethnic 
backgrounds 
1056 5-20 yrs 
at 
baseline 
49%/51% at 
baseline 
Not done Illumina Infinium II Omni Express Individuals with ambiguous sex, genotype missingness > 5%, and relatedness (pi_hat 
> 0.2) were excluded. PCA was performed to exclude individuals of non-European 
ancestry. 
HRC r1.1.2016 
(Michigan) 
SNP missing call rate <95%, SNP missing 
rate <95%, MAF <0.05, non-European 
individuals 
Botnia study (LADA) Finnish 
(Botnia 
region, 
Western 
Finland) 
157 54.82 ± 
11-72 
yrs 
42% Male in-house RIP, RSR 
EIA 
Illumina Human Core Exome  Exclude individuals: Call rate < 95%; ambiguous gender; genome-wide heterozygosity 
(3 SD from mean); relatedness (pi-hat >= 0.2); average pi-hat outliers; population 
outliers.Exclude SNPs: monomorphic; (MAF >= 0.05 and SNP missing rate > 0.05); 
(MAF < 0.05 and SNP missing rate > 0.01); (MAF >= 0.05 and HWE <= 0.00000057); 
(MAF < 0.05 and HWE <= 0.0001) 
HRC r1.1.2016 
(Michigan) 
Include:  
MAF > 0.01;  
INFO > 0.4;  
(MAF < 0.05 and HWE > 0.0001 or MAF >= 
0.05 and HWE > 0.00000057) 
Genetics of Diabetes 
Audit and Research 
(GoDARTS) 
(LADA/T2D/Population 
CTL) 
Scottish 206 mean 
58.54 
STD 
12.42 
49.0% Male RSR ELISA (RS-
GDE96-F) 
Affymatrix 6; Illumina Infinium II 
Omni Express 
Individuals with ambiguous sex or geno-pheno sex discrepancy, genotype 
missingness > 2%, and relatedness (pi_hat > 0.125) were excluded. PCA was 
performed to exclude individuals of non-European ancestry. 
HRC r1.1.2016 
(Sanger) 
None 
The Nord-Trøndelag 
Health Study (LADA) 
Norwegian 139 Mean 
67.5 and 
range 
57.4 
53.2% Male AntiGAD was 
measured by 
immuno-
precipitation using 
translation labeled 
3H-GAD65 as 
labeled reagent 
(Novo Nordisk, 
Denmark).  
IlluminaHumanCore arrays 
(UM_HUNT_Biobank_11788091, 
HumanCoreExome-12-v1-0, and 
HumanCoreE xome-12-v1-1) 
Samples that failed to reach a 99% call rate, had contamination > 2.5% as estimated 
with BAF Regress, large chromosomal copy number variants, lower call rate of a 
technical duplicate pair and twins, gonosomal constellations other than XX and XY, or 
whose inferred sex contradicted the reported gender, were excluded. Samples that 
passed quality control were analysed in a second round of genotype calling following 
the Genome Studio quality control protocol. 
chr1-22: HRC.r1-1 + 2,200 
whole-genome sequenced 
HUNT samples; chrX: 
HRC.r1-1 (Michigan) 
Imputation was performed on the samples of 
recent European ancestry using Minimac3 
(v2.0.1, 
http://genome.sph.umich.edu/wiki/Minimac3) 
and the Haplotype Reference Consortium 
reference panel (release version 1.1). A 
maximal set of relatively unrelated 
individuals (kinship coefficient < 0.0884) 
was chosen using KING and FastIndep.  
The Nord-Trøndelag 
Health Study (T2D) 
695 Mean 
67.2 and 
range 
55.0 
53.2% Male IlluminaHumanCore arrays 
(UM_HUNT_Biobank_11788091, 
HumanCoreExome-12-v1-0, and 
HumanCoreE xome-12-v1-1) 
chr1-22: HRC.r1-1 + 2,200 
whole-genome sequenced 
HUNT samples; chrX: 
HRC.r1-1 (Michigan) 
The Nord-Trøndelag 
Health Study (Non-
diabetic population 
controls) 
695 Mean 
67.5 and 
range 
57.8 
53.2% Male IlluminaHumanCore arrays 
(UM_HUNT_Biobank_11788091, 
HumanCoreExome-12-v1-0, and 
HumanCoreE xome-12-v1-1) 
chr1-22: HRC.r1-1 + 2,200 
whole-genome sequenced 
HUNT samples; chrX: 
HRC.r1-1 (Michigan)   
All New Diabetics In 
Scania 
(ANDIS)(LADA) 
Swedish 440 LADA: 
59(35-
94) 
55/45 Enzyme-Linked 
Immunosorbent 
Assay (ELISA) or 
Radioimmunoassay 
at Clinical 
Chemistry in 
Malmö 
Illumina Infinium Omni Express 
Exome 
Exclude individuals: Call rate < 95%;  
ambiguous gender; genome-wide heterozygosity (3 SD from mean);  
duplicates or related individuals (pi-hat >= 0.2); average pi-hat outliers;population 
outliers.Exclude SNPs:  
monomorphic; (MAF >= 0.05 and SNP missing rate > 0.05); (MAF < 0.05 and SNP 
missing rate > 0.01); (MAF >= 0.05 and HWE <= 0.00000057); (MAF < 0.05 and HWE 
<= 0.0001) 
HRC r1.1.2016 (Michigan) Include:  
MAF > 0.01;  
INFO > 0.4;  
(MAF < 0.05 and HWE > 0.0001 or MAF >= 
0.05 and HWE > 0.00000057) 
Diabetes Registry 
Vasa  (LADA / T1D / 
T2D) 
Finnish 3290 
(LADA 
139, T1D 
365 , T2D 
2786) 
LADA 
57.84 
±10.22; 
T1D 
15.80 
±9.03; 
T2D 
59.63 ± 
10.29 
LADA 46.3% 
Male; T1D 
53.0% Male; 
T2D 56.5% 
Male 
Enzyme 
Immunoassay (EIA) 
Illumina Human CoreExome Exclude individuals: Call rate < 95%;  
ambiguous gender; genome-wide heterozygosity (3 SD from mean); duplicates or 
related individuals (pi-hat >= 0.2); average pi-hat outliers; population outliers.Exclude 
SNPs: monomorphic;  
(MAF >= 0.05 and SNP missing rate > 0.05); (MAF < 0.05 and SNP missing rate > 
0.01); (MAF >= 0.05 and HWE <= 0.00000057);(MAF < 0.05 and HWE <= 0.0001) 
HRC r1.1.2016(Michigan) Include:  
MAF > 0.01;  
INFO > 0.4;  
(MAF < 0.05 and HWE > 0.0001 or MAF >= 
0.05 and HWE > 0.00000057) 
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Malmö controls (Non-
diabetic population 
controls) 
Swedish  3126 72.5(5.6) 
range 
61-85 
41/59 Not done Illumina Infinium Omni Express 
Exome  
Exclude individuals:  
Call rate < 95%;  
ambiguous gender;  
genome-wide heterozygosity (3 SD from mean);  
duplicates or related individuals (pi-hat >= 0.2);  
population outliers. 
Exclude SNPs:  
monomorphic;  
SNP missing rate > 0.05;  
HWE <= 10e-6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
HRC r1.1.2016(Michigan) Include:  
MAF > 0.01;  
INFO > 0.4;  
(MAF < 0.05 and HWE > 0.0001 or MAF >= 
0.05 and HWE > 0.00000057) 
Scania Diabetes 
Registry  (LADA 
cases/ T1D cases/ 
T2D cases) 
Swedish 3567 LADA 
only: 59( 
36-90) 
57/43 Radioimmunoassay Illumina Infinium Omni Express 
Exome + ??? 
Exclude individuals: Call rate < 95%;  
ambiguous gender; genome-wide heterozygosity (3 SD from mean);  
duplicates or related individuals (pi-hat >= 0.2); average pi-hat outliers; population 
outliers. Exclude SNPs: monomorphic;  
(MAF >= 0.05 and SNP missing rate > 0.05); (MAF < 0.05 and SNP missing rate > 
0.01); (MAF >= 0.05 and HWE <= 0.00000057); (MAF < 0.05 and HWE <= 0.0001) 
HRC r1.1.2016(Michigan) Include:  
MAF > 0.01;  
INFO > 0.4;  
(MAF < 0.05 and HWE > 0.0001 or MAF >= 
0.05 and HWE > 0.00000057) 
Copenhagen controls 
(population controls) 
Danish 1974 64.42 
(range, 
34.44) 
49.9% male Not done Illumina Human Core Exome  Prior to imputation we removed variants that had a missingness of more than 5% 
(across batches), a minor allele frequency of less than 5%, or a hardy-weinberg 
equilibrium pvalue < 10e-5. 
Haplotype Reference 
Consortium (r1.1) (Sanger) 
None 
The 1936 birth cohort 
(population controls) 
Danish 624 non-
diabetic 
individuals 
(502 
NGTs, 
122 
IFG/IGTs) 
See 
above 
See above See above See above See above Haplotype Reference 
Consortium (r1.1) (Sanger) 
See above 
ADDITION-PRO 
(controls) 
Danish 350 non-
diabetic 
individuals 
(812 
NGTs, 
538 
IFG/IGTs) 
See 
above 
See above See above See above See above Haplotype Reference 
Consortium (r1.1) (Sanger) 
See above 
Danish Centre for 
strategic Research in 
Type 2 Diabetes 
(DD2) (LADA) 
Danish 539 58.32 
(range, 
67.31) 
56.2% male 
 
Illumina Human Core Exome  Prior to imputation we removed variants that had a missingness of more than 5% 
(across batches), a minor allele frequency of less than 5%, or a hardy-weinberg 
equilibrium pvalue < 10e-5. 
Haplotype Reference 
Consortium (r1.1) (Sanger) 
None 
Danish Centre for 
strategic Research in 
Type 2 Diabetes 
(DD2) (LADA) 
Danish 158 See 
above 
See above AESKULISA See above See above Haplotype Reference 
Consortium (r1.1) (Sanger) 
See above 
Vejle Biobank (LADA) Danish 124 See 
above 
See above AESKULISA See above See above Haplotype Reference 
Consortium (r1.1) (Sanger) 
See above 
OUH (LADA) Danish 66 See 
above 
See above RSR RIA See above See above Haplotype Reference 
Consortium (r1.1) (Sanger) 
See above 
CIMT (LADA) Danish 31 See 
above 
See above RSR ELISA See above See above Haplotype Reference 
Consortium (r1.1) (Sanger) 
See above 
Inter99 (LADA) Danish 19 See 
above 
See above RSR ELISA See above See above Haplotype Reference 
Consortium (r1.1) (Sanger) 
See above 
SDC (LADA) Danish 141 See 
above 
See above RSR ELISA (n=52) 
or AESKULISA 
(n=89)  
See above See above Haplotype Reference 
Consortium (r1.1) (Sanger) 
See above 
Supp. Table 5-1. Cohort Information
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 Directly Genotypes Markers Imputed Markers    
Cohort Lambda Count Lambda Count N LADA N Ctrls total markers 
LADACTRL               
Swedish 1.0297 575268 1.0131 7131633 805 3126 7706901 
ActionLADA 1.1662 5397740 1.0000 0 1353 1014 5397740 
Danish 1.0000 0 1.0274 5271474 476 1807 5271474 
    totals 2634 5947 7868002 
LADAT1D               
Cohort Lambda Count Lambda Count N LADA N T1D total markers 
Swedish + ActionLADA 1.0301 575963 1.0286 7137816 2158 603 7713779 
Finnish 1.0359 254991 1.0314 7607304 296 365 7862295 
    totals 2454 968 8328843 
LADAT2D               
Cohort Lambda Count Lambda Count N LADA N T2D total markers 
Swedish + ActionLADA 1.0621 575855 1.0399 7142626 2158 2599 7718481 
Finnish 1.0251 255224 1.0216 7614587 296 2786 7869811 
GODARTS-Illumina 1.0000 0 0.9854 5386729 97 2098 5386729 
GODARTS-Affymetrix 1.0000 0 0.9774 5383813 89 2218 5383813 
HUNT 1 0 1.0242 5546184 139 695 5546184 
    totals 2779 10396 8465706 
 
Supp. Table 5-2. Cohort information for GWAMA 
 
 
 
 
 
 
 
 
 
 
 135 
 
LADA Assuming disease prevalence of 0.0036 
MAF 1.1 1.2 1.3 1.4 1.5 
0.1 0 0.017 0.254 0.758 0.976 
0.2 0.001 0.13 0.764 0.992 1 
0.3 0.002 0.27 0.917 0.999 1 
0.4 0.003 0.346 0.948 1 1 
0.5 0.003 0.342 0.939 0.999 1 
T1D Assuming disease prevalence of 0.0033 
  1.1 1.2 1.3 1.4 1.5 
0.1 0 0.017 0.253 0.758 0.976 
0.2 0.001 0.129 0.763 0.992 1 
0.3 0.002 0.27 0.917 0.999 1 
0.4 0.003 0.346 0.948 1 1 
0.5 0.003 0.342 0.939 0.999 1 
T2D Assuming disease prevalence of 0.045 
  1.1 1.2 1.3 1.4 1.5 
0.1 0 0.017 0.253 0.758 0.976 
0.2 0.001 0.174 0.84 0.997 1 
0.3 0.003 0.345 0.954 1 1 
0.4 0.005 0.43 0.974 1 1 
0.5 0.005 0.426 0.968 1 1 
      
      
      
Supp. Table 5-3. Power Calculations. 
Power was calculated using CaTS calculator. (http://csg.sph.umich.edu/abecasis/cats/) 
Number of cases: 2700, number of controls: 5500, significance level: 0.00000005
 
 
 
Original gene set ID Original gene set description 
Nominal P 
value 
False discovery rate < 
5% 
MP:0005078 abnormal cytotoxic T cell physiology 6.392E-07 No 
ENSG00000131153 GINS2 subnetwork 6.832E-07 No 
ENSG00000149554 CHEK1 subnetwork 2.411E-06 No 
KEGG_CELL_CYCLE KEGG_CELL_CYCLE 1.167E-05 No 
ENSG00000123374 CDK2 subnetwork 1.513E-05 No 
ENSG00000141510 TP53 subnetwork 3.328E-05 No 
ENSG00000170312 CDK1 subnetwork 4.780E-05 No 
ENSG00000198793 MTOR subnetwork 6.033E-05 No 
MP:0004045 abnormal cell cycle checkpoint function 8.531E-05 No 
ENSG00000134259 NGF subnetwork 9.766E-05 No 
REACTOME_P75NTR_SIGNALS_VIA_NF:KB REACTOME_P75NTR_SIGNALS_VIA_NF:KB 9.993E-05 No 
GO:0007260 tyrosine phosphorylation of STAT protein 1.006E-04 No 
MP:0003333 liver fibrosis 1.122E-04 No 
REACTOME_NF:KB_IS_ACTIVATED_AND_SIGNALS_SURVI
VAL 
REACTOME_NF:KB_IS_ACTIVATED_AND_SIGNALS_SURVI
VAL 1.184E-04 No 
ENSG00000127314 RAP1B subnetwork 1.267E-04 No 
GO:0051247 positive regulation of protein metabolic process 1.375E-04 No 
REACTOME_PI3K_CASCADE REACTOME_PI3K_CASCADE 1.381E-04 No 
MP:0008501 increased IgG2b level 1.798E-04 No 
MP:0001654 hepatic necrosis 1.906E-04 No 
ENSG00000180228 PRKRA subnetwork 2.149E-04 No 
GO:0042509 regulation of tyrosine phosphorylation of STAT protein 2.225E-04 No 
ENSG00000168040 FADD subnetwork 2.517E-04 No 
ENSG00000120008 WDR11 subnetwork 2.669E-04 No 
GO:0032270 positive regulation of cellular protein metabolic process 2.820E-04 No 
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MP:0002020 increased tumor incidence 2.837E-04 No 
ENSG00000171861 RNMTL1 subnetwork 3.582E-04 No 
ENSG00000138376 BARD1 subnetwork 3.638E-04 No 
MP:0002834 decreased heart weight 3.735E-04 No 
MP:0002495 increased IgA level 3.805E-04 No 
ENSG00000127191 TRAF2 subnetwork 3.925E-04 No 
ENSG00000153201 RANBP2 subnetwork 4.834E-04 No 
GO:0042516 regulation of tyrosine phosphorylation of Stat3 protein 5.024E-04 No 
ENSG00000185658 BRWD1 subnetwork 5.105E-04 No 
ENSG00000163539 CLASP2 subnetwork 5.416E-04 No 
ENSG00000134057 CCNB1 subnetwork 5.663E-04 No 
ENSG00000066117 SMARCD1 subnetwork 5.726E-04 No 
ENSG00000132646 PCNA subnetwork 5.766E-04 No 
ENSG00000142856 ITGB3BP subnetwork 5.893E-04 No 
MP:0001861 lung inflammation 5.987E-04 No 
ENSG00000104823 ECH1 subnetwork 6.190E-04 No 
REACTOME_ASSEMBLY_OF_HIV_VIRION REACTOME_ASSEMBLY_OF_HIV_VIRION 6.410E-04 No 
ENSG00000123219 CENPK subnetwork 6.448E-04 No 
ENSG00000115163 CENPA subnetwork 6.679E-04 No 
ENSG00000206215 ENSG00000206215 subnetwork 6.811E-04 No 
ENSG00000206287 RING1 subnetwork 6.811E-04 No 
ENSG00000204227 RING1 subnetwork 6.811E-04 No 
ENSG00000100368 CSF2RB subnetwork 6.882E-04 No 
GO:0001819 positive regulation of cytokine production 6.893E-04 No 
MP:0005334 abnormal fat pad morphology 7.367E-04 No 
ENSG00000198961 PJA2 subnetwork 8.300E-04 No 
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ENSG00000130338 TULP4 subnetwork 8.563E-04 No 
MP:0005166 decreased susceptibility to injury 8.792E-04 No 
ENSG00000153044 CENPH subnetwork 9.019E-04 No 
MP:0011099 complete lethality throughout fetal growth and development 9.193E-04 No 
ENSG00000137285 TUBB2B subnetwork 9.232E-04 No 
ENSG00000157106 SMG1 subnetwork 9.847E-04 No 
ENSG00000166793 YPEL4 subnetwork 9.959E-04 No 
Supp. Table 5-4. DEPICT gene set enrichment analysis p<0.001
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Supp. Table 5-5. DEPICT tissue enrichment 
 
 
MeSH term MeSH first level term MeSH second level term Nominal P value False discovery rate < 5% 
A15.382.490.555.567.537 Killer Cells  Natural Hemic and Immune Systems 0.008 No 
A11.118.637.555.567.569 T Lymphocytes Cells 0.008 No 
A15.145 Blood Hemic and Immune Systems 0.010 No 
A15.145.229 Blood Cells Hemic and Immune Systems 0.010 No 
A11.118.637 Leukocytes Cells 0.011 No 
A11.872.378 Hematopoietic Stem Cells Cells 0.015 No 
A11.118.637.555.567.569.200.700 T Lymphocytes  Regulatory Cells 0.017 No 
A15.145.229.637.555.567.569.200 CD4 Positive T Lymphocytes Hemic and Immune Systems 0.018 No 
A15.145.229.334 Erythrocytes Hemic and Immune Systems 0.020 No 
A15.382.520 Lymphatic System Hemic and Immune Systems 0.021 No 
A10.549 Lymphoid Tissue Tissues 0.021 No 
A02.835.583.443.800.800 Synovial Fluid Musculoskeletal System 0.021 No 
A11.118.637.555.567.562.440 Precursor Cells  B Lymphoid Cells 0.023 No 
A11.872.378.294 Lymphoid Progenitor Cells Cells 0.023 No 
A15.378.316 Bone Marrow Cells Hemic and Immune Systems 0.025 No 
A15.378 Hematopoietic System Hemic and Immune Systems 0.025 No 
A11.443 Erythroid Cells Cells 0.025 No 
A10.549.400 Lymph Nodes Tissues 0.026 No 
A11.627 Myeloid Cells Cells 0.028 No 
A15.145.229.637.555 Leukocytes  Mononuclear Hemic and Immune Systems 0.032 No 
A11.118.637.415 Granulocytes Cells 0.032 No 
A15.382.680 Phagocytes Hemic and Immune Systems 0.035 No 
A15.382.490.555.567.622 Lymphocytes  Null Hemic and Immune Systems 0.035 No 
A15.382.490.315.583 Neutrophils Hemic and Immune Systems 0.036 No 
A11.627.635 Myeloid Progenitor Cells Cells 0.042 No 
A15.382 Immune System Hemic and Immune Systems 0.045 No 
A15.382.520.604.700 Spleen Hemic and Immune Systems 0.049 No 
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Supp. Table 5-6. Initial GWAS (LADACTRL) and with HUNT & GoDARTS Replication
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Supp. Table 5-7.Linkage Disequilibrium in Chr10p15.  
Genome-wide significant signals associated with T1D from various publications (and top LADA signal) - pairwise r2 
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15:389
28677 G A 
0.
23
9 
1.
06
3 
0.0
38 
-
1.4
50 
0.15
015
3 
0.823 3.234 
0.35
7 
0.
07
2 
4 9414 --++ 0.972 
0.
88
5 
Imput
ed 
rs193
778 
16:113
51211 G A 
0.
25
0 
1.
05
9 
0.0
42 
1.3
98 
0.16
535
2 
0.782 2.559 
0.46
5 
0.
00
0 
4 9415 +++- 0.999 
0.
99
7 
Imput
ed 
rs112
03203 
21:438
36186 A G 
0.
37
7 
1.
05
1 
0.0
38 
1.3
52 
0.17
944
8 
0.746 4.701 
0.19
5 
0.
36
2 
4 9414 ++-+ 0.995 
0.
98
3 
Imput
ed 
rs575
3037 
22:305
81722 T C 
0.
38
0 
1.
05
1 
0.0
37 
1.3
46 
0.18
141
8 
0.741 3.821 
0.28
1 
0.
21
5 
4 9414 +++- 1.000 
1.
00
0 
Geno
typed 
rs145
6988 
14:984
88007 G T 
0.
68
1 
1.
05
3 
0.0
36 
-
1.3
06 
0.19
481 0.710 
3.98
3 
0.26
3 
0.
24
7 
4 9415 +--- 1.000 
1.
00
0 
Geno
typed 
rs112
58747 
10:647
2891 T G 
0.
23
2 
1.
05
4 
0.0
43 
1.2
21 
0.22
552
1 
0.647 1.127 
0.77
1 
0.
00
0 
4 9415 ++-+ 0.991 
0.
96
1 
Imput
ed 
rs602
662 
19:492
06985 G A 
0.
48
8 
0.
96
0 
0.0
36 
1.1
36 
0.25
959
8 
0.586 5.381 
0.14
6 
0.
44
3 
4 9415 +-+- 0.997 
0.
99
1 
Imput
ed 
rs228
1808 
20:161
0551 C T 
0.
63
4 
1.
04
3 
0.0
38 
1.0
99 
0.27
513
1 
0.560 3.133 
0.37
2 
0.
04
3 
4 9414 ++-- 1.000 
0.
99
8 
Geno
typed 
rs108
77012 
12:581
62085 G T 
0.
33
8 
0.
96
3 
0.0
38 
0.9
75 
0.33
294
8 
0.478 0.618 
0.89
2 
0.
00
0 
4 9415 ++++ 0.995 
0.
98
0 
Imput
ed 
rs261
1215 
4:1665
74267 A G 
0.
77
0 
1.
04
5 
0.0
43 
-
0.9
36 
0.35
301
2 
0.452 0.502 
0.91
8 
0.
00
0 
4 9414 ---+ 0.985 
0.
92
2 
Imput
ed 
rs119
54020 
5:3588
3251 G C 
0.
40
6 
1.
03
4 
0.0
37 
0.9
02 
0.37
051
8 
0.431 10.783 
0.01
3 
0.
72
2 
4 9414 ++-- 0.998 
0.
99
3 
Imput
ed 
rs402
072 
19:472
19122 T C 
0.
15
3 
1.
04
4 
0.0
46 
-
0.8
64 
0.39
092
3 
0.408 3.173 
0.36
6 
0.
05
5 
4 9414 +-+- 0.995 
0.
96
7 
Imput
ed 
rs153
8171 
6:1267
52884 G C 
0.
46
6 
1.
03
1 
0.0
36 
0.8
58 
0.39
433
5 
0.404 3.559 
0.31
3 
0.
15
7 
4 9414 +++- 1.000 
0.
99
9 
Imput
ed 
rs102
72724 
7:5047
7213 T C 
0.
26
8 
0.
96
8 
0.0
40 
0.8
16 
0.41
773
9 
0.379 2.767 
0.42
9 
0.
00
0 
4 9414 +-+- 0.999 
0.
99
4 
Imput
ed 
rs113
01008
1 
3:4645
7412 T C 
0.
12
0 
1.
04
4 
0.0
51 
-
0.7
73 
0.44
278
6 
0.354 0.858 
0.83
6 
0.
00
0 
4 9414 --+- 0.992 
0.
93
5 
Imput
ed 
rs792
8968 
11:205
0299 T A 
0.
24
5 
1.
03
3 
0.0
43 
0.7
60 
0.45
034
6 
0.346 4.883 
0.18
1 
0.
38
6 
4 9414 
-
++
+ 
0.932 
0.
72
5 
Imput
ed 
rs382
5932 
15:792
35446 C T 
0.
64
6 
0.
97
2 
0.0
36 
-
0.7
52 
0.45
548
7 
0.342 0.631 
0.88
9 
0.
00
0 
4 9414 ---- 0.895 
0.
67
1 
Imput
ed 
rs230
4256 
19:104
75652 C A 
0.
28
0 
1.
02
9 
0.0
37 
-
0.7
08 
0.48
198
3 
0.317 2.145 
0.54
3 
0.
00
0 
4 9414 +--+ 1.000 
0.
99
9 
Geno
typed 
rs105
17086 
4:2608
5511 A G 
0.
29
3 
1.
02
7 
0.0
39 
0.6
85 
0.49
639
8 
0.304 0.720 
0.86
8 
0.
00
0 
4 9414 +-+- 0.999 
0.
99
7 
Geno
typed 
rs601
338 
19:492
06674 G A 
0.
46
0 
0.
97
8 
0.0
35 
0.6
22 
0.53
708
8 
0.270 5.594 
0.13
3 
0.
46
4 
4 9414 +-+- 0.999 
0.
99
5 
Imput
ed 
rs992
4471 
16:285
91530 A G 
0.
15
3 
1.
03
0 
0.0
49 
0.6
05 
0.54
833
9 
0.261 1.206 
0.75
2 
0.
00
0 
4 9415 ++-+ 0.938 
0.
66
9 
Imput
ed 
rs669
1977 
1:2008
14959 C T 
0.
20
6 
0.
97
4 
0.0
41 
-
0.5
87 
0.55
997
2 
0.252 3.537 
0.31
6 
0.
15
2 
4 9414 
-
++
+ 
0.995 
0.
98
0 
Imput
ed 
rs924
043 
6:1703
79025 C T 
0.
80
3 
0.
97
4 
0.0
49 
-
0.5
00 
0.61
988
5 
0.208 1.750 
0.62
6 
0.
00
0 
4 9414 -++- 0.984 
0.
91
7 
Imput
ed 
rs478
222 
2:2530
1755 A T 
0.
42
0 
1.
01
8 
0.0
35 
-
0.4
89 
0.62
74 0.202 
3.24
5 
0.35
5 
0.
07
5 
4 9414 -+-+ 0.994 
0.
97
8 
Imput
ed 
rs722
988 
10:334
26147 C T 
0.
37
6 
1.
01
4 
0.0
37 
0.3
79 
0.70
674
3 
0.151 2.264 
0.51
9 
0.
00
0 
4 9415 +--+ 0.995 
0.
98
4 
Imput
ed 
rs484
9135 
2:1116
15079 G T 
0.
67
3 
1.
01
4 
0.0
39 
0.3
50 
0.72
821
5 
0.138 1.533 
0.67
5 
0.
00
0 
4 9414 
-
++
+ 
0.999 
0.
99
7 
Imput
ed 
rs682
7756 
4:1231
84411 T C 
0.
60
0 
0.
98
7 
0.0
36 
0.3
48 
0.73
015
1 
0.137 4.384 
0.22
3 
0.
31
6 
4 9414 +-++ 0.998 
0.
99
3 
Imput
ed 
rs692
0220 
6:1380
06504 A G 
0.
21
9 
1.
01
4 
0.0
42 
0.3
08 
0.75
948
7 
0.119 3.607 
0.30
7 
0.
16
8 
4 9415 -++- 1.000 
1.
00
0 
Geno
typed 
rs694
739 
11:640
97233 A G 
0.
37
8 
1.
01
1 
0.0
35 
-
0.3
07 
0.76
021 0.119 
4.41
1 
0.22
0 
0.
32
0 
4 9414 +--- 1.000 
1.
00
0 
Geno
typed 
rs121
48472 
15:792
31478 T C 
0.
12
4 
1.
01
4 
0.0
51 
-
0.2
54 
0.80
096 0.096 
2.99
7 
0.39
2 
0.
00
0 
4 9415 -++- 0.926 
0.
46
4 
Imput
ed 
rs146
5788 
14:692
63599 C T 
0.
68
9 
1.
01
0 
0.0
39 
0.2
50 
0.80
375
9 
0.095 1.438 
0.69
7 
0.
00
0 
4 9414 
-
++
+ 
1.000 
1.
00
0 
Geno
typed 
rs494
8088 
7:5102
7194 C A 
0.
84
3 
1.
02
1 
0.0
88 
0.2
21 
0.82
642
2 
0.083 1.021 
0.60
0 
0.
00
0 
3 7047 +?-+ 1.000 
0.
99
8 
Geno
typed 
rs722
1109 
17:387
70286 C T 
0.
61
5 
1.
00
2 
0.0
36 
0.0
40 
0.96
852 0.014 
1.66
2 
0.64
5 
0.
00
0 
4 9414 +-++ 1.000 
0.
99
8 
Geno
typed 
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SNP LOCUS Risk 
Allele 
Disease risk allele 
frequency in LADA 
cohort 
Published effect 
size 
Power to detect 
signal 
α = 
0.00000005 
α = 
0.05 
rs7454108 HLA_DQB1 -- -- -- -- -- 
rs9272346 MHC A 0.58 5.58 100% 100% 
rs2187668 HLA_DRB1 -- -- -- -- -- 
rs3129889 HLA_DRB1_
15 
A 0.88 14.88 100% 100% 
rs6679677 PTPN22 A 0.12 1.82 100% 100% 
rs689 INS,IGF2 T 0.71 2.39 100% 100% 
rs1769673
6 
SH2B3 G 0.45 1.34 100% 100% 
rs1175552
7 
BACH2 G 0.44 1.13 3.80% 95.70
% 
rs597325 BACH2 G 0.58 1.19 38.60% 100% 
rs7292803
8 
BACH2 A 0.18 1.2 12.70% 99.10
% 
rs229541 IL2RB A 0.42 1.12 2% 92% 
rs941576 DLK1 A 0.45 1.14 6.60% 97.50
% 
rs1157131
6 
CTLA4 G 0.38 1.22 66.40% 100% 
rs7090530 IL2RA A 0.59 1.22 66.30% 100% 
rs7272739
4 
RASGRP1 T 0.20 1.15 2.10% 92.80
% 
rs6183966
0 
IL2RA C 0.08 1.62 100% 100% 
rs4763879 CD69 A 0.38 1.09 - 71.70
% 
rs9653442 AFF3 C 0.52 1.11 1.10% 88.20
% 
rs1049216
6 
CD69 G 0.48 1.15 10.90% 98.80
% 
rs1270871
6 
CLEC16A A 0.34 1.23 70.90% 100% 
rs1079579
1 
IL2RA G 0.42 1.16 15.70% 99.30
% 
rs1738074 RSPH3 C 0.58 1.09 - 72.70
% 
rs1615504 DOK6 T 0.51 1.13 3.90% 95.80
% 
rs1245350
7 
FBXL20 G 0.51 1.11 1.10% 88.30
% 
rs9585056 UBAC2 C 0.71 1.12 - 86.90
% 
rs2542151 PTPN2 G 0.77 1.3 85.30% 100% 
rs1990760 GCG, FAP, 
IFIH1, GCA, 
KCNH7 
T 0.61 1.15 9% 98.40
% 
rs7804356  SKAP2 T 0.22 1.14 1.70% 97.50
% 
rs1050954
0 
RNLS T 0.29 1.14 3.40% 95.20
% 
rs3024493 MAPKAPK2 C 0.16 1.22 16.00% 99.40
% 
rs1117046
6 
ITGB7 T 0.07 1.19 - 78.40
% 
rs911263 RAD51B T 0.67 1.12 1.20% 89.20
% 
rs6476839 GLIS3 T 0.41 1.12 1.90% 92.20
% 
rs1290830
9 
RASGRP1 G 0.24 1.19 18.40% 99.50
% 
rs193778 CLEC16A G 0.25 1.14 2.30% 93.40
% 
rs1120320
3 
UBASH3A A 0.38 1.14 5.50% 97.10
% 
rs5753037 NF2 T 0.38 1.11 - 86.70
% 
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rs1456988 C14orf64 G 0.68 1.12 1.10% 88.70
% 
rs1125874
7 
PRKCQ G 0.77 1.45 100% 100% 
rs602662 FUT2 A 0.51 1.12 2.10% 92.80
% 
rs2281808 SIRPD C 0.63 1.11 - 85.80
% 
rs1087701
2 
CYP27B1 G 0.34 1.22 61.40% 100% 
rs2611215 TMEM192 A 0.77 1.19 14% 99.20
% 
rs1195402
0 
IL7R G 0.41 1.11 - 87.50
% 
rs402072 DACT3 T 0.15 1.15 - 86.50
% 
rs1538171 CENPW G 0.47 1.12 2% 92.80
% 
rs1027272
4 
IKZF1 T 0.27 1.15 4.70% 96.60
% 
rs1130100
81 
CCR5 T 0.12 1.19 2.50% 93.70
% 
rs7928968 INS,IGF2 T 0.25 1.25 67.60% 100% 
rs3825932 CHRNB4 T 0.35 1.16 12.80% 99.10
% 
rs2304256 ICAM1 C 0.28 1.16 8.30% 98.30
% 
rs1051708
6 
SLC34A2 A 0.29 1.09 - 66.10
% 
rs601338 FUT2 A 0.54 1.34 100% 100% 
rs9924471 SBK1 A 0.15 1.25 31.60% 99.90
% 
rs6691977 KIF14 C 0.21 1.13 - 86% 
rs924043 WDR27 C 0.80 1.19 9.00% 98.50
% 
rs478222 DNMT3A A 0.42 1.15 10.20% 98.7 
rs722988 ITGB1 C 0.38 1.11 - 86.70
% 
rs4849135 ACOXL G 0.67 1.12 1.20% 89.20
% 
rs6827756 KIAA1109 T 0.60 1.13 3.20% 95% 
rs6920220 TNFAIP3 A 0.22 1.12 - 81.70
% 
rs694739 BAD A 0.38 1.05 - 30% 
rs1214847
2 
CHRNB4 T 0.12 1.2 3.70% 95.50
% 
rs1465788 RAD51B C 0.69 1.16 9.00% 98.40
% 
rs4948088 COBL C 0.84 1.3 55.50% 100% 
rs7221109 CCR7 C 0.61 1.05 - 30% 
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rs10842994 12:27965150 C T 
0.199 1.169 0.037 1.070 1.278 -3.444 0.001 3.198 1.896 0.594 0.000 
4 9415 ---- 
KLHDC5 0.998 0.987 
Imputed 
rs10401969 19:19407718 T C 
0.088 0.820 0.072 0.726 0.927 3.176 0.002 2.788 0.806 0.848 0.000 
4 9415 ++++ 
CILP2 0.999 0.988 
Imputed 
rs10203174 2:43690030 C T 
0.110 1.193 0.046 1.064 1.339 -3.016 0.003 2.558 3.069 0.381 0.023 
4 9414 ---- 
THADA 0.999 0.993 
Imputed 
rs11634397 15:80432222 G A 
0.642 1.121 0.041 1.040 1.208 2.976 0.003 2.502 5.130 0.162 0.415 
4 9415 +++- 
ZFAND6 0.977 0.923 
Imputed 
rs8108269 19:46158513 G T 
0.308 1.112 0.042 1.030 1.200 2.716 0.007 2.153 2.231 0.526 0.000 
4 9414 +++- 
GIPR 1.000 0.999 
Genotyped 
rs7903146 10:114758349 T C 
0.280 1.108 0.042 1.025 1.197 2.575 0.011 1.974 4.975 0.174 0.397 
4 9415 +-++ 
TCF7L2 0.972 0.896 
Imputed 
rs10923931 1:120517959 T G 
0.102 1.160 0.064 1.034 1.302 2.522 0.012 1.909 4.832 0.185 0.379 
4 9415 ++-+ 
NOTCH2 0.990 0.930 
Imputed 
rs849135 7:28196413 G A 
0.476 1.088 0.032 1.014 1.167 -2.349 0.020 1.704 5.835 0.120 0.486 
4 9414 +--- 
JAZF1 0.999 0.998 
Imputed 
rs9936385 16:53819169 C T 
0.411 1.088 0.038 1.014 1.168 2.335 0.020 1.689 4.717 0.194 0.364 
4 9415 ++++ 
FTO 1.000 0.999 
Genotyped 
rs163184 11:2847069 G T 
0.488 1.087 0.038 1.013 1.166 2.326 0.021 1.678 2.877 0.411 0.000 
4 9415 ++++ 
KCNQ1 0.976 0.925 
Imputed 
rs7403531 15:38822905 T C 
0.713 1.111 0.045 1.002 1.231 -2.006 0.047 1.332 2.755 0.252 0.274 
3 7047 -?-- 
RASGRP1 0.969 0.861 
Imputed 
rs4275659 12:123447928 C T 
0.675 1.081 0.042 0.999 1.169 1.943 0.054 1.270 7.983 0.046 0.624 
4 9415 -+++ 
MPHOSPH9 0.970 0.886 
Imputed 
rs516946 8:41519248 C T 
0.724 1.086 0.045 0.998 1.183 1.909 0.058 1.235 3.287 0.350 0.087 
4 9414 ++++ 
ANK1 0.970 0.886 
Imputed 
rs2796441 9:84308948 G A 
0.406 1.072 0.033 0.998 1.152 -1.907 0.058 1.233 4.573 0.206 0.344 
4 9414 -+-- 
TLE1 1.000 0.999 
Genotyped 
rs17168486 7:14898282 T C 
0.178 1.092 0.049 0.996 1.196 1.877 0.063 1.204 3.763 0.288 0.203 
4 9415 +++- 
DGKB 0.995 0.978 
Imputed 
rs2943640 2:227093585 C A 
0.623 1.069 0.039 0.993 1.150 1.779 0.077 1.111 0.775 0.855 0.000 
4 9414 ++++ 
IRS1 0.998 0.991 
Imputed 
rs6878122 5:76427311 G A 
0.681 1.072 0.036 0.991 1.159 -1.744 0.083 1.079 7.855 0.049 0.618 
4 9415 -++- 
ZBED3 0.991 0.966 
Imputed 
rs4458523 4:6289986 G T 
0.570 1.066 0.038 0.992 1.145 1.743 0.084 1.078 0.094 0.993 0.000 
4 9414 ++++ 
WFS1 0.996 0.987 
Imputed 
rs6723108 2:135479980 T G 
0.486 1.065 0.038 0.991 1.144 1.709 0.090 1. 047 2.095 0.553 0.000 
4 9415 ++++ 
TMEM163 0.939 0.803 
Imputed 
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rs4402960 3:185511687 T G 
0.301 1.068 0.040 0.988 1.153 1.663 0.099 1.005 1.513 0.679 0.000 
4 9415 +-++ 
IGF2BP 0.999 0.997 
Imputed 
rs7756992 6:20679709 G A 
0.283 1.068 0.041 0.988 1.154 1.661 0.099 1.003 1.454 0.693 0.000 
4 9415 +++- 
CDKAL1 0.997 0.989 
Imputed 
rs1552224 11:72433098 A C 
0.171 0.926 0.049 0.843 1.018 1.595 0.113 0.946 5.509 0.138 0.455 
4 9415 ++-+ 
ARAP1 (CENTD2) 1.000 1.000 
Genotyped 
rs2334499 11:1696849 T C 
0.424 0.947 0.033 0.882 1.016 -1.511 0.134 0.874 1.056 0.788 0.000 
4 9414 ---- 
DUSP8 0.970 0.906 
Imputed 
rs10811661 9:22134094 T C 
0.160 1.079 0.044 0.978 1.190 -1.509 0.134 0.873 4.491 0.213 0.332 
4 9414 +--- 
CDKN2A/B 0.998 0.988 
Imputed 
rs243088 2:60568745 T A 
0.475 1.054 0.037 0.981 1.131 1.440 0.153 0.816 3.395 0.335 0.116 
4 9414 +-+- 
BCL11A 0.995 0.984 
Imputed 
rs6813195 4:153520475 T C 
0.284 0.945 0.036 0.874 1.021 -1.430 0.156 0.808 4.347 0.226 0.310 
4 9414 ---+ 
TMEM154 0.999 0.996 
Genotyped 
rs12970134 18:57884750 A G 
0.277 1.055 0.041 0.975 1.142 1.327 0.188 0.727 3.175 0.365 0.055 
4 9415 ++-- 
MC4R 1.000 0.999 
Genotyped 
rs12899811 15:91544076 A G 
0.311 0.952 0.039 0.883 1.028 1.257 0.212 0.673 1.999 0.573 0.000 
4 9414 +-++ 
PRC1 0.920 0.740 
Imputed 
rs17106184 1:50909985 G A 
0.104 1.077 0.052 0.959 1.209 -1.254 0.213 0.671 1.154 0.764 0.000 
4 9414 ---- 
FAF1 0.997 0.976 
Imputed 
rs2075423 1:214154719 G T 
0.345 1.047 0.035 0.973 1.127 -1.236 0.220 0.658 2.434 0.487 0.000 
4 9414 -+-- 
PROX1 0.987 0.956 
Imputed 
rs17791513 9:81905590 A G 
0.071 1.091 0.060 0.950 1.251 -1.235 0.220 0.657 0.917 0.821 0.000 
4 9414 --+- 
TLE4 0.992 0.903 
Imputed 
rs7845219 8:95937502 T C 
0.451 1.044 0.033 0.972 1.120 -1.186 0.239 0.621 1.336 0.720 0.000 
4 9414 ---- 
TP53INP1 0.998 0.995 
Imputed 
rs6808574 3:187740523 T C 
0.594 0.959 0.037 0.892 1.030 1.148 0.254 0.594 4.030 0.258 0.256 
4 9414 ++-+ 
LPP 0.988 0.963 
Imputed 
rs7041847 9:4287466 A G 
0.496 1.039 0.033 0.968 1.115 -1.060 0.293 0.533 4.199 0.241 0.286 
4 9414 +--- 
GLIS3 0.993 0.977 
Imputed 
rs7163757 15:62391608 C T 
0.444 0.965 0.036 0.899 1.036 0.979 0.331 0.480 4.202 0.240 0.286 
4 9414 +++- 
C2CD4A 1.000 1.000 
Genotyped 
rs9470794 6:38106844 C T 
0.080 0.938 0.058 0.826 1.067 -0.971 0.335 0.475 0.901 0.825 0.000 
4 9414 --+- 
ZFAND3 0.995 0.953 
Imputed 
rs6795735 3:64705365 T C 
0.404 0.966 0.034 0.899 1.037 -0.960 0.341 0.468 3.986 0.263 0.247 
4 9414 +--- 
ADAMTS9 0.994 0.981 
Imputed 
rs459193 5:55806751 G A 
0.703 1.040 0.041 0.959 1.127 0.946 0.348 0.459 4.414 0.220 0.320 
4 9414 ++-+ 
ANKRD55 1.000 0.999 
Genotyped 
rs831571 3:64048297 C T 
0.761 1.045 0.047 0.953 1.146 0.940 0.351 0.455 0.331 0.954 0.000 
4 9414 ++++ 
PSMD6 0.990 0.954 
Imputed 
rs2261181 12:66212318 T C 
0.086 1.058 0.064 0.933 1.199 0.883 0.381 0.420 0.891 0.828 0.000 
4 9415 +++- 
HMGA2 0.997 0.979 
Imputed 
rs7178572 15:77747190 G A 
0.674 0.966 0.037 0.894 1.044 -0.878 0.383 0.416 5.408 0.144 0.445 
4 9414 +-+- 
HMG20A 0.997 0.988 
Imputed 
rs11717195 3:123082398 T C 
0.238 1.034 0.039 0.952 1.122 -0.788 0.434 0.362 1.328 0.723 0.000 
4 9414 ---+ 
ADCY5 0.996 0.981 
Imputed 
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rs3786897 19:33893008 A G 
0.428 1.029 0.034 0.958 1.105 -0.783 0.437 0.360 0.472 0.925 0.000 
4 9414 --+- 
PEPD 0.964 0.883 
Imputed 
rs1359790 13:80717156 G A 
0.265 0.970 0.040 0.895 1.050 0.755 0.454 0.343 0.545 0.909 0.000 
4 9414 +-++ 
SPRY2 1.000 0.999 
Genotyped 
rs10830963 11:92708710 C G 
0.284 1.031 0.037 0.953 1.115 -0.755 0.454 0.343 0.220 0.974 0.000 
4 9414 ---+ 
MTNR1B 0.967 0.874 
Imputed 
rs1111875 10:94462882 C T 
0.408 1.027 0.034 0.957 1.103 -0.744 0.460 0.337 5.037 0.169 0.404 
4 9415 --++ 
HHEX/IDE 0.999 0.995 
Imputed 
rs4430796 17:36098040 A G 
0.525 1.026 0.036 0.956 1.102 0.723 0.473 0.325 3.262 0.353 0.080 
4 9415 --++ 
HNF1B 0.981 0.941 
Imputed 
rs7612463 3:23336450 A C 
0.125 1.038 0.054 0.933 1.155 0.684 0.497 0.303 0.730 0.866 0.000 
4 9415 -+++ 
UBE2E2 1.000 0.999 
Genotyped 
rs1802295 10:70931474 T C 
0.340 0.975 0.036 0.905 1.050 -0.667 0.508 0.294 0.997 0.802 0.000 
4 9414 --++ 
VPS26A 1.000 0.999 
Genotyped 
rs12427353 12:121426901 G C 
0.198 1.023 0.042 0.938 1.117 -0.519 0.607 0.217 13.097 0.004 0.771 
4 9414 +-++ 
HNF1A 0.998 0.987 
Imputed 
rs3802177 8:118185025 G A 
0.312 0.981 0.038 0.910 1.058 0.496 0.622 0.206 5.188 0.159 0.422 
4 9415 ++-+ 
SLC30A8 0.928 0.753 
Imputed 
rs702634 5:53271420 A G 
0.657 0.982 0.037 0.911 1.059 -0.466 0.644 0.191 0.849 0.838 0.000 
4 9414 +-+- 
ARL15 0.999 0.998 
Genotyped 
rs11063069 12:4374373 G A 
0.206 1.019 0.043 0.934 1.111 0.422 0.675 0.170 1.818 0.611 0.000 
4 9414 +-++ 
CCND2 0.908 0.592 
Imputed 
rs4812829 20:42989267 A G 
0.170 0.981 0.044 0.893 1.076 -0.413 0.682 0.166 1.074 0.783 0.000 
4 9414 ---+ 
HNF4A 0.994 0.962 
Imputed 
rs7955901 12:71433293 T C 
0.545 1.015 0.035 0.946 1.088 0.401 0.690 0.161 6.318 0.097 0.525 
4 9414 +-++ 
TSPAN8 0.998 0.993 
Imputed 
rs13233731 7:130437689 G A 
0.495 0.986 0.035 0.919 1.058 0.382 0.704 0.152 2.679 0.444 0.000 
4 9414 +-+- 
KLF14 1.000 1.000 
Imputed 
rs6467136 7:127164958 G A 
0.529 1.007 0.035 0.939 1.080 0.192 0.849 0.071 3.862 0.277 0.223 
4 9414 +--- 
GCC1 0.998 0.995 
Imputed 
rs10278336 7:44245363 G A 
0.435 1.006 0.035 0.938 1.080 0.176 0.861 0.065 1.572 0.666 0.000 
4 9414 -+++ 
GCK 0.994 0.980 
Imputed 
rs780094 2:27741237 C T 
0.607 1.004 0.036 0.934 1.081 0.118 0.906 0.043 0.486 0.922 0.000 
4 9415 +++- 
GCKR 1.000 0.999 
Genotyped 
rs5215 11:17408630 T C 
0.597 0.996 0.035 0.926 1.070 -0.116 0.908 0.042 1.988 0.575 0.000 
4 9414 +-+- 
KCNJ11 0.998 0.994 
Imputed 
rs2028299 15:90374257 C A 
0.675 1.004 0.038 0.929 1.086 -0.108 0.915 0.039 0.135 0.987 0.000 
4 9414 -+-+ 
AP3S2 0.995 0.982 
Imputed 
rs16861329 3:186666461 C T 
0.122 1.004 0.051 0.903 1.117 -0.077 0.939 0.027 4.751 0.191 0.369 
4 9414 +-+- 
ST64GAL1 0.980 0.872 
Imputed 
rs9505118 6:7290437 G A 
0.412 1.002 0.035 0.933 1.076 0.057 0.955 0.020 2.601 0.457 0.000 
4 9414 +++- 
SSR1/RREB1 1.000 1.000 
Genotyped 
rs7593730 2:161171454 C T 
0.745 0.999 0.043 0.916 1.090 -0.020 0.984 0.007 0.853 0.837 0.000 
4 9415 -++- 
RBMS1 1.000 1.000 
Genotyped 
rs12571751 10:80942631 A G 
0.463 1.000 0.035 0.932 1.073 0.004 0.997 0.001 2.753 0.431 0.000 
4 9414 ++-+ 
ZMIZ1 1.000 0.999 
Genotyped 
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Supp. Table 5-10A. T2D loci in LADACTR
 
S
N
P
 
LOCUS 
AverageCal
l Rsq 
Genotype
d 
Risk 
Allele 
Disease risk allele f 
requency in LADA 
cohort 
Published effect 
size 
Power to detect signal 
α = 
0.00000005 
α = 
0.05 
rs1084299
4 KLHDC5 0.99757 
0.9874
8 Imputed 
C 
0.20 1.09 0.10% 
55.60% 
rs1040196
9 CILP2 0.99885 
0.9882
2 Imputed C 0.91 1.13 - 54.70% 
rs1020317
4 THADA 0.99902 
0.9929
2 Imputed C 0.11 1.15 - 76.70% 
rs1163439
7 ZFAND6 0.97661 
0.9231
8 Imputed G 0.64 1.09 - 70.10% 
rs8108269 GIPR 0.99968 
0.9987
9 Genotyped G 0.31 1.06 - 37.20% 
rs7903146 TCF7L2 0.97237 
0.8964
2 Imputed T 0.28 1.4 100.00% 100% 
rs1092393
1 NOTCH2 0.99031 
0.9303
5 Imputed T 0.10 1.11 - 48.30% 
rs849135 JAZF1 0.99948 
0.9982
5 Imputed G 0.48 1.12 2.10% 92.80% 
rs9936385 FTO 0.9998 
0.9994
4 Genotyped C 0.41 1.13 3.50% 95.40% 
rs163184 KCNQ1 0.97639 
0.9246
9 Imputed G 0.49 1.09 - 74% 
rs7403531 
RASGRP1 
0.96912 
0.8608
9 Imputed T 0.71 1.02 - 8.40% 
rs4275659 MPHOSPH9 0.97022 
0.8862
1 Imputed C 0.67 1.07 - 48.20% 
rs516946 ANK1 0.97022 
0.8862
1 Imputed C 0.67 1.07 - 48.20% 
rs2796441 TLE1 0.99962 
0.9987
5 Genotyped G 0.41 1.07 - 52.20% 
rs1716848
6 DGKB 0.99547 
0.9784
5 Imputed T 0.18 1.13 - 81.90% 
rs2943640 IRS1 0.99758 
0.9908
9 Imputed C 0.62 1.09 - 71.20% 
rs6878122 ZBED3 0.99149 
0.9663
2 Imputed G 0.68 1.13 3.00% 92.80% 
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rs4458523 WFS1 0.99578 
0.9871
2 Imputed G 0.57 1.09 - 73% 
rs6723108 TMEM163 0.93865 
0.8030
1 Imputed T 0.49 1.01 - 6% 
rs4402960 IGF2BP 0.99909 
0.9966
6 Imputed T 0.30 1.13 2.90% 92.70% 
rs7756992 CDKAL1 0.9969 
0.9891
1 Imputed G 0.28 1.2 33.00% 99.90% 
rs1552224 
ARAP1 
(CENTD2) 
0.99994 
0.9996
5 Genotyped A 0.17 
1.13 
- 
80.20% 
rs2334499 DUSP8 0.96986 
0.9061
4 Imputed T 0.42 1.07 - 52.40% 
rs1081166
1 CDKN2A/B 0.99828 
0.9884
2 Imputed T 0.16 1.19 6.40% 97.50% 
rs243088 BCL11A 0.99521 
0.9842
1 Imputed T 0.47 1.09 - 73.90% 
rs6813195 TMEM154 0.99889 
0.9960
1 Genotyped C 0.72 1.08 - 54.60% 
rs1297013
4 MC4R 0.99981 
0.9992
3 Genotyped A 0.28 1.08 - 55.50% 
rs1289981
1 PRC1 0.91964 
0.7402
6 Imputed G 0.69 1.09 - 66.80% 
rs1710618
4 FAF1 0.99712 
0.9755
8 Imputed G 0.10 1.11 - 48.30% 
rs2075423 PROX1 0.98715 
0.9557
7 Imputed G 0.35 1.08 - 60.80% 
rs1779151
3 TLE4 0.99184 
0.9030
5 Imputed A 0.07 1.21 1.10% 85.50% 
rs7845219 TP53INP1 0.99821 
0.9950
9 Imputed T 0.45 1.08 - 63.90% 
rs6808574 LPP 0.98842 
0.9631
2 Imputed C 0.41 1.08 - 63% 
rs7041847 GLIS3 0.99314 
0.9771
4 Imputed A 0.50 1.05 - 31.40% 
rs7163757 C2CD4A 0.99994 
0.9997
8 Genotyped C 0.44 1.06 - 41.70% 
rs9470794 ZFAND3 0.99457 
0.9526
6 Imputed T 0.92 1.01 - 5.30% 
rs6795735 ADAMTS9 0.99419 0.981 Imputed C 0.40 1.07 - 51.90% 
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rs459193 ANKRD55 0.9996 
0.9985
2 Genotyped G 0.70 1.05 - 27% 
rs831571 PSMD6 0.99034 
0.9543
1 Imputed C 0.76 1.03 - 11.80% 
rs2261181 HMGA2 0.99715 
0.9792
5 Imputed T 0.09 1.16 - 74.40% 
rs7178572 HMG20A 0.99704 
0.9877
9 Imputed G 0.67 1.08 - 58.60% 
rs1171719
5 ADCY5 0.99606 
0.9811
7 Imputed T 0.24 1.09 - 61% 
rs3786897 PEPD 0.96442 
0.8830
8 Imputed A 0.43 1.02 - 9.10% 
rs1359790 SPRY2 0.99976 
0.9990
1 Genotyped G 0.27 1.11 - 80.50% 
rs1083096
3 MTNR1B 0.96662 
0.8736
1 Imputed G 0.72 1.11 - 80.20% 
rs1111875 HHEX/IDE 0.99865 
0.9948
3 Imputed C 0.41 1.15 10.00% 98.60% 
rs4430796 HNF1B 0.98054 
0.9407
5 Imputed G 0.47 1.13 3.90% 95.80% 
rs7612463 UBE2E2 0.99979 
0.9988
1 Genotyped C 0.88 1.11 - 52.50% 
rs1802295 VPS26A 0.99982 
0.9991
8 Genotyped T 0.34 1.02 - 8.80% 
rs1242735
3 HNF1A 0.9977 
0.9870
3 Imputed G 0.20 1.12 - 95.30% 
rs3802177 SLC30A8 0.92842 
0.7528
9 Imputed G 0.31 1.16 14.10% 98.70% 
rs702634 ARL15 0.99949 
0.9981
3 Genotyped A 0.66 1.08 - 59.20% 
rs1106306
9 CCND2 0.90818 
0.5922
4 Imputed G 0.21 1.11 - 73.70% 
rs4812829 HNF4A 0.99378 
0.9615
8 Imputed A 0.17 1.07 - 34% 
rs7955901 TSPAN8 0.99777 
0.9933
5 Imputed C 0.46 1.09 - 73.90% 
rs1323373
1 KLF14 0.99989 
0.9996
3 Imputed G 0.50 1.11 1.10% 88.30% 
rs6467136 GCC1 0.99828 
0.9948
5 Imputed A 0.47 1.01 - 6% 
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rs1027833
6 GCK 0.99398 
0.9804
4 Imputed A 0.44 1.05 - 31% 
rs780094 GCKR 0.99984 
0.9993
7 Genotyped C 0.61 1.04 - 21.10% 
rs5215 KCNJ11 0.9982 0.9941 Imputed C 0.40 1.08 - 62.70% 
rs2028299 AP3S2 0.99535 
0.9824
3 Imputed C 0.67 1.04 - 19.90% 
rs1686132
9 ST64GAL1 0.97976 
0.8724
4 Imputed C 0.12 1.03 - 9% 
rs9505118 
SSR1/RREB
1 0.99994 
0.9997
8 Genotyped A 0.59 1.07 - 51.80% 
rs7593730 RBMS1 0.99999 
0.9999
6 Genotyped C 0.75 1.11 - 77.20% 
rs1257175
1 ZMIZ1 0.99952 
0.9986
2 Genotyped A 0.46 1.09 - 73.80% 
Supp. Table 5-10B. Power to detect T2D loci in LADACTRL 
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Stratification by top 1 GAD tertile, top 2 GAD tertiles, or bottom 1 GAD tertile, each vs. population controls, in ActionLADA and Swedish LADA cases. Only genome-wide 
significant loci are shown. 
Top 1 GAD titer tertile 
Rs 
number 
Ref. 
allele 
Oth
er 
allel
e 
eaf OR OR 
se 
OR 
95L 
OR 
95U 
z P -
log10
P 
Q 
statist
ic 
Q 
P 
i2 N 
studi
es 
N 
sampl
es 
effec
ts 
6:32626475 A G 0.313 3.30 0.25 2.81 3.88 14.5
3 
1.89E-
47 
46.72 81.60 0.00
0 
0.98
8 
2.00 4940 ++ 
12:112553032 A T 0.450 1.56 0.10 1.37 1.77 6.73 2.01E-
11 
10.70 0.04 0.83
6 
0.00
0 
2.00 4940 ++ 
11:2181060 G T 0.732 1.55 0.11 1.34 1.79 5.96 2.95E-
09 
8.53 1.11 0.29
3 
0.09
6 
2.00 4940 ++ 
1:114415368 C G 0.780 0.64 0.05 0.55 0.75 -
5.84 
5.95E-
09 
8.23 0.62 0.43
0 
0.00
0 
2.00 4940 -- 
Top 2 GAD titer tertiles 
6:32626475 A G 0.3260
08 
3.11
0 
0.19
2 
2.733 3.53
8 
17.2
3 
7.86E-
66 
65.10
5 
105.8
97 
0.00
0 
0.99
1 
2.000 5425.0
00 
++ 
11:2182224 T A 0.7385
89 
1.56
3 
0.08
7 
1.393 1.75
4 
7.60 4.18E-
14 
13.37
9 
2.612 0.10
6 
0.61
7 
2.000 5425.0
00 
++ 
1:114377568 G A 0.8831
28 
0.58
9 
0.04
4 
0.503 0.68
9 
-
6.60 
5.38E-
11 
10.26
9 
4.866 0.02
7 
0.79
4 
2.000 5425.0
00 
-- 
12:112553032 A T 0.4528
65 
1.36
2 
0.06
8 
1.228 1.51
0 
5.86 5.57E-
09 
8.254 0.062 0.80
3 
0.00
0 
2.000 5425.0
00 
++ 
Bottom 1 GAD titer tertile 
6:32626475 A G 0.294 2.42
1 
0.18
6 
2.06 2.85 10.6
4 
2.13E-
26 
25.67
2 
7.158 0.00
7 
0.86
0 
2.000 4875.0
00 
++ 
TCF7L2(10:114758349) in GAD tertile analyses 
Top 1 GAD titer 
tertile 
T C 0.2786
49 
1.05
0 
0.07
0 
0.914 1.20
7 
0.68
7 
0.493 0.307 0.087 0.76
8 
0.00
0 
2.000 4941.0
00 
++ 
Top 2 GAD titer 
tertiles 
T C 0.2801
89 
1.06
3 
0.05
8 
0.950 1.18
9 
1.06
7 
0.288 0.540 0.899 0.34
3 
0.00
0 
2.000 5426.0
00 
+- 
Bottom 1 GAD titer 
tertile 
T C 0.2734
35 
1.09
3 
0.07
6 
0.944 1.26
5 
1.18
6 
0.236 0.628 3.734 0.05
3 
0.73
2 
2.000 4876.0
00 
+- 
Supp. Table 5-11. GAD tertiles 
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DRB1-DQA1-
DQB1 
B
M
D
C
S
 
L
A
D
A
 
T
1
D
 
LADA vs 
BMDCS OR 
LADA vs BMDCS 
p 
LADA vs T1D 
OR 
LADA vs T1D 
p 
01:01-01:01-05:01 0.097 
0.06
9 
0.05
4 0.7[0.58-0.84] 0.00012548 0.76[0.63-0.91] 0.0029333 
03:01-05:01-02:01 0.117 
0.22
3 
0.33
4 
2.17[1.86-
2.53] < 2.22e-16 1.75[1.58-1.93] < 2.22e-16 
04:01-03:01-03:02 0.053 
0.19
3 
0.22
8 
4.32[3.51-
5.35] < 2.22e-16 1.23[1.11-1.37] 0.00011523 
04:04-03:01-03:02 0.038 
0.04
3 
0.08
2 1.13[0.86-1.5] 0.36897 2.01[1.66-2.44] 7.05E-14 
04:05-03:01-03:02 0.004 
0.00
9 
0.02
2 
2.27[1.04-
5.66] 0.030787 2.56[1.71-3.88] 9.08E-07 
07:01-02:01-02:02 0.093 
0.07
4 
0.04
1 
0.78[0.65-
0.94] 0.0086422 0.54[0.44-0.66] 3.07E-10 
07:01-02:01-03:03 0.041 
0.01
4 
0.00
2 
0.33[0.23-
0.47] 1.19E-11 0.16[0.07-0.33] 5.53E-09 
11:01-05:01-03:01 0.071 
0.02
7 
0.00
7 
0.36[0.28-
0.47] < 2.22e-16 0.24[0.15-0.37] 1.47E-12 
13:01-01:03-06:03 0.058 
0.04
9 
0.01
2 
0.84[0.67-
1.07] 0.14127 0.23[0.16-0.31] < 2.22e-16 
14:01-01:01-05:03 0.018 
0.00
6 
0.00
1 
0.31[0.18-
0.53] 1.52E-06 0.17[0.04-0.5] 0.00022447 
15:01-01:02-06:02 0.139 
0.04
6 
0.00
3 0.3[0.25-0.36] < 2.22e-16 0.05[0.02-0.1] < 2.22e-16 
 
Supp. Table 5-12. Established T1D HLA haplotype frequencies in LADA, T1D and controls 
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Supp. Table 5-13. TCF7L2 associations 
 
rs7903146-T (TCF7L2)       
 
Ncas
es 
Ncontr
ols 
MAF LADA 
cases 
MAF 
controls OR P 
LADACTRL_SWE_SWE 805 3126 0.301 0.271 
1.1
82 0.009 
LADACTRL_ACLADA_BMDCS 1353 1014 0.296 0.297 
0.9
86 
0.8255
95 
LADACTRL_DAN_DAN 476 1807 0.298 0.276 
1.1
14 
0.2472
67 
LADACTRL_HUNT 139 695 0.295 0.242 
1.3
00 
0.0669
26 
LADA vs CTRLS meta-analysis 
(+HUNT) 2773 6642 0.298 0.271 
1.1
07 
0.0160
6 
       
       
       
 
Ncas
es 
Ncontr
ols 
MAF LADA 
cases 
MAF T1D 
cases OR P 
LADAT1D_FIN_FIN 296 365 0.221 0.193 
1.1
48 
0.3453
33 
LADAT1D_SWE-CHOP_SWE 2158 603 0.298 0.242 
1.3
00 0.0018 
LADA vs T1D meta-analysis 2454 968 0.260 0.218 
1.2
60 
0.0017
94 
       
       
 
Ncas
es 
Ncontr
ols 
MAF LADA 
cases 
MAF T2D 
cases OR P 
LADAT2D_FIN_FIN 296 2785 0.221 0.223 
0.9
31 
0.5012
35 
LADAT2D_SWE-CHOP_SWE 2158 2599 0.298 0.337 
0.7
93 
5.84E-
06 
LADAT2D_GoDARTS1 97 2098 0.298 0.345 
0.8
06 
0.1663
33 
LADAT2D_GoDARTS2 89 2218 0.264 0.339 
0.7
00 
0.0287
021 
LADAT2D_HUNT 139 695 0.295 0.340 
0.7
81 
0.1005
6 
LADA vs T2D meta-analysis 2779 10395 0.275 0.317 
0.8
07 
4.02E-
07 
       
Additional sensitivity analyses             
  
Ncas
es 
Ncontr
ols 
MAF LADA 
cases 
MAFcontro
ls OR P 
Danish LADA vs controls (with normal 
fasting glucose) 476 8341 0.3 0.26 
1.1
8 0.017 
        
Swedish LADA vs controls (incl. 
diabetics) 884 3126 0.31 0.27 1.2 0.0038 
Swedish LADA vs non-diabetic controls 884 2618 0.31 0.26 
1.2
8 0.0001 
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Supp. Figure 5-1. QQ plots for (A) LADA vs. population controls, (B) LADA vs. T1D, 
and (C) LADA vs. T2D 
A
. 
B
. 
C
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Supp. Figure 5-2. Manhattan plots for (A) LADA vs. population controls, (B) LADA vs. T1D, and (C) LADA vs. T2D 
A
. 
B
C
158 
 
 
 159 
. 
Supp. Figure 5-3. QQ plots showing established T1D (red) and T2D (blue) loci in 
LADA vs. population controls. A) All loci; B) zoomed in at 1 > P > 10-4 (excluding 
top T1D signals). 
 
A
. 
B
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Supplemental Note: Cohort Information 
This study makes use of data generated by the Wellcome Trust Case Control 
Consortium. A full list of the investigators who contributed to the generation of the 
data is available from www.wtccc.org.uk. Funding for the project was provided by 
the Wellcome Trust under award 076113. 
Cohort name: Action Lada 
Cohort type: LADA cases 
Inclusion/exclusion criteria: Patients were designated with diabetes according to 
standard criteria, and LADA was defined as follows: patients 1) aged 30–70 years, 2) with 
diabetes associated autoantibodies, and 3) who did not require insulin treatment for at 
least 6 months post diagnosis. Type 1 autoimmune diabetic patients were defined as 
case subjects with diabetes and with diabetes-associated autoantibodies where insulin 
was started at diagnosis or within 1 month of diagnosis. Inclusion criteria for all patients 
were that patients have diabetes (with at least two recorded fasting blood glucose 
measurements >7 mmol/L), that time from diagnosis was 5 years for all patients, and that 
patients were aged 30–70 years at the time of recruitment. Exclusion criteria were 
insufficient dataset, current pregnancy, renal disease with raised creatinine or proteinuria, 
or acute illness at the time of testing. 
Recruitment Location: Queen Mary University of London and the Action Lada 
consortium in Europe 
Number of study subjects: 1098 
Acknowledgements: We would like to acknowledge the Action Lada consortium. 
Funding: This study was partially funded by the 5th Framework Programme of the 
European Union. 
Cohort reference: REC Reference P/02/240 
Conflicts of interest: No potential conflicts of interest relevant to this work. 
Cohort name: Action Lada ‘Plus’ 
Cohort type: LADA cases 
Inclusion/exclusion criteria: Patients were designated with diabetes according to 
standard criteria, and LADA was defined as follows: patients 1) aged 30–70 years, 2) with 
diabetes associated autoantibodies, and 3) who did not require insulin treatment for at 
least 6 months post diagnosis. Type 1 autoimmune diabetic patients were defined as 
case subjects with diabetes and with diabetes-associated autoantibodies where insulin 
was started at diagnosis or within 1 month of diagnosis. Inclusion criteria for all patients 
were that patients have diabetes (with at least two recorded fasting blood glucose 
measurements >7 mmol/L), that time from diagnosis was 5 years for all patients, and that 
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patients were aged 30–70 years at the time of recruitment. Exclusion criteria were 
insufficient dataset, current pregnancy, renal disease with raised creatinine or proteinuria, 
or acute illness at the time of testing. 
Recruitment Location: The Mayo, Rochester, MN, USA; Cornell Medical 
College, New York City, NY, USA; University of Alabama, Birmingham, 
AL, USA; University of Pennsylvania, Philadelphia, PA, USA; MODEL 
Clinical Research, Baltimore, MD, USA; Adventist Health System, Sunbelt 
Inc. d/b/a Florida Hospital, Orlando, FL, USA; Atlanta Diabetes 
Associates, Atlanta, GA, USA; Geisinger Health System, Danville, PA, 
USA; University of Leicester, Leicester, UK; T1D Exchange, Benaroya 
Research Institute, Seattle, WA; Health Diagnostic Lab Inc., Richmond, 
VA; National Disease Research Interchange, Philadelphia, PA. 
 
Number of study subjects: 441 
Acknowledgements:  
Funding:  
Cohort reference:  
Conflicts of interest:  
 
Cohort name: All New Diabetics In Scania (ANDIS) 
Cohort type (population controls/ LADA cases/ T1D cases/ T2D cases): LADA cases 
Inclusion/exclusion criteria: 
GAD  
ELISA: Negative:< 5 kE/L, Positive:=> 10 kE/L  
RIA: Negative:0-34 U/ml, Positive:> 50 U/ml 
LADA  
Age at onset ≥ 35 years 
GAD (ELISA) > 10 kE/L 
GAD (RIA) >50 U/ml 
 
Non-Scandinavian individuals excluded 
Recruitment Location: Scania, Sweden  
Number of study subjects: 440 
Acknowledgements: We thank all the patients and the health care providers across 
Scania and Ostrobothnia for their support and their willingness to participate. We would 
also like to thank Johan Hultman, Jasmina Kravic, Maria Fälemark, Christina Rosborn, 
Gabriella Gremsperger, Maria Sterner, Malin Neptin, Lisa Sundman, Paula Kokko, and 
Ulrika Blom-Nilsson for excellent technical and administrative support. Finally we would 
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like to thank Rita Jedlert and Region Skåne (Scania County) as well as the ANDIS 
steering committee for their support. 
Funding: Supported by grants from the Swedish Research Council (including project 
grants Dnr.521-2010-3490 and infrastructure grants Dnr. 2010-5983 and Dnr 2012-5538 
to LG), Linnéus grant 349-2006-237, a strategic research grant (Exodiab Dnr 2009-1039), 
an ERC Advanced Research grant (GA 269045) and Academy of Finland (grants no. 
263401 and 267882) to LG. 
Cohort reference: http://andis.ludc.med.lu.se/ 
Conflicts of interest: None 
Cohort name: Bone Mineral Density in Childhood Study (BMDCS) 
Cohort type (population controls/ LADA cases/ T1D cases/ T2D cases): population 
controls 
Cohort description: The Bone Mineral Density in Childhood Study is a multicenter, 
longitudinal study of bone accrual in healthy children.  
Inclusion/exclusion criteria: Only individuals of European ancestry were included. 
Recruitment Location: Children’s Hospital of Los Angeles (Los Angeles, CA), Cincinnati 
Children’s Hospital Medical Center (Cincinnati, OH), Creighton University (Omaha, NE), 
Children’s Hospital of Philadelphia (Philadelphia, PA), and Columbia University (New 
York, NY)  
Number of study subjects: 1056 
Acknowledgements: We appreciate the dedication of the study participants and their 
families, and the support of Dr. Karen Winer, Scientific Director of the Bone Mineral 
Density in Childhood Study. 
Funding: The BMDCS was funded by the National Institutes of Health [grant number 
R01 HD58886 to B.Z. and S.G.]; the Eunice Kennedy Shriver National Institute of Child 
Health and Human Development [grant numbers N01-HD-1-3228, -3329, -3330, -3331, -
3332, -3333]; the Clinical and Translational Science Awards Program [grant number 8 
UL1 TR000077]; American Diabetes Association Grant 1-17-PDF-077 [to D.C.]; and the 
Institute for Translational Medicine and Theraputics (ITMAT) Transdisciplinary Program in 
Translational Medicine and Therapeutics (to D.C., B.V., and S.G.). The project described 
was supported by the National Center for Research Resources [grant number 
UL1RR024134], and is now at the National Center for Advancing Translational Sciences 
[grant number UL1TR000003].  The content is solely the responsibility of the authors and 
does not necessarily represent the official views of the NIH. The funders had no role in 
the design and conduct of the study; collection, management, analysis, and interpretation 
of the data; preparation, review, or approval of the manuscript; and decision to submit the 
manuscript for publication.  
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Conflicts of interest: None 
Study cohort: Copenhagen Controls 
The Copenhagen Control sample is collected from two cohorts (The 1936 birth cohort 
and ADDITION-PRO), and comprises 1974 non-diabetic adults. The control subjects had 
a mean age of 64.42 (range, 34.44), and 49.9% were male. 
Cohort name: The 1936 birth cohort 
Cohort type (population controls/ LADA cases/ T1D cases/ T2D cases): Population 
controls 
Cohort description/inclusion/exclusion criteria: The cohort consists of all subjects 
born in 1936, who, on 2 April 1976, were resident in one of four municipalities nearby 
Glostrup Hospital, Denmark (n=695). The cohort was collected to assess the age-specific 
prevalence of diabetes mellitus and impaired glucose tolerance in 60-year-old individuals 
in 1996/97. 
Recruitment Location: The samples were collected from four municipalities nearby 
Glostrup Hospital, Denmark (1936 control cohort). The samples were collected in 2009–
2011 from four Danish research centres (Steno Diabetes Center, Aarhus University 
Hospital, Holstebro Hospital, and Hospital of South West Jutland, Esbjerg). 
Number of study subjects: 624 non-diabetic individuals (502 NGTs, 122 IFG/IGTs) 
Acknowledgements: The authors are grateful to the staff at the Centre of Preventive 
Medicine, and to MD, general practitioner, Professor Hanne Hollnagel Dr Med. Sci., who 
initiated the study of the 1936 cohort. 
Funding: The collection of the cohort was financially supported by The Danish Heart 
Foundation and The Danish Medical Research Council. 
Cohort reference: Drivsholm T. Increasing prevalence of diabetes mellitus and impaired 
glucose tolerance among 60-year-old Danes. Diabet Med 2001. 
Conflicts of interest: NA 
 
Cohort name: ADDITION-PRO 
Cohort type (population controls/ LADA cases/ T1D cases/ T2D cases): Controls 
Cohort description/inclusion/exclusion criteria: ADDITION-PRO is a longitudinal 
cohort study of 2082 adults (>45 years) collected to have IGT, IFG, or NGT either with 
high or low risk of developing type 2 diabetes (based on information about age, sex, 
gestational diabetes, family history of diabetes, hypertension, BMI, and level of physical 
activity).  
The samples were collected in 2009–2011from four Danish research centres (Steno 
Diabetes Center, Aarhus University Hospital, Holstebro Hospital, and Hospital of South 
West Jutland, Esbjerg). 
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Number of study subjects: 1350 non-diabetic individuals (812 NGTs, 538 IFG/IGTs) 
Acknowledgements: The ADDITION-PRO study is managed by the ADDITION-DK 
steering committee (Torsten Lauritzen, Knut Borch-Johnsen, Annelli Sandbæk, Marit E. 
Jørgensen, and Daniel Witte). 
Funding: The ADDITION-PRO study was funded by an unrestricted grant from the 
European Foundation for the Study of Diabetes/Pfizer for Research into Cardiovascular 
Disease Risk Reduction in Patients with Diabetes (74550801), the Danish Council for 
Strategic Research, internal research and equipment funds from Steno Diabetes Center 
and supported by research grants from the Novo Nordisk Foundation.  
Cohort reference: Johansen et al. Protocol for ADDITION-PRO: a longitudinal cohort 
study of the cardiovascular experience of individuals at high risk for diabetes recruited 
from Danish primary care. BMC Public Health 2012. 
Conflicts of interest: NA 
Study cohort: Copenhagen LADA 
The Copenhagen LADA sample (n=539) is collected from six cohorts (DD2, Vejle 
Biobank, OUH, CIMT, Inter99, and SDC). The LADA patients had a mean age of 58.32 
(range, 67.31), and 56.2% were male. 
The following inclusion criteria for LADA have been applied in all sub-cohorts: GADA 
positive, ≥20 years at the time of diagnosis, and treated without insulin for the first year 
after diagnosis or having fasting serum C-peptide ≥300 pmol/L at the time of 
investigation. 
Cohort name: Danish Centre for strategic Research in Type 2 Diabetes (DD2) 
Cohort type (population controls/ LADA cases/ T1D cases/ T2D cases): LADA cases 
Cohort description/inclusion/exclusion criteria: DD2 is nationwide cohort, enrolling 
patients with newly diagnosed type 2 diabetes from general practitioners and hospital 
specialist outpatient clinics since 2010. GADA was measured in 5966 patients, with an 
AESKULISA assay. 
Number of study subjects: 158 LADA cases 
Acknowledgements: The DD2-project partners are listed on the website ww.DD2.nu. 
Funding: The DD2 study is supported by the Danish Agency for Science (grant no. 09-
067009 and 09-075724), the Danish Health and Medicines Authority, the Danish 
Diabetes Association, and an unrestricted donation from Novo Nordisk A/S. 
Cohort reference: Thomsen et al. The Danish Centre for Strategic Research in Type 2 
Diabetes (DD2): Organization of diabetes care in Denmark and supplementary data 
sources for data collection among DD2 study participants. Clin Epidemiol 2012. 
Conflicts of interest: NA 
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Cohort name: Vejle Biobank 
Cohort type (population controls/ LADA cases/ T1D cases/ T2D cases): LADA cases 
Cohort description/inclusion/exclusion criteria: The Vejle Diabetes Biobank was 
established as a regional Bio bank and comprises individuals with diabetes and a gender- 
and age-matched control population. All participants were aged between 25 and 75 years 
(both ages included) and residing in the former County of Vejle area on December 31, 
2006. Altogether, 3320 patients with type 2 diabetes or type 1 diabetes were recruited 
from the central database at Vejle Hospital Laboratory Center. GADA were measured in 
all 3320 patients, with an AESKULISA assay. 
Number of study subjects: 124 LADA cases 
Acknowledgements: The laboratory technologists Britta Kristensen, Lene Juul Hansen, 
Annette Kaaris, Jan Johannsen, Merete Willumsen, Birgitte Henriksen, Camilla Davidsen, 
and Sara Egsgaard are acknowledged for their continued engagement and dedicated 
work. 
Funding: The Vejle Biobank project was funded by the Danish Council for Independent 
Research/Medical Sciences, the Research Council of Vejle Hospital, the Department of 
Internal Medicine, Vejle Hospital, Vejle County, the Danish Research Fund, the Lions 
Club International Denmark, and anonymous donations. 
Cohort reference: Petersen et al. Vejle Diabetes Biobank – a resource for studies of the 
etiologies of diabetes and its comorbidities. Clin Epidemiol. 2016. 
Conflicts of interest: NA 
 
Cohort name: OUH 
Cohort type (population controls/ LADA cases/ T1D cases/ T2D cases): LADA cases 
Cohort description/inclusion/exclusion criteria: The OUH LADA cohort is collected 
from a database of patients with diabetes newly referred to Odense University Hospital 
(OUH), Denmark, between 1997 and 2011. GAD autoantibodies were measured in 5,671 
patients with diabetes, applying an RSR RIA assay, 279 were GADA positive, above 30 
years of age, and had fasting C-peptide above 300 pmol/l. Of these DNA was available 
for 66. 
Number of study subjects: 66 LADA cases 
Acknowledgements: Department of Endocrinology, Odense University Hospital, 
Denmark, is acknowledged for their collection of the OUH cohort. 
Funding: NA 
Cohort reference: NA 
Conflicts of interest: NA 
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Cohort name: CIMT 
Cohort type (population controls/ LADA cases/ T1D cases/ T2D cases): LADA cases 
Cohort description/inclusion/exclusion criteria: The CIMT trial is a multicenter 
randomized placebo controlled superiority trail conducted from 2008 to 2012 at eight 
hospitals in the capital region of Denmark. Inclusion criteria included diagnosis of type 2 
diabetes, >30 years at diagnosis, BMI >25 kg/m2, HbA1c>7.5%, treatment with oral anti-
diabetic drugs for ≥1 year, and/or insulin treatment for ≥3 months. Exclusion criteria 
included: major cardiovascular disease within the past 3 months, carotid artery stenosis 
>70%, heart failure, recent cancer, renal or liver disease, alcohol or drug abuse, unstable 
retinopathy, pregnancy, breastfeeding, fertile women not using anticonception, or allergy 
towards trial medication. Altogether, 412 type 2 diabetes patients were included in the 
trial and were screened for the presence of GADA with an RSR ELISA kit.  
Number of study subjects: 31 LADA cases 
Acknowledgements: The CIMT trial group is acknowledged for their effort in collecting 
and characterizing the cohort. 
Funding: The CIMT study was funded by an unrestricted grant from Novo Nordisk A/S.  
Cohort reference: Lundby et al. Study rationale and design of the CIMT trial: the 
Copenhagen Insulin and Metformin Therapy trial. Diabetes Obes Metab 2009. 
Conflicts of interest: NA 
 
Cohort name: Inter99 
Cohort type (population controls/ LADA cases/ T1D cases/ T2D cases): LADA cases 
Cohort description/inclusion/exclusion criteria: Inter99 is a population based 
intervention cohort, comprising individuals from the Copenhagen area. Altogether 6784 
individuals participated in the baseline examination. GADA were measured in 2531 
individuals, with an RSR ELISA kit. 
Number of study subjects: 19 LADA cases 
Acknowledgements: The staff from Research Centre for Prevention and Health, The 
capital region, Glostrup, Denmark is acknowledged their effort in making the Inter99 
study possible.  
Funding: The Inter99 study is funded by The Danish Medical Research Council, The 
Danish Centre for Evaluation and Health Technology Assessment, Novo Nordisk, 
Copenhagen County, The Danish Heart Foundation, The Danish Pharmaceutical 
Association, Augustinus foundation, Ib Henriksen foundation and Becket foundation. 
Cohort reference: Jørgensen et al. A randomized non-pharmacological intervention 
study for prevention of ischaemic heart disease: baseline results Inter99. Eur J 
Cardiovasc Prev Rehabil. 2003. 
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Conflicts of interest: NA 
 
Cohort name: SDC 
Cohort type (population controls/ LADA cases/ T1D cases/ T2D cases): LADA cases 
Cohort description/inclusion/exclusion criteria: The SDC cohort comprises patients 
>18 years with type 2 diabetes (n=1676) recruited from the outpatient clinic at Steno 
Diabetes Center, Gentofte, Denmark. Individuals in pregnancy, having another cause of 
diabetes or being of another ethnicity than Danish were excluded. GADA were measured 
in 1595 individuals. Of the 141 LADA patients, GADA were measured with RSR ELISA in 
52 patients, and with AESKULISA in 89 patients.  
Number of study subjects: 141 LADA cases 
Acknowledgements: NA 
Funding: NA 
Cohort reference: NA 
Conflicts of interest: NA 
 
Copenhagen general acknowledgements: Novo Nordisk Foundation Center for Basic 
Metabolic Research is an independent research center at the University of Copenhagen 
and is partly funded by an unrestricted donation from the Novo Nordisk Foundation. This 
work was supported by a research grant from the Danish Diabetes Academy supported 
by the Novo Nordisk Foundation, and grants from The Danish Council for Independent 
Research - Medical Sciences. 
 
Cohort name: Diabetes Registry Vasa (DIREVA) 
Cohort type (population controls/ LADA cases/ T1D cases/ T2D cases): LADA 
cases/ T1D cases/ T2D cases 
Inclusion/exclusion criteria: LADA 
Age at onset ≥ 35 years 
C-peptide (KLU) > 0.2 nmol/L 
GAD65a (EIA) ≥ 10 U/ml 
 
T1D 
Age at onset < 35 years   
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C-peptide (KLU) < 0.2 nmol/L 
 
T2D 
Age at onset ≥ 35 years 
C-peptide (KLU) ≥ 0.2 nmol/L 
GAD65a (EIA) <10 U/ml 
 
Recruitment Location: Vasa, Finland 
Number of study subjects: 3290 
Acknowledgements: Same as for ANDIS 
Funding: DIREVA was supported by the Vasa Hospital district. 
+funding overlapping with ANDIS  
Cohort reference: NA 
Conflicts of interest: None 
Cohort name: GoDARTS 
Cohort type (population controls/ LADA cases/ T1D cases/ T2D cases):  
• population controls (replication study only) 969 
• LADA cases 206 
• T2D cases 4413 
Inclusion/exclusion criteria: 
• Age diagnosis <35 
• No insulin within 1 year diagnosis 
• GADA positive 
Recruitment Location: Univeersity of Dundee 
Number of study subjects: (see above) 
Acknowledgements: The Wellcome Trust United Kingdom Type 2 Diabetes Case 
Control Collection (GoDARTS) cohort collection was funded by The Wellcome Trust and 
informatics support is provided by the Chief Scientist Office, Scotland. E.R.P. holds a 
Wellcome Trust New Investigator Award (102820/Z/13/Z). 
Funding: NA 
Cohort reference: Diabetes Care. 2014;37(3):718-24. (PMID: 24186880) 
Conflicts of interest: NA 
Cohort name: HUNT 
Cohort type (population controls/ LADA cases/ T1D cases/ T2D cases): LADA and 
T2D cases and non-diabetic population controls 
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Inclusion/exclusion criteria: LADA: Self-reported yes to having diabetes, positive for 
GAD antibodies, initial age at diagnosis >30 years old and no insulin treatment within one 
year of diagnosis. 
T2D: Self-reported yes to having diabetes, GAD antibodies negative, initial age at 
diagnosis >30 years old and no insulin treatment within one year of diagnosis. Age and 
gender matched to the LADA cases. 
Non-diabetic controls: Self-reported no to ever having diabetes and had non-fasting 
serum glucose <7.0 mmol/l. Age and gender matched to the LADA cases. 
Recruitment Location: HUNT Research Centre, Department of Public Health and 
Nursing, Faculty of Medicine and Health Sciences, the Norwegian University of Science 
and Technology, Norway 
Number of study subjects: 139 LADA, 695 T2D and 695 non-diabetic controls 
Acknowledgements: The Nord-Trøndelag Health Study (The HUNT Study) is a 
collaboration between HUNT Research Centre (Faculty of Medicine and Health Sciences, 
NTNU, Norwegian University of Science and Technology), Nord-Trøndelag County 
Council, Central Norway Regional Health Authority, and the Norwegian Institute of Public 
Health. 
Funding: The K.G. Jebsen Center for Genetic Epidemiology is financed by Stiftelsen 
Kristian Gerhard Jebsen; Faculty of Medicine and Health Sciences, NTNU, Norwegian 
University of Science and Technology; the Liaison Committee between the Central 
Norway Regional Health Authority and NTNU; and the Liaison Committee between St. 
Olavs Hospital and the Faculty of Medicine and Health Sciences at NTNU.  
 
The genotyping was financed by the National Institute of Health (NIH), University of 
Michigan, The Norwegian Research Council, the Liaison Committee between the Central 
Norway Regional Health Authority and NTNU, and the Liaison Committee between St. 
Olavs Hospital and the Faculty of Medicine and Health Sciences at NTNU. 
Cohort references: 
Holmen J, Midthjell K, Krüger Ø, Langhammer A, Holmen TL, Bratberg GH, Vatten L, 
Lund-Larsen PG. The Nord-Trøndelag Health Study 1995–97 (HUNT2): 
objectives. contents. methods and participation. Norsk Epidemiologi 2003. 13(1): 
p. 19-32. 
 
Krokstad S, et al. Cohort Profile: the HUNT Study. Norway. Int J Epidemiol. 2013. 42(4): 
p. 968-77. 
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Nielsen JB et al (2018) Genome-wide Study of Atrial Fibrillation Identifies Seven Risk 
Loci and Highlights Biological Pathways and Regulatory Elements Involved in Cardiac 
Development. Am J Hum Genet. 102(1):103-115 [29290336].  
 
Conflicts of interest: There are no disclosures to report. 
Cohort name: Malmö Diet and Cancer study 
Cohort type (population controls/ LADA cases/ T1D cases/ T2D cases): Non-diabetic 
controls 
Inclusion/exclusion criteria: 
Diabetes 
Number of study subjects: 3126 
Acknowledgements: NA 
Funding: NA 
Cohort reference: Berglund G, Nilsson P, Eriksson KF, Nilsson JA, Hedblad B, 
Kristenson H, et al. Long-term outcome of the Malmo preventive project: mortality and 
cardiovascular morbidity. J Intern Med. 2000;247(1):19-29. Epub 2000/02/15. 
Conflicts of interest: None 
Cohort name: Scania Diabetes Registry (SDR) 
Cohort type (population controls/ LADA cases/ T1D cases/ T2D cases): LADA 
cases/ T1D cases/ T2D cases 
Inclusion/exclusion criteria: 
SDR 
GAD (Wallenberg lab (AU ref < 5.0)  
GAD (Wallenberg lab (IU/ml ref <32)  
C-peptide (Klin kem (RIA) ref 0.25-0.75) 
C-peptide (Klin kem ref 0.3-1.3) 
C-peptide (Lund (ref 0.25-0.75) 
 
LADA 
Age at onset ≥ 35 
GAD ≥ 10 AU 
GAD ≥ 50 IU/ml 
 
T1D 
Age  at onset < 35 
GAD ≥ 20 AU 
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GAD ≥ 100 IU/ml 
C-peptide ≥ 0.25 (Klin kem (RIA)) 
C-peptide ≥ 0.3 (Klin kem) 
C-peptide ≥ 0.25 (Lund) 
 
T2D 
BMI > 25 
GAD < 5 AU 
GAD ≤ 34 IU/ml 
C-peptide (Klin kem (RIA)) ≥ 0.75 
C-peptide (Klin kem) ≥ 1.3 
C-peptide (Lund) ≥ 0.75 
For patients that did not fulfill the criteria for any of the above, the diagnosis given by their 
physician was used 
 
Non-Scandinavian individuals excluded 
Number of study subjects: 3567 
Acknowledgements: NA 
Funding: NA 
Cohort reference: Lindholm E, Agardh E, Tuomi T, Groop L, Agardh CD. Classifying 
diabetes according to the new WHO clinical stages. Eur J Epidemiol. 2001;17(11):983-9. 
Epub 2002/10/17. 
Conflicts of interest:  None 
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Chapter 6.  Genetic Discrimination between LADA and childhood-
onset type 1 diabetes within the MHC  
Supplemental Tables 
 
Cohort  Details Genotyping 
chip 
Quality 
Control (QC) 
ActionLada  
 
(LADA  Cases , 
N=1051) 
Populations: British, 
German 
 
Aged 30-70 Patients were 
designated with diabetes 
according to standard 
criteria, and LADA was 
defined as follows: patients 
1) aged 30–70 years, 2) 
with diabetes associated 
autoantibodies, and 3) who 
did not require insulin 
treatment for at least 6 
months post diagnosis. 
Only samples of European 
ancestry were included. 
Cohort overlaps with 
Cousminer DL et al. 
Diabetes Care (2018) 
Illumina 
Infinium II 
Omni Express 
Genotyping 
QC: Individuals 
with ambiguous 
sex, genotype 
missingness > 
5%, and 
relatedness 
(pi_hat > 0.2) 
were excluded. 
PCA was 
performed to 
exclude 
individuals of 
non-European 
ancestry. 
Imputation QC: 
MAF <0.01 
ActionLada 
'Plus' 
 
(LADA Cases 
N=441) 
Populations: American and 
British 
 
LADA was defined as 
follows: patients 1) aged 
30–70 years, 2) with 
diabetes associated 
autoantibodies, and 3) who 
did not require insulin 
treatment for at least 6 
months post diagnosis. A 
description of participants 
and study design can be 
found in Hawa MI et al. 
Diabetes Care (2013). More 
details such as exclusion 
criteria, etc can be found in 
Cousminer DL et al. 
Diabetes Care (2018) 
Illumina 
Infinium II 
Omni Express 
Genotyping 
QC: Individuals 
with ambiguous 
sex, genotype 
missingness > 
5%, and 
relatedness 
(pi_hat > 0.2) 
were excluded. 
PCA was 
performed to 
exclude 
individuals of 
non-European 
ancestry. 
Imputation QC: 
MAF <0.01 
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Bone Mineral 
Density in 
Childhood 
Study (BMDCS) 
 
(Population 
controls,N=1296) 
Populations: American of 
diverse ethnic backgrounds 
   
Samples of European 
descent only were included. 
More details such as 
recruitment,  exclusion 
criteria, etc can be found in 
Cousminer DL et al. 
Diabetes Care (2018) 
Illumina 
Infinium II 
Omni Express 
Genotyping 
QC: Individuals 
with  
ambiguous sex, 
genotype 
missingness > 
5%, and 
relatedness 
(pi_hat > 0.2) 
were excluded. 
PCA was 
performed to 
exclude 
individuals of 
non-European 
ancestry. 
Imputation QC: 
MAF <0.01  
Non-hodgkin 
lyphomia 
Controls 
(dbGaP) 
 
(Population 
controls, 
N=1683) 
Populations: USA, Multiple 
European countries, 
Australia 
 
More details such as 
recruitment, inclusion and 
exlusion, etc can be found 
in Berndt et al 
 
Illumina Omni 
Express 
Genotyping 
QC: Individuals 
with genotype 
missingness > 
5%  were 
excluded. PCA 
was performed 
to exclude 
individuals of 
non-European 
ancestry. 
Imputation QC: 
MAF <0.01 
Wellcome Trust 
Case Control 
Consortium 
(WTCCC)  
 
1958 British 
Birth Control 
Cohort 
(N=3000) 
 
Populations: England, 
Scotland and Wales  
More details such as 
recruitment, inclusion and 
exclusion criteria, etc can 
be found in WTCCC Nature 
(2007) 
Illumina 1.2 M Genotyping 
QC: Individuals 
with ambiguous 
sex, genotype 
missingness > 
5%, and 
duplicates and 
relatedness 
(pi_hat > 0.2) 
were excluded. 
PCA was 
performed to 
exclude 
individuals of 
non-European 
ancestry. 
Single 
nucleotide 
polymorphisms 
(SNPs) with a 
call rate <95%, 
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Hardy-
Weinberg 
equilibrium 
P<10-5 and 
with A/T and 
G/C alleles 
were removed. 
Imputation QC: 
MAF <0.01 
WTCCC T1D 
(N=2000) 
Affymetrix 
500 M 
Genotyping 
QC: Individuals 
with ambiguous 
sex, genotype 
missingness > 
5%, and 
rduplicates 
were excluded. 
PCA was 
performed to 
exclude 
individuals of 
non-European 
ancestry. 
Single 
nucleotide 
polymorphisms 
(SNPs) with a 
call rate <95%, 
Hardy-
Weinberg 
equilibrium 
P<10-5 and 
with A/T and 
G/C alleles 
were removed. 
Imputation QC: 
MAF <0.01 
WTCCC T1D 
(N=1990) 
Affymetrix 
500 M 
Genotyping 
QC: Individuals 
with  
ambiguous sex, 
duplicates, and 
genotype 
missingness > 
5%. PCA was 
performed to 
exclude 
individuals of 
non-European 
ancestry. 
Single 
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nucleotide 
polymorphisms 
(SNPs) with a 
call rate <95%, 
Hardy-
Weinberg 
equilibrium 
P<10-5 and 
with A/T and 
G/C alleles 
were removed. 
Imputation QC: 
MAF <0.01 
Swedish 
Replication 
LADA(N=823) 
 
All New 
Diabetics In 
Scania (ANDIS), 
and Scania 
Diabetes 
Registry (SDR) 
Population : Scania, 
Sweden 
ANDIS:  GAD (ELISA: 
Negative:< 5 U/ml, 
Positive:=> 10 U/ml, RIA: 
Negative:0-34 U/ml, 
Positive:> 50 U/ml); LADA: 
Age at onset ≥ 35 years, 
GAD (ELISA) > 10 kE/L, 
GAD (RIA) >50 U/ml, 
Cohort reference: 
http://andis.ludc.med.lu.se/; 
SDR: GAD (Wallenberg lab 
(AU ref < 5.0), GAD 
(Wallenberg lab (IU/ml ref 
<32); LADA: Age at onset ≥ 
35, GAD ≥ 10 AU, GAD ≥ 
50 IU/ml, For patients that 
did not fulfill the criteria for 
any of the above, the 
diagnosis given by their 
physician was used, Cohort 
reference: Lindholm E, 
Agardh E, Tuomi T, Groop 
L, Agardh CD. Classifying 
diabetes according to the 
new WHO clinical stages. 
Eur J Epidemiol. 
2001;17(11):983-9. Epub 
2002/10/17 
 
Illumina 
Infinium 
Omni 
Express 
Exome 
Exclude 
individuals:  
Call rate < 
95%;  
ambiguous 
gender;  
genome-wide 
heterozygosity 
(3 SD from 
mean);  
duplicates or 
related 
individuals (pi-
hat >= 0.2);  
average pi-hat 
outliers;  
population 
outliers. 
Exclude SNPs:  
monomorphic;  
(MAF >= 0.05 
and SNP 
missing rate > 
0.05);  
(MAF < 0.05 
and SNP 
missing rate > 
0.01);  
(MAF >= 0.05 
and HWE <= 
0.00000057);  
(MAF < 0.05 
and HWE <= 
0.0001) 
Imputation QC: 
MAF <0.01 
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Swedish 
Replication T1D 
(N=656) 
 
Scania Diabetes 
Registry (SDR) 
Population : Scania, 
Sweden 
GAD (Wallenberg lab (AU 
ref < 5.0), GAD (Wallenberg 
lab (IU/ml ref <32), C-
peptide (Klin kem (RIA) ref 
0.25-0.75), C-peptide (Klin 
kem ref 0.3-1.3), C-peptide 
(Lund (ref 0.25-0.75); T1D: 
Age  at onset < 35, GAD ≥ 
20 AU, GAD ≥ 100 IU/ml, 
C-peptide ≥ 0.25 (Klin kem 
(RIA)), C-peptide ≥ 0.3 (Klin 
kem), C-peptide ≥ 0.25 
(Lund), For patients that did 
not fulfill the criteria for any 
of the above, the diagnosis 
given by their physician was 
used, Cohort reference: 
Lindholm E, Agardh E, 
Tuomi T, Groop L, Agardh 
CD. Classifying diabetes 
according to the new WHO 
clinical stages. Eur J 
Epidemiol. 
2001;17(11):983-9. Epub 
2002/10/17 
 
Illumina 
Infinium Omni 
Express 
Exome 
Exclude 
individuals:  
Call rate < 
95%;  
ambiguous 
gender;  
genome-wide 
heterozygosity 
(3 SD from 
mean);  
duplicates or 
related 
individuals (pi-
hat >= 0.2);  
average pi-hat 
outliers;  
population 
outliers. 
Exclude SNPs:  
monomorphic;  
(MAF >= 0.05 
and SNP 
missing rate > 
0.05);  
(MAF < 0.05 
and SNP 
missing rate > 
0.01);  
(MAF >= 0.05 
and HWE <= 
0.00000057);  
(MAF < 0.05 
and HWE <= 
0.0001) 
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Imputation QC: 
MAF <0.01 
 
Swedish 
Replication 
Population-
based controls 
(N=3218) 
 
Malmö Diet and 
Cancer Study–
Cardiovascular 
Cohort (MDC-
CC) 
 
Population: Malmö, Sweden 
More details such as 
recruitment, inclusion and 
exclusion criteria, etc can 
be found in Rosvall M, 
Persson M, Ostling G, et al. 
Risk factors for the 
progression of carotid 
intima-media thickness over 
a 16-year follow-up period: 
the Malmo Diet and Cancer 
Study. Atherosclerosis. Apr 
2015;239(2):615-621. 
 
Illumina 
Infinium Omni 
Express 
Exome 
Exclude 
individuals:  
Call rate < 
95%;  
ambiguous 
gender;  
genome-wide 
heterozygosity 
(3 SD from 
mean);  
duplicates or 
related 
individuals (pi-
hat >= 0.2);  
population 
outliers. 
Exclude SNPs:  
monomorphic;  
SNP missing 
rate > 0.05;  
HWE <= 10e-6 
Imputation QC: 
MAF <0.01 
 
Supp. Table 6-1. Cohort information
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supp. Table 6-2. Power Calculations for detecting MHC Class I variants in LADA. Assumptions include a multiplicative model for non-MHC 
Class I signals, a significance level of 8.93x10-6,a disease prevalence of 0.0036, and 1,428 LADA cases and 2,979 controls.
 Odds Ratio  
MAF 3 2 1.8 1.6 1.4 1.35 
0.01 89.70% 14.50% 5.30% 1.30% 0.20% 0.10% 
0.03 100% 90.90% 64.90% 25.80% 3.80% 1.90% 
0.05 100% 99.80% 95.60% 65.10% 14.70% 7.60% 
0.1 100% 100% 100% 98.50% 58.10% 37.60% 
0.2 100% 100% 100% 100% 95.40% 84.30% 
0.3 100% 100% 100% 100% 99.4% 95.9% 
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